"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2014/0228248 A1,087-127-301-370-22X,2014-08-14,2014,US 201214347463 A,2012-09-24,US 201214347463 A;;US 201161579020 P;;US 201161540158 P;;US 2012/0056865 W,2011-09-28,METHODS AND COMPOSITIONS FOR DETECTING INFECTIONS,"The present invention provides, inter alia, methods for detecting whether a subject has an infection. These methods include (a) incubating a test sample from a subject suspected of having an infection with a labeled molecule, such as a labeled nucleoside analog, that is preferentially incorporated into a pathogenic microorganism for a period of time sufficient for the pathogenic microorganism to incorporate the labeled molecule; (b) removing any unincorporated labeled molecule from the test sample; and (c) detecting the labeled molecule within the pathogenic microorganism, if any, in the test sample, wherein the presence of labeled molecule within the pathogenic microorganism indicates that the subject has an infection.",BIOMED VALLEY DISCOVERIES INC,SAHA SAURABH;;BETTEGOWDA CHETAN;;TUNG DAVID,,https://lens.org/087-127-301-370-22X,Patent Application,yes,3,4,2,2,0,C12Q1/689;;C12Q1/701;;C12Q1/04;;C12Q1/485;;C12Q1/18;;C12Q1/04;;C12Q1/485;;C12Q1/701;;C12Q1/689;;C12Q1/18;;C12Q1/16,C12Q1/04;;C12Q1/18;;C12Q1/16;;C12Q1/48,506/10;;435/34;;435/5;;435/35;;435/15;;435/287.1;;435/32;;506/15,1,1,076-872-930-898-431,pmc545851;;10.1073/pnas.0408861102;;15653773,Bettegowda et al 2005 PNAS 102(4) 1145-1150,DISCONTINUED
2,WO,A1,WO 2013/048952 A1,146-119-103-918-926,2013-04-04,2013,US 2012/0056865 W,2012-09-24,US 201161540158 P;;US 201161579020 P,2011-09-28,METHODS AND COMPOSITIONS FOR DETECTING INFECTIONS,"The present invention provides, inter alia, methods for detecting whether a subject has an infection. These methods include (a) incubating a test sample from a subject suspected of having an infection with a labeled molecule, such as a labeled nucleoside analog, that is preferentially incorporated into a pathogenic microorganism for a period of time sufficient for the pathogenic microorganism to incorporate the labeled molecule; (b) removing any unincorporated labeled molecule from the test sample; and (c) detecting the labeled molecule within the pathogenic microorganism, if any, in the test sample, wherein the presence of labeled molecule within the pathogenic microorganism indicates that the subject has an infection.",BIOMED VALLEY DISCOVERIES INC;;SAHA SAURABH;;BETTEGOWDA CHETAN;;TUNG DAVID,SAHA SAURABH;;BETTEGOWDA CHETAN;;TUNG DAVID,,https://lens.org/146-119-103-918-926,Patent Application,yes,4,2,2,2,0,C12Q1/689;;C12Q1/701;;C12Q1/04;;C12Q1/485;;C12Q1/18;;C12Q1/04;;C12Q1/485;;C12Q1/701;;C12Q1/689;;C12Q1/18;;C12Q1/16,C12Q1/68,,1,1,076-872-930-898-431,pmc545851;;10.1073/pnas.0408861102;;15653773,"BETTEGOWDA ET AL.: ""Imaging bacterial infections with radiolabeled 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodouracif."", PNAS, vol. 102, no. 4, 25 January 2005 (2005-01-25), pages 1145 - 1150, XP002356266",PENDING
3,AT,T1,AT E459364 T1,196-897-969-629-214,2010-03-15,2010,AT 04809987 T,2004-10-21,US 51292303 P;;US 2004/0034625 W,2003-10-22,VERBESSERTE BAKTERIOLYSE-KOMBINATIONSTHERAPIE FÜR DIE BEHANDLUNG VON TUMOREN,"Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane, docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sporulated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.",UNIV JOHNS HOPKINS,DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH;;VOGELSTEIN BERT,,https://lens.org/196-897-969-629-214,Granted Patent,no,0,0,14,14,0,A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742;;A61P35/00;;A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742,A01N63/00;;A61K/;;A61K35/742,,0,0,,,,INACTIVE
4,WO,A9,WO 2005/039492 A9,022-060-633-473-776,2005-06-02,2005,US 2004/0034625 W,2004-10-21,US 51292303 P,2003-10-22,IMPROVED COMBINATION BACTERIOLYTIC THERAPY FOR THE TREATMENT OF TUMORS,"Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sponzlated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.",UNIV JOHNS HOPKINS;;DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT,DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT,,https://lens.org/022-060-633-473-776,Patent Application,no,0,0,14,14,0,A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742;;A61P35/00;;A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742,A01N63/00;;A61K/;;A61K35/742,,0,0,,,,PENDING
5,DE,D1,DE 602004025834 D1,003-966-421-514-961,2010-04-15,2010,DE 602004025834 T,2004-10-21,US 51292303 P;;US 2004/0034625 W,2003-10-22,DIE BEHANDLUNG VON TUMOREN,"Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane, docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sporulated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.",UNIV JOHNS HOPKINS,DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT,,https://lens.org/003-966-421-514-961,Granted Patent,no,0,0,14,14,0,A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742;;A61P35/00;;A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742,A01N63/00;;A61K/;;A61K31/337;;A61K31/427;;A61K35/742;;A61K45/06;;A61P35/00,,0,0,,,,ACTIVE
6,US,B2,US 8613917 B2,043-360-739-883-323,2013-12-24,2013,US 201113198850 A,2011-08-05,US 201113198850 A;;US 56876507 A;;US 2004/0034625 W;;US 51292303 P,2003-10-22,Combination bacteriolytic therapy for the treatment of tumors,"Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane, docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sporulated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.",DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT;;UNIV JOHNS HOPKINS,DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT,THE JOHNS HOPKINS UNIVERSITY (2006-06-06),https://lens.org/043-360-739-883-323,Granted Patent,yes,6,2,14,14,2,A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742;;A61P35/00;;A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742,A61K35/00;;A01N63/00;;A01N63/02;;A61K/;;A61K35/742;;C12N1/20;;C12N3/00,424/93.41;;424/780;;435/242;;435/252.7;;435/842,7,6,064-339-043-730-471;;052-435-975-479-613;;179-405-855-196-115;;078-315-674-964-479;;042-484-362-677-13X;;102-858-139-063-854,10.1073/pnas.251543698;;11724950;;pmc64999;;10.1016/s0928-8244(00)00231-5;;11172989;;10.1111/j.1574-695x.2001.tb01547.x;;10.1002/3527600108.ch8;;10.1126/science.274.5295.2009;;8984658;;1203896;;14739784;;10.4161/cbt.3.3.704,"L. Dang et al., ""Combination Bacteriolytic Therapy for the Treatment of Experimental Tumors,"" Proceedings of the National Academy of Sciences of USA, Dec. 18, 2001; vol. 98, No. 26, pp. 15155-15160.;;J. Theys et al., ""Improvement of Clostridium Tumor Targeting Vectors Evaluated in Rat Rhabdomyosarcomas,"" FEMS Immunology and Medical Microbiology, Feb. 1, 20001, vol. 30, No. 1, pp. 37-41.;;N.P. Minton et al., ""Clostridia in Cancer Therapy,"" Clostridia Biotechnology and Medical Applications, Feb. 15, 2001, pp. 251-270.;;T. Fojo et al., ""Taxol and Other Microtubule-Interactive Agents,"" Current Opinion in Oncologic, Endocrine and Metabolicinvestigational Drugs, Jan. 1, 2001, vol. 2, No. 3, pp. 293-304.;;R. F. Service, ""Chemical Synthesis: Tumor-Killer Made: How Does It Work?"" Science, Dec. 20, 1996, vol. 274, No. 5295, pp. 2009.;;F. Valeriote et al., ""Synergistic Interaction of Anticancer Agents: A Cellular Perspective,"" Cancer Chemotherapy Reports, Sep. 1, 1975, vol. 59, No. 5, pp. 895-900.;;L. Dang et al., ""Targeting Vascular and Avascular Compartments of Tumors with C, novyi-NT and Anti-Microtubule Agents,"" Cancer Biology & Therapy, Mar. 2004, vol. 3, No. 3., pp. 326-337.",ACTIVE
7,EP,B1,EP 1675465 B1,055-198-422-195-357,2010-03-03,2010,EP 04809987 A,2004-10-21,US 2004/0034625 W;;US 51292303 P,2003-10-22,IMPROVED COMBINATION BACTERIOLYTIC THERAPY FOR THE TREATMENT OF TUMORS,"Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane, docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sporulated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.",UNIV JOHNS HOPKINS,DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT,,https://lens.org/055-198-422-195-357,Granted Patent,yes,3,3,14,14,0,A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742;;A61P35/00;;A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742,A61K35/74;;A01N63/00;;A61K/;;A61K31/337;;A61K31/427;;A61K35/742;;A61K45/06;;A61P35/00,,7,0,,,"DANG LONG H ET AL: ""Combination bacteriolytic therapy for the treatment of experimental tumors"" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, vol. 98, no. 26, 18 December 2001 (2001-12-18), pages 15155-15160, XP003010304 ISSN: 0027-8424;;THEYS J ET AL: ""IMPROVEMENT OF CLOSTRIDIUM TUMOUR TARGETING VECTORS EVALUATED IN RAT RHABDOMYOSARCOMAS"" FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, ELSEVIER SCIENCE B.V., AMSTERDAM, NL, vol. 30, no. 1, 1 February 2001 (2001-02-01), pages 37-41, XP001097591 ISSN: 0928-8244;;MINTON N P ET AL: ""Clostridia in Cancer Therapy"" CLOSTRIDIA BIOTECHNOLOGY AND MEDICAL APPLICATIONS, WILEY-VCH, DE, 15 February 2001 (2001-02-15), pages 251-270, XP001247867;;FOJO T ET AL: ""TAXOL AND OTHER MICROTUBULE-INTERACTIVE AGENTS"" CURRENT OPINION IN ONCOLOGIC, ENDOCRINE AND METABOLICINVESTIGATIONAL DRUGS, CURRENT DRUGS, LONDON, GB, vol. 2, no. 3, 1 January 2000 (2000-01-01), pages 293-304, XP001004848 ISSN: 1464-8466;;SERVICE R F: ""CHEMICAL SYNTHESIS: TUMOR-KILLER MADE; HOW DOES IT WORK?"" SCIENCE, WASHINGTON, DC, vol. 274, no. 5295, 20 December 1996 (1996-12-20), page 2009, XP000990222 ISSN: 0036-8075;;VALERIOTE F ET AL: ""SYNERGISTIC INTERACTION OF ANTICANCER AGENTS: A CELLULAR PERSPECTIVE"" CANCER CHEMOTHERAPY REPORTS, vol. 59, no. 5, 1 September 1975 (1975-09-01), pages 895-900, XP009019750;;DANG LONG H ET AL: ""Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents."" CANCER BIOLOGY & THERAPY, vol. 3, no. 3, March 2004 (2004-03), pages 326-337, XP002483666 ISSN: 1538-4047",ACTIVE
8,US,A1,US 2011/0311500 A1,086-673-851-785-886,2011-12-22,2011,US 201113198850 A,2011-08-05,US 201113198850 A;;US 56876507 A;;US 2004/0034625 W;;US 51292303 P,2003-10-22,COMBINATION BACTERIOLYTIC THERAPY FOR THE TREATMENT OF TUMORS,"Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane, docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sporulated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.",DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT;;UNIV JOHNS HOPKINS,DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT,THE JOHNS HOPKINS UNIVERSITY (2006-06-06),https://lens.org/086-673-851-785-886,Patent Application,yes,0,0,14,14,2,A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742;;A61P35/00;;A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742,A61K35/74;;A01N63/00;;A61K/;;A61K35/742;;A61P35/00,424/93.41,0,0,,,,ACTIVE
9,WO,A2,WO 2005/039492 A2,008-886-892-443-604,2005-05-06,2005,US 2004/0034625 W,2004-10-21,US 51292303 P,2003-10-22,IMPROVED COMBINATION BACTERIOLYTIC THERAPY FOR THE TREATMENT OF TUMORS,"Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sponzlated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.",UNIV JOHNS HOPKINS;;DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT,DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT,,https://lens.org/008-886-892-443-604,Patent Application,yes,0,14,14,14,0,A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742;;A61P35/00;;A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742,A01N63/00;;A61K/;;A61K35/742,,0,0,,,,PENDING
10,EP,A2,EP 1675465 A2,150-251-347-921-85X,2006-07-05,2006,EP 04809987 A,2004-10-21,US 2004/0034625 W;;US 51292303 P,2003-10-22,IMPROVED COMBINATION BACTERIOLYTIC THERAPY FOR THE TREATMENT OF TUMORS,"Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane, docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sporulated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.",UNIV JOHNS HOPKINS,DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT,,https://lens.org/150-251-347-921-85X,Patent Application,yes,0,0,14,14,0,A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742;;A61P35/00;;A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742,A61K35/74;;A01N63/00;;A61K/;;A61K31/337;;A61K31/427;;A61K35/742;;A61K45/06;;A61P35/00,,0,0,,,,ACTIVE
11,WO,A3,WO 2005/039492 A3,186-009-978-506-143,2005-06-30,2005,US 2004/0034625 W,2004-10-21,US 51292303 P,2003-10-22,IMPROVED COMBINATION BACTERIOLYTIC THERAPY FOR THE TREATMENT OF TUMORS,"Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sponzlated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.",UNIV JOHNS HOPKINS;;DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT,DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT,,https://lens.org/186-009-978-506-143,Search Report,yes,1,0,14,14,0,A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742;;A61P35/00;;A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742,A01N63/00;;A61K/;;A61K35/742,,0,0,,,,PENDING
12,WO,A3,WO 2005/039491 A3,011-562-203-751-925,2005-06-23,2005,US 2004/0034624 W,2004-10-21,US 51292203 P,2003-10-22,CERTAIN IMPROVED COMBINATION BACTERIOLYTIC THERAPY FOR THE TREATMENT OF TUMORS,"Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis such as HTI-286 and vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxanes docetaxel and MAC-321, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sporulated bacteria Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.",UNIV JOHNS HOPKINS;;DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT,DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT,,https://lens.org/011-562-203-751-925,Search Report,yes,1,0,3,3,0,A61K35/742;;A61K31/195;;A61K31/4045;;A61K38/06,A01N63/00;;A61K/,,0,0,,,,PENDING
13,US,B2,US 9572843 B2,196-691-926-029-91X,2017-02-21,2017,US 201314106987 A,2013-12-16,US 201314106987 A;;US 201113198850 A;;US 56876507 A;;US 2004/0034625 W;;US 51292303 P,2003-10-22,Combination bacteriolytic therapy for the treatment of tumors,"Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane, docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sporulated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.",UNIV JOHNS HOPKINS,DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT,THE JOHNS HOPKINS UNIVERSITY (2006-06-06),https://lens.org/196-691-926-029-91X,Granted Patent,yes,6,1,14,14,2,A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742;;A61P35/00;;A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742,A61K35/742;;A01N63/00;;A61K/;;A61K31/337;;A61K31/427;;A61K45/06,,7,6,064-339-043-730-471;;052-435-975-479-613;;179-405-855-196-115;;078-315-674-964-479;;042-484-362-677-13X;;102-858-139-063-854,10.1073/pnas.251543698;;11724950;;pmc64999;;10.1016/s0928-8244(00)00231-5;;11172989;;10.1111/j.1574-695x.2001.tb01547.x;;10.1002/3527600108.ch8;;10.1126/science.274.5295.2009;;8984658;;1203896;;14739784;;10.4161/cbt.3.3.704,"L. Dang et al., ""Combination Bacteriolytic Therapy for the Treatment of Experimental Tumors,"" Proceedings of the National Academy of Sciences of USA, Dec. 18, 2001; vol. 98, No. 26, pp. 15155-15160.;;J. Theys et al., ""Improvement of Clostridium Tumor Targeting Vectors Evaluated in Rat Rhabdomyosarcomas,"" FEMS Immunology and Medical Microbiology, Feb. 1, 20001, vol. 30, No. 1, pp. 37-41.;;N.P. Minton et al., ""Clostridia in Cancer Therapy,"" Clostridia Biotechnology and Medical Applications, Feb. 15, 2001, pp. 251-270.;;T. Fojo et al., ""Taxol and Other Microtubule-Interactive Agents,"" Current Opinion in Oncologic, Endocrine and Metabolicinvestigational Drugs, Jan. 1, 2001, vol. 2, No. 3, pp. 293-304.;;R. F. Service, ""Chemical Synthesis: Tumor-Killer Made: How Does It Work?"" Science, Dec. 20, 1996, vol. 274, No. 5295, pp. 2009.;;F. Valeriote et al., ""Synergistic Interaction of Anticancer Agents: A Cellular Perspective,"" Cancer Chemotherapy Reports, Sep. 1, 1975, vol. 59, No. 5, pp. 895-900.;;L. Dang et al., ""Targeting Vascular and Avascular Compartments of Tumors with C, novyi-NT and Anti-Microtubule Agents,"" Cancer Biology & Therapy, Mar. 2004, vol. 3, No. 3., pp. 326-337.",ACTIVE
14,WO,A2,WO 2005/039491 A2,051-479-154-421-439,2005-05-06,2005,US 2004/0034624 W,2004-10-21,US 51292203 P,2003-10-22,CERTAIN IMPROVED COMBINATION BACTERIOLYTIC THERAPY FOR THE TREATMENT OF TUMORS,"Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis such as HTI-286 and vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxanes docetaxel and MAC-321, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sporulated bacteria Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.",UNIV JOHNS HOPKINS;;DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT,DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT,,https://lens.org/051-479-154-421-439,Patent Application,yes,0,4,3,3,0,A61K35/742;;A61K31/195;;A61K31/4045;;A61K38/06,A01N63/00;;A61K/,,0,0,,,,PENDING
15,WO,A9,WO 2005/039491 A9,120-285-931-254-459,2005-06-02,2005,US 2004/0034624 W,2004-10-21,US 51292203 P,2003-10-22,CERTAIN IMPROVED COMBINATION BACTERIOLYTIC THERAPY FOR THE TREATMENT OF TUMORS,"Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis such as HTI-286 and vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxanes docetaxel and MAC-321, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sporulated bacteria Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.",UNIV JOHNS HOPKINS;;DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT,DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT,,https://lens.org/120-285-931-254-459,Patent Application,no,0,0,3,3,0,A61K35/742;;A61K31/195;;A61K31/4045;;A61K38/06,A01N63/00;;A61K/,,0,0,,,,PENDING
16,US,A1,US 2014/0328813 A1,174-330-357-604-897,2014-11-06,2014,US 201314106987 A,2013-12-16,US 201314106987 A;;US 201113198850 A;;US 56876507 A;;US 2004/0034625 W;;US 51292303 P,2003-10-22,Combination Bacteriolytic Therapy for the Treatment of Tumors,"Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane, docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sporulated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.",UNIV JOHNS HOPKINS,DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT,THE JOHNS HOPKINS UNIVERSITY (2006-06-06),https://lens.org/174-330-357-604-897,Patent Application,yes,0,0,14,14,2,A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742;;A61P35/00;;A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742,A61K35/74;;A01N63/00;;A61K/;;A61K31/337;;A61K35/742;;A61K45/06,424/93.41,0,0,,,,ACTIVE
17,EP,A4,EP 1675465 A4,133-019-562-267-093,2008-07-30,2008,EP 04809987 A,2004-10-21,US 2004/0034625 W;;US 51292303 P,2003-10-22,IMPROVED COMBINATION BACTERIOLYTIC THERAPY FOR THE TREATMENT OF TUMORS,"Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane, docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sporulated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.",UNIV JOHNS HOPKINS,DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT,,https://lens.org/133-019-562-267-093,Search Report,no,2,0,14,14,0,A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742;;A61P35/00;;A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742,A61K35/74;;A01N63/00;;A61K/;;A61K31/337;;A61K31/427;;A61K35/742;;A61K45/06;;A61P35/00,,7,6,064-339-043-730-471;;052-435-975-479-613;;179-405-855-196-115;;078-315-674-964-479;;042-484-362-677-13X;;102-858-139-063-854,10.1073/pnas.251543698;;11724950;;pmc64999;;10.1016/s0928-8244(00)00231-5;;11172989;;10.1111/j.1574-695x.2001.tb01547.x;;10.1002/3527600108.ch8;;10.1126/science.274.5295.2009;;8984658;;1203896;;14739784;;10.4161/cbt.3.3.704,"DANG LONG H ET AL: ""Combination bacteriolytic therapy for the treatment of experimental tumors"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, vol. 98, no. 26, 18 December 2001 (2001-12-18), pages 15155 - 15160, XP003010304, ISSN: 0027-8424;;THEYS J ET AL: ""IMPROVEMENT OF CLOSTRIDIUM TUMOUR TARGETING VECTORS EVALUATED IN RAT RHABDOMYOSARCOMAS"", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, ELSEVIER SCIENCE B.V., AMSTERDAM, NL, vol. 30, no. 1, 1 February 2001 (2001-02-01), pages 37 - 41, XP001097591, ISSN: 0928-8244;;MINTON N P ET AL: ""Clostridia in Cancer Therapy"", CLOSTRIDIA BIOTECHNOLOGY AND MEDICAL APPLICATIONS, WILEY-VCH, DE, 15 February 2001 (2001-02-15), pages 251 - 270, XP001247867;;FOJO T ET AL: ""TAXOL AND OTHER MICROTUBULE-INTERACTIVE AGENTS"", CURRENT OPINION IN ONCOLOGIC, ENDOCRINE AND METABOLICINVESTIGATIONAL DRUGS, CURRENT DRUGS, LONDON, GB, vol. 2, no. 3, 1 January 2000 (2000-01-01), pages 293 - 304, XP001004848, ISSN: 1464-8466;;SERVICE R F: ""CHEMICAL SYNTHESIS: TUMOR-KILLER MADE; HOW DOES IT WORK?"", SCIENCE, WASHINGTON, DC, vol. 274, no. 5295, 20 December 1996 (1996-12-20), pages 2009, XP000990222, ISSN: 0036-8075;;VALERIOTE F ET AL: ""SYNERGISTIC INTERACTION OF ANTICANCER AGENTS: A CELLULAR PERSPECTIVE"", CANCER CHEMOTHERAPY REPORTS, vol. 59, no. 5, 1 September 1975 (1975-09-01), pages 895 - 900, XP009019750;;DANG LONG H ET AL: ""Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents."", CANCER BIOLOGY & THERAPY, vol. 3, no. 3, March 2004 (2004-03-01), pages 326 - 337, XP002483666, ISSN: 1538-4047",ACTIVE
18,US,A1,US 2007/0148135 A1,199-853-840-128-130,2007-06-28,2007,US 56876504 A,2004-10-21,US 56876504 A;;US 51292303 P;;US 2004/0034625 W,2003-10-22,Combination bacteriolytic therapy for the treatment of tumors,"Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sponzlated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.",UNIV JOHNS HOPKINS,DANG LONG;;BETTEGOWDA CHETAN;;KENZLER KENNETH W;;VOGELSTEIN BERT,JOHNS HOPKINS UNIVERSITY THE (2006-06-06),https://lens.org/199-853-840-128-130,Patent Application,yes,4,26,14,14,0,A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742;;A61P35/00;;A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742,A61K35/74;;A01N63/00;;A61K/;;A61K31/337;;A61K31/427;;A61K35/742,424/93.4;;424/623;;514/449;;514/365,0,0,,,,ACTIVE
19,US,B2,US 8007782 B2,093-373-873-166-188,2011-08-30,2011,US 56876504 A,2004-10-21,US 56876504 A;;US 51292303 P;;US 2004/0034625 W,2003-10-22,Combination bacteriolytic therapy for the treatment of tumors,"Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sponzlated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.",UNIV JOHNS HOPKINS,DANG LONG;;BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT,JOHNS HOPKINS UNIVERSITY THE (2006-06-06),https://lens.org/093-373-873-166-188,Granted Patent,yes,6,6,14,14,2,A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742;;A61P35/00;;A61K31/337;;A61K31/427;;A61K45/06;;Y10S435/842;;A61K35/742,A01N63/00;;A01N63/02;;A61K/;;A61K35/00;;A61K35/742;;C12N1/20;;C12N3/00,424/93.41;;424/780;;435/242;;435/252.7;;435/842,8,6,064-339-043-730-471;;052-435-975-479-613;;179-405-855-196-115;;078-315-674-964-479;;042-484-362-677-13X;;102-858-139-063-854,10.1073/pnas.251543698;;11724950;;pmc64999;;10.1016/s0928-8244(00)00231-5;;11172989;;10.1111/j.1574-695x.2001.tb01547.x;;10.1002/3527600108.ch8;;10.1126/science.274.5295.2009;;8984658;;1203896;;14739784;;10.4161/cbt.3.3.704,"Dang, Long H. et al, ""Combination bacteriolytic therapy for the treatment of exper. tumors,"" PNAS, p. 1-6, Oct. 2001.;;D. Long et al., ""Combination Bacteriolytic Therapy for the Treatment of Experimental Tumors,"" Proceedings of the National Academy of Sciences of USA, Dec. 18, 2001; vol. 98, No. 26, pp. 15155-15160.;;J. Theys et al., ""Improvement of Clostridium Tumor Targeting Vectors Evaluated in Rat Rhabdomyosarcomas,"" FEMS Immunology and Medical Microbiology, Feb. 1, 2001, vol. 30, No. 1, pp. 37-41.;;N.P. Minton et al., ""Clostridia in Cancer Therapy,"" Clostridia Biotechnology and Medical Applications, Feb. 15, 2001, pp. 251-270.;;T. Fojo et al., ""Taxol and Other Microtubule-Interactive Agents,"" Current Opinion in Oncologic, Endocrine and Metabolicinvestigational Drugs, Jan. 1, 2001, vol. 2, No. 3, pp. 293-304.;;R. F. Service, ""Chemical Synthesis: Tumor-Killer Made: How Does it Work?"" Science, Dec. 20, 1996, vol. 274, No. 5295, pp. 2009.;;F. Valeriote et al., ""Synergistic Interaction of Anticancer Agents: A Cellular Perspective,"" Cancer Chemotherapy Reports, Sep. 1, 1975, vol. 59, No. 5, pp. 895-900.;;D. Long et al., ""Targeting Vascular and Avascular Compartments of Tumors with C. novyi-NT and Anti-Microtubule Agents,"" Cancer Biology & Therapy, Mar. 2004, vol. 3, No. 3, pp. 326-337.",ACTIVE
20,WO,A1,WO 2023/239866 A1,087-136-337-152-51X,2023-12-14,2023,US 2023/0024846 W,2023-06-08,US 202263350906 P,2022-06-10,METHODS FOR IDENTIFYING CNS CANCER IN A SUBJECT,"Provided herein are methods of identifying a subject as having a central nervous system (CNS) cancer that include (a) obtaining a DNA sample from the subject; (b) analyzing a plurality of chromosomal sequences in the DNA sample; (c) determining at least a portion of a nucleic acid sequence of one or more of the plurality of chromosomal sequences; (d) mapping the determined nucleic acid sequence to a reference chromosome; (e) dividing the DNA sample into a plurality of genomic intervals; (f) quantifying a plurality of features for the one or more nucleic acid sequences mapped to the genomic intervals; and (g) comparing the plurality of features in a first genomic interval with the plurality of features in one or more different genomic intervals and detecting a chromosomal abnormality in the DNA sample, thereby identifying the subject as having the CNS cancer.",UNIV JOHNS HOPKINS,DOUVILLE CHRISTOPHER;;BETTEGOWDA CHETAN;;VOGELSTEIN BERT;;KINZLER KENNETH W;;PAPADOPOULOS NICKOLAS,,https://lens.org/087-136-337-152-51X,Patent Application,yes,4,0,1,1,0,A61K51/00;;C12Q1/6827;;C12Q1/6844;;A61P35/00;;C12Q1/6886,C12Q1/6886;;A61K51/00;;A61P35/00;;C12Q1/6827;;C12Q1/6844,,2,2,072-581-297-535-591;;076-014-104-710-686,10.1073/pnas.1910041117;;32075918;;10.1101/660258;;pmc7060727;;35244537;;pmc9094745;;10.7554/elife.74238,"DOUVILLE ET AL.: ""Assessing aneuploidy with repetitive element sequencing"", PROC. NAT. . ACAD. SCI., vol. 117, no. 9, 3 March 2020 (2020-03-03), pages 4858 - 4863, XP055735132, DOI: 10.1073/pnas.1910041117;;MATTOX AUSTIN K, DOUVILLE CHRISTOPHER, SILLIMAN NATALIE, PTAK JANINE, DOBBYN LISA, SCHAEFER JOY, POPOLI MARIA, BLAIR CHERIE, JUDGE: ""Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma"", ELIFE, ELIFE SCIENCES PUBLICATIONS LTD., GB, vol. 11, 1 February 2022 (2022-02-01), GB , XP093118282, ISSN: 2050-084X, DOI: 10.7554/eLife.74238",PENDING
21,EP,A1,EP 2283871 A1,136-281-988-997-109,2011-02-16,2011,EP 10012858 A,2005-06-20,EP 05788432 A;;US 58122204 P,2004-06-18,Imaging infection with compounds that bind to thymidine kinase,"The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.",UNIV JOHNS HOPKINS,POMPER MARTIN;;BETTEGOWDA CHETAN;;FOSS CATHERINE;;ZHOU SHIBIN;;KINZLER KENNETH;;VOGELSTEIN BERT,,https://lens.org/136-281-988-997-109,Patent Application,yes,12,0,22,22,0,A61K51/1241;;A61K51/1231;;A61K51/0491;;A61K51/1241;;A61K51/1231;;A61K51/0491,A61K49/00;;A61K51/00,,12,7,076-872-930-898-431;;039-901-395-841-545;;057-506-930-709-101;;008-342-521-824-904;;076-872-930-898-431;;057-506-930-709-101;;008-342-521-824-904,pmc545851;;10.1073/pnas.0408861102;;15653773;;14513292;;10.1007/s00259-003-1269-z;;10.1021/jm010922s;;11708929;;10.1021/jm020827z;;12408716;;pmc545851;;10.1073/pnas.0408861102;;15653773;;10.1021/jm010922s;;11708929;;10.1021/jm020827z;;12408716,"BETTEGOWDA C. ET AL.: ""Imaging bacterial infections with radiolabelled 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodouracil"", PNAS, vol. 102, no. 4, 25 January 2005 (2005-01-25), pages 1145 - 1150, XP002356266;;DENG, W-P. ET AL.: ""Non-invasive in vivo imaging with radiolabelled FIAU for monitoring cancer gene therapy using herpes simplex virus type 1 kthymidine kinase and ganciclovir"", EUR. J. NUCL. MED. MOL. IMAGING, vol. 31, no. 1, January 2004 (2004-01-01), pages 99 - 109, XP002356281;;GOLANKIEWICZ B ET AL: ""FLUORESCENT TRICYCLIC ANALOGUES OF ACYCLOVIR AND GANCICLOVIR. A STRUCTURE-ANTIVIRAL ACTIVITY STUDY"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 44, 2001, pages 4284 - 4287, XP001119790, ISSN: 0022-2623;;GOSLINSKI T ET AL.: ""Synthesis and biological activity of strongly fluoroescent tricyclic analogues of acyclovir and ganciclovir"", J. MED. CHEM., vol. 45, no. 1, 2002, pages 5052 - 5057, XP002356282;;J. NUCL. MED, vol. 43, 2002, pages 239 - 45;;J. PHARMACOL. EXP. THER., vol. 259, 1991, pages 1351 - 9;;BETTEGOWDA ET AL., PNAS, vol. 102, 2005, pages 1145 - 50;;GOLANKIEWICZ ET AL., J MED. CHEM., vol. 44, 2001, pages 4284 - 7;;GOSLINSKI ET AL., J. MED. CHEM., vol. 45, 2002, pages 5052 - 7;;""Remington's Pharmaceutical Sciences"", MACK PUBLISHING;;""Remington's Pharmaceutical Sciences"", MACK PUBLISHING COMPANY;;ESCHERICHIA COLI",DISCONTINUED
22,AT,T1,AT E555813 T1,138-864-939-509-524,2012-05-15,2012,AT 05788432 T,2005-06-20,US 58122204 P;;US 2005/0021888 W,2004-06-18,BILDGEBUNG VON INFEKTIONEN MIT AN THYMIDINKINASE BINDENDEN VERBINDUNGEN,"The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.",UNIV JOHNS HOPKINS,POMPER MARTIN;;BETTEGOWDA CHETAN;;FOSS CATHERINE;;ZHOU SHIBIN;;KINZLER KENNETH;;VOGELSTEIN BERT,,https://lens.org/138-864-939-509-524,Granted Patent,no,0,0,22,22,0,A61K51/1241;;A61K51/1231;;A61K51/0491;;A61K51/1241;;A61K51/1231;;A61K51/0491,,,0,0,,,,ACTIVE
23,CA,C,CA 2571346 C,055-605-504-623-170,2014-08-12,2014,CA 2571346 A,2005-06-20,US 58122204 P;;US 2005/0021888 W,2004-06-18,IMAGING INFECTION WITH COMPOUNDS THAT BIND TO THYMIDINE KINASE,"The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.",UNIV JOHNS HOPKINS,POMPER MARTIN G;;BETTEGOWDA CHETAN;;FOSS CATHERINE;;ZHOU SHIBIN;;KINZLER KENNETH;;VOGELSTEIN BERT,,https://lens.org/055-605-504-623-170,Granted Patent,no,0,0,22,22,0,A61K51/1241;;A61K51/1231;;A61K51/0491;;A61K51/1241;;A61K51/1231;;A61K51/0491,A61K49/00;;A61K51/00,,0,0,,,,INACTIVE
24,US,B2,US 8691186 B2,154-784-171-610-413,2014-04-08,2014,US 201213596632 A,2012-08-28,US 201213596632 A;;US 62960708 A;;US 2005/0021888 W;;US 58122204 P,2004-06-18,Imaging infection with compounds that bind to thymidine kinase,"The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.",POMPER MARTIN G;;BETTEGOWDA CHETAN;;FOSS CATHERINE;;ZHOU SHIBIN;;KINZLER KENNETH;;VOGELSTEIN BERT;;UNIV JOHNS HOPKINS,POMPER MARTIN G;;BETTEGOWDA CHETAN;;FOSS CATHERINE;;ZHOU SHIBIN;;KINZLER KENNETH;;VOGELSTEIN BERT,,https://lens.org/154-784-171-610-413,Granted Patent,yes,5,1,22,22,4,A61K51/1241;;A61K51/1231;;A61K51/0491;;A61K51/1241;;A61K51/1231;;A61K51/0491,A61K49/04;;A61K51/00,424/1.89;;424/1.73;;424/9.1;;424/9.2;;424/9.4,13,13,003-185-048-086-636;;023-222-794-513-607;;081-129-485-256-659;;057-506-930-709-101;;076-872-930-898-431;;064-339-043-730-471;;133-124-946-804-307;;139-496-186-192-621;;027-340-028-343-63X;;133-124-946-804-307;;003-185-048-086-636;;008-342-521-824-904;;039-901-395-841-545,10.1016/s0168-3659(01)00340-6;;11489512;;10774880;;10.1007/s002590050035;;10.1038/89991;;11433353;;10.1021/jm010922s;;11708929;;pmc545851;;10.1073/pnas.0408861102;;15653773;;10.1073/pnas.251543698;;11724950;;pmc64999;;6742789;;10.1002/ana.410150607;;10.1099/00221287-131-11-3091;;4093763;;10.1099/00221287-130-7-1863;;6381650;;6742789;;10.1002/ana.410150607;;10.1016/s0168-3659(01)00340-6;;11489512;;10.1021/jm020827z;;12408716;;14513292;;10.1007/s00259-003-1269-z,"J. Tjuvajev et al Salmoonella-based tumor targeted cancer therapy: tumor amplified protein expression therapy (TAPET) for diagnostic imaging, J. Control Release 74, 313-315, 2001.;;Roland Haubner et al., In vivo imaging of herpes simplex virus type 1 thymidine kinase gene expression: early kinetics of radiolabelled FIAU, European Journal of Nuclear Medicine, 2000, 27, 283-291.;;Bennett J.J., et al. ""Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer."" Nat Med. Jul. 2001;7(7):859-63.;;Bozenna Golankiewicz et al., ""Fluorescent Tricyclic Analogues of Acyclovir and Ganciclovir, A Structure-Antiviral Activity Study"", J. Med. Chem., vol. 44, (2001), pp. 4284-4287.;;Chetan Bettegowda et al., ""Imaging bacterial infections with radiolabeled 1-2(2'-deoxy-2'-fluoro-B-D-arabinofuranosyl)-5-iodouracil"", PNAS, vol. 2, No. 4, Jan. 25, 2005, pp. 1145-1150.;;Dang L.H., et al. ""Combination bacteriolytic therapy for the treatment of experimental tumors."" Proc Natl Acad Sci U S A. Dec. 18, 2001;98(26):15155-60.;;Saito Y et al., ""Diagnostic imaging of herpes simplex virus encephalitis using a radiolabeled antiviral drugs : autoradiographic assessmjent in an animal model"" Annals of Neurology vol. 15(6). Jun. 1984, pp. 548-558.;;Saito H., et al. ""Further studies on thymidine kinase: distribution pattern of the enzyme in bacteria."" J Gen Microbiol. Nov. 1985;131(11):3091-8.;;Saito H., et al. ""Thymidine kinase of bacteria: activity of the enzyme in actinomycetes and related organisms."" J Gen Microbiol. Jul. 1984;130(7):1863-70.;;Saito et al. Diagnostic Imaging of Herpes Simplex Virus Encephaliitis Using a Radiolabeled Antiviral Drug: Autoradiographi Assessment in an animal moedl, Ann. Neurol 15, 548-558, 1984.;;Tjuvajev et al. Salmoonella-based tumor targeted cancer therapy: tumor amplified protein expression therapy (TAPET) for diagnostic imaging, J. Control Release 74, 313-315, 2001.;;Tomasz Goslinkski et al, ""Synthesis and Biological Activity of Strongly Fluorescent Tricyclic Analogues of Acyclovir and Ganciclovir"", J. Med. Chem., vol. 45, (2002), pp. 5052-5057.;;Win-Ping Deng et al., ""Non-invasive in vivo imaging with radiolabeled FIAU for monitoring cancer gene therapy using herpes simplex virus type 1 thymidien kinase and ganciclovir"", European Journal of Nuclear Medicine and Molecular Imaging, vol. 31, No. 1, Jan. 2004, pp. 99-109.",INACTIVE
25,US,B2,US 10174384 B2,009-013-969-354-241,2019-01-08,2019,US 201615071800 A,2016-03-16,US 201615071800 A;;US 201562133714 P,2015-03-16,Use of the ZMIZ1 marker in directing treatment and predicting survival in cancer,"The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions for treating cancer and predicting patient survival. In one embodiment, a method comprises (a) obtaining a biological sample from the patient; and (b) detecting hypermethylation of ZMIZ1 using primers that specifically bind to CpG island 139 at the alternative promoter of the ZMIZ1 gene.",UNIV JOHNS HOPKINS,MATHIOS DIMITRIOS;;LIM MICHAEL;;HA PATRICK;;BETTEGOWDA CHETAN;;HWANG TAEYOUNG;;PARK CHUL-KEE,THE JOHNS HOPKINS UNIVERSITY (2016-05-20),https://lens.org/009-013-969-354-241,Granted Patent,yes,1,0,2,2,26,C12Q1/6886;;C12Q1/6886;;C12Q2600/118;;C12Q2600/118;;C12Q2600/154;;C12Q2600/154;;C12Q2600/158;;C12Q2600/158,C12Q1/6886,,21,21,016-309-751-596-017;;116-661-842-369-15X;;041-263-190-664-782;;032-042-147-850-410;;138-232-369-002-928;;022-634-280-119-21X;;125-852-897-442-770;;003-870-113-367-334;;001-568-098-749-368;;016-120-637-765-340;;037-278-969-310-045;;044-497-397-883-430;;030-251-266-314-117;;019-060-827-002-536;;002-015-261-929-841;;047-012-002-314-534;;019-116-100-461-723;;002-833-076-930-124;;074-754-211-678-782;;076-263-582-377-731;;167-234-288-653-48X,17194187;;10.1371/journal.pmed.0030486;;pmc1716188;;10.1158/1078-0432.ccr-11-2635-t;;22261801;;10.1093/carcin/23.2.231;;11872627;;pmc3910500;;24120142;;10.1016/j.cell.2013.09.034;;11306450;;12042769;;10.1038/nrg816;;19269895;;10.1016/s1470-2045(09)70025-7;;20399149;;pmc2872684;;10.1016/j.ccr.2010.03.017;;18772396;;pmc2820389;;10.1126/science.1164382;;20613842;;pmc3998662;;10.1038/nature09165;;pmc3817542;;23938295;;10.1038/cr.2013.110;;10.1186/1471-2105-11-587;;pmc3012676;;21118553;;pmc3444709;;22810491;;10.1007/s00401-012-1016-2;;pmc2944787;;20885785;;10.1371/journal.pgen.1001134;;10.1016/j.ccr.2009.12.020;;10.3410/f.718384247.793495043;;pmc2818769;;20129251;;pmc3672356;;10.1038/jid.2013.77;;23426136;;16777850;;10.1074/jbc.m508365200;;10.1093/nar/gkm476;;pmc1935018;;17584785;;pmc275443;;10.1093/emboj/cdg585;;14609956;;10.1371/journal.pone.0025040;;pmc3176788;;21949845;;pmc2223308;;10.1128/mcb.00771-07;;17967885,"Shames et al. PloS Medicine. 2006. 3(12):e486. (Year: 2006).;;Walter et al. Clin Cancer Res. 2012. 18(8):2360-2373. (Year: 2012).;;Tan et al. Carcinogenesis. 2002. 23(2):231-236. (Year: 2002).;;Brennan et al (2013) the somatic genomic landscape of glioblastoma. Cell. Oct. 10, 2013; 155(2):462-77.;;Esteller et al (2001) p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res. Apr. 1, 2001;61(7):2816-21.;;Jones et al (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet. Jun. 2002;3(6):415-28.;;Stupp et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. May 2009;10(5):459-66. doi: 10.1016/S1470-2045(09)70025-7. Epub Mar. 9, 2009.;;Noushmehr et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. May 18, 2010;17(5):510-22. doi: 10.1016/j.ccr.2010.03.017. Epub Apr. 15, 2010.;;Parsons et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science. Sep. 26, 2008;321 (5897):1807-12. doi: 10.1126/science.1164382. Epub Sep. 4, 2008.;;Maunakea et al (2010) Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature. Jul. 8, 2010;466(7303):253-7. doi: 10.1038/nature09165.;;Maunakea et al (2013) Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition. Cell Res. Nov. 2013;23(11):1256-69. doi: 10.1038/cr.2013.110. Epub Aug. 13, 2013.;;Du et al (2010) Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics. Nov. 30, 2010;11:587. doi: 10.1186/1471-2105-11-587.;;Bady et al (2012) MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. Oct. 2012;124(4):547-60. doi: 10.1007/s00401-012-1016-2. Epub Jul. 19, 2012.;;Illingworth et al (2010) Orphan CpG islands identify numerous conserved promoters in the mammalian genome. PLoS Genet. Sep. 23, 2010;6(9):e1001134. doi: 10.1371/journal.pgen.1001134.;;Verhaak et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized py abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. Jan. 19, 2010;17(1):98-110. doi: 10.1016/j.ccr.2009.12.020.;;Rogers et al (2013) Ectopic expression of Zmiz1 induces cutaneous squamous cell malignancies in a mouse model of cancer. J Invest Dermatol. Jul. 2013;133(7):1863-9. doi: 10.1038/jid.2013.77. Epub Feb. 20, 2013.;;Li et al (2006) The novel PIAS-like protein hZimp10 enhances Smad transcriptional activity. J Biol Chem. Aug. 18, 2006;281(33):23748-56. Epub Jun. 15, 2006.;;Lee et al (2007) The novel PIAS-like protein hZimp10 is a transcriptional co-activator of the p53 tumor suppressor. Nucleic Acids Res. 2007;35(13):4523-34. Epub Jun. 21, 2007.;;Sharma et al (2003) hZimp10 is an androgen receptor co-activator and forms a complex with SUMO-1 at replication foci. EMBO J. Nov. 17, 2003;22(22):6101-14.;;Li et al (2011) ZMIZ1 preferably enhances the transcriptional activity of androgen receptor with short polyglutamine tract. PLoS One. 2011;6(9):e25040. doi: 10.1371/journal.pone.0025040. Epub Sep. 20, 2011.;;Beliakoff et al (2008) The PIAS-like protein Zimp10 is essential for embryonic viability and proper vascular development. Mol Cell Biol. Jan. 2008;28(1):282-92. Epub Oct. 29, 2007.",ACTIVE
26,ES,T3,ES 2387094 T3,073-079-437-048-879,2012-09-13,2012,ES 05788432 T,2005-06-20,US 58122204 P;;US 2005/0021888 W,2004-06-18,Visualización de una infección con compuestos que se unen a timidina cinasa,"The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.",UNIV JOHNS HOPKINS,POMPER MARTIN G;;BETTEGOWDA CHETAN;;FOSS CATHERINE;;ZHOU SHIBIN;;KINZLER KENNETH;;VOGELSTEIN BERT,,https://lens.org/073-079-437-048-879,Granted Patent,no,0,0,22,22,0,A61K51/1241;;A61K51/1231;;A61K51/0491;;A61K51/1241;;A61K51/1231;;A61K51/0491,A61K49/00,,0,0,,,,ACTIVE
27,US,A1,US 2013/0064767 A1,125-343-183-831-023,2013-03-14,2013,US 201213596632 A,2012-08-28,US 201213596632 A;;US 62960708 A;;US 2005/0021888 W;;US 58122204 P,2004-06-18,IMAGING INFECTION WITH COMPOUNDS THAT BIND TO THYMIDINE KINASE,"The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.",POMPER MARTIN G;;BETTEGOWDA CHETAN;;FOSS CATHERINE;;ZHOU SHIBIN;;KINZLER KENNETH;;VOGELSTEIN BERT;;UNIV JOHNS HOPKINS,POMPER MARTIN G;;BETTEGOWDA CHETAN;;FOSS CATHERINE;;ZHOU SHIBIN;;KINZLER KENNETH;;VOGELSTEIN BERT,,https://lens.org/125-343-183-831-023,Patent Application,yes,0,1,22,22,4,A61K51/1241;;A61K51/1231;;A61K51/0491;;A61K51/1241;;A61K51/1231;;A61K51/0491,A61K49/00;;A61K51/04;;A61K49/04,424/1.73;;424/9.2,0,0,,,,INACTIVE
28,WO,A1,WO 2017/011440 A1,112-520-978-895-648,2017-01-19,2017,US 2016/0041862 W,2016-07-12,US 201562192424 P,2015-07-14,DETECTION OF TUMOR-DERIVED DNA IN CEREBROSPINAL FLUID,"As cell-free DNA from brain and spinal cord tumors cannot usually be detected in the blood, we assessed the cerebrospinal fluid (CSF) that bathes the CNS for tumor DNA, here termed CSF-tDNA. The results suggest that CSF-tDNA could be useful for the management of patients with primary tumors of the brain or spinal cord.",UNIV JOHNS HOPKINS,BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT;;WANG YUXUAN;;DIAZ LUIS;;PAPADOPOULOS NICKOLAS,,https://lens.org/112-520-978-895-648,Patent Application,yes,1,0,4,4,70,C12Q1/6886;;C12Q1/6886;;C12Q2600/156;;C12Q2600/156,C12Q1/68,,5,4,100-738-532-520-514;;044-419-519-646-22X;;090-571-144-401-684;;004-023-312-700-266,25605683;;pmc5412506;;10.1373/clinchem.2014.235457;;7726135;;10.1093/ajcp/103.4.404;;12873974;;10.1073/pnas.1511694112;;26195750;;pmc4534284,"PAN ET AL.: ""Brain tumor mutations detected in cerebral spinal fluid"", CLINICAL CHEMISTRY, vol. 61, no. 3, 20 January 2015 (2015-01-20), pages 514 - 522, XP055347118;;RHODES ET AL.: ""PCR-detection of tumor-derived p53 DNA in cerebrospinal fluid"", AMERICAN JOURNAL OF CLINICAL PATHOLOGY, vol. 103, no. 4, April 1995 (1995-04-01), pages 404 - 408, XP055347120;;WONG ET AL.: ""Detection of mitochondrial DNA mutations in the tumor and cerebrospinal fluid of medulloblastoma patients"", CANCER RESEARCH, vol. 63, no. 14, 15 July 2003 (2003-07-15), pages 3866 - 3871, XP055347124;;WANG ET AL.: ""Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord"", PNAS, vol. 112, no. 31, 20 July 2015 (2015-07-20), pages 9704 - 9709, XP055347126;;See also references of EP 3322824A4",PENDING
29,EP,A1,EP 3322824 A1,139-387-586-565-367,2018-05-23,2018,EP 16825025 A,2016-07-12,US 201562192424 P;;US 2016/0041862 W,2015-07-14,DETECTION OF TUMOR-DERIVED DNA IN CEREBROSPINAL FLUID,,UNIV JOHNS HOPKINS,BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT;;WANG YUXUAN;;DIAZ LUIS;;PAPADOPOULOS NICKOLAS,,https://lens.org/139-387-586-565-367,Patent Application,yes,0,0,4,4,70,C12Q1/6886;;C12Q1/6886;;C12Q2600/156;;C12Q2600/156,C12Q1/68,,0,0,,,,PENDING
30,US,B2,US 8273326 B2,000-367-496-509-426,2012-09-25,2012,US 62960705 A,2005-06-20,US 62960705 A;;US 58122204 P;;US 2005/0021888 W,2004-06-18,Imaging infection with compounds that bind to thymidine kinase,"The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.",POMPER MARTIN G;;BETTEGOWDA CHETAN;;FOSS CATHERINE;;ZHOU SHIBIN;;KINZLER KENNETH;;VOGELSTEIN BERT;;UNIV JOHNS HOPKINS,POMPER MARTIN G;;BETTEGOWDA CHETAN;;FOSS CATHERINE;;ZHOU SHIBIN;;KINZLER KENNETH;;VOGELSTEIN BERT,THE JOHNS HOPKINS UNIVERSITY (2011-08-31),https://lens.org/000-367-496-509-426,Granted Patent,yes,4,1,22,22,0,A61K51/1241;;A61K51/1231;;A61K51/0491;;A61K51/1241;;A61K51/1231;;A61K51/0491,A61K49/04;;A61K51/00,424/1.89;;424/1.73;;424/9.1;;424/9.2;;424/9.4,13,12,133-124-946-804-307;;003-185-048-086-636;;076-872-930-898-431;;039-901-395-841-545;;057-506-930-709-101;;133-124-946-804-307;;008-342-521-824-904;;008-342-521-824-904;;081-129-485-256-659;;064-339-043-730-471;;139-496-186-192-621;;027-340-028-343-63X,6742789;;10.1002/ana.410150607;;10.1016/s0168-3659(01)00340-6;;11489512;;pmc545851;;10.1073/pnas.0408861102;;15653773;;14513292;;10.1007/s00259-003-1269-z;;10.1021/jm010922s;;11708929;;6742789;;10.1002/ana.410150607;;10.1021/jm020827z;;12408716;;10.1021/jm020827z;;12408716;;10.1038/89991;;11433353;;10.1073/pnas.251543698;;11724950;;pmc64999;;10.1099/00221287-131-11-3091;;4093763;;10.1099/00221287-130-7-1863;;6381650,"Yuraka Saito et al. Diagnostic Imaging of Herpes Simplex Virus Encephaliitis Using a Radiolabeled Antiviral Drug: Autoradiographi Assessment in an animal moedl, Ann. Neurol 15, 548-558, 1984.;;J. Tjuvajev et al Salmoonella-based tumor targeted cancer therapy: tumor amplified protein expression therapy (TAPET) for diagnostic imaging, J. Control Release 74, 313-315, 2001.;;Chetan Bettegowda et al., ""Imaging bacterial infections with radiolabeled 1-2(2'-deoxy-2'-fluoro-B-D-arabinofuranosyl)-5-iodouracil"", PNAS, vol. 2, No. 4, Jan. 25, 2005, pp. 1145-1150.;;Win-Ping Deng et al., ""Non-invasive in vivo imaging with radiolabeled FIAU for monitoring cancer gene therapy using herpes simplex virus type 1 thymidien kinase and ganciclovir"", European Journal of Nuclear Medicine and Molecular Imaging, vol. 31, No. 1, Jan. 2004, pp. 99-109.;;Bozenna Golankiewicz et al., ""Fluorescent Tricyclic Analogues of Acyclovir and Ganciclovir, A Structure-Antiviral Activity Study"", J. Med. Chem., vol. 44 (2001), pp. 4284-4287.;;Saito Y et al., ""Diagnostic imaging of herpes simplex virus encephalitis using a radiolabeled antiviral drugs : autoradiographic assessmjent in an animal model"" Annals of Neurology vol. 15(6). Jun. 1984 pp. 548-558.;;Tomasz Goslinheki et al, ""Synthesis and Biological Activity of Strongly Fluorescent Tricyclic Analogues of Acyclovir and Ganciclovir"", J. Med. Chem., vol. 45, (2002), pp. 5052-5057.;;Bozenna Golankiewicz et al., ""Fluorescent Tricyclic Analogues of Acyclovir and Ganciclovir, A Structure-Antiviral Activity Study"", J. Med. Chem., vol. 44, (2001) pp. 4284-4287.;;Tomasz Goslinkski et al, ""Synthesis and Biological Activity of Strongly Fluorescent Tricyclic Analogues of Acyclovir and Ganciclovir"", J. Med. Chem., vol. 45, (2002) pp. 5052-5057.;;Bennett J.J., et al. ""Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer."" Nat Med. Jul. 2001;7(7):859-63.;;Dang L.H., et al. ""Combination bacteriolytic therapy for the treatment of experimental tumors."" Proc Natl Acad Sci U S A. Dec. 18, 2001;98(26):15155-60.;;Saito H., et al. ""Further studies on thymidine kinase: distribution pattern of the enzyme in bacteria."" J Gen Microbiol. Nov. 1985;131(11):3091-8.;;Saito H., et al. ""Thymidine kinase of bacteria: activity of the enzyme in actinomycetes and related organisms."" J Gen Microbiol. Jul. 1984;130(7):1863-70.",ACTIVE
31,US,A1,US 2016/0273050 A1,085-724-678-346-767,2016-09-22,2016,US 201615071800 A,2016-03-16,US 201615071800 A;;US 201562133714 P,2015-03-16,USE OF THE ZMIZ1 MARKER IN DIRECTING TREATMENT AND PREDICTING SURVIVAL IN CANCER,"The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions for treating cancer and predicting patient survival. In one embodiment, a method comprises (a) obtaining a biological sample from the patient; and (b) detecting hypermethylation of ZMIZ1 using primers that specifically bind to CpG island 139 at the alternative promoter of the ZMIZ1 gene.",UNIV JOHNS HOPKINS,MATHIOS DIMITRIOS;;LIM MICHAEL;;HA PATRICK;;BETTEGOWDA CHETAN;;HWANG TAEYOUNG;;PARK CHUL-KEE,THE JOHNS HOPKINS UNIVERSITY (2016-05-20),https://lens.org/085-724-678-346-767,Patent Application,yes,0,3,2,2,26,C12Q1/6886;;C12Q1/6886;;C12Q2600/118;;C12Q2600/118;;C12Q2600/154;;C12Q2600/154;;C12Q2600/158;;C12Q2600/158,C12Q1/68,,0,0,,,,ACTIVE
32,CA,A1,CA 2571346 A1,074-591-207-696-343,2006-01-05,2006,CA 2571346 A,2005-06-20,US 58122204 P;;US 2005/0021888 W,2004-06-18,IMAGING INFECTION WITH COMPOUNDS THAT BIND TO THYMIDINE KINASE,"The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.",UNIV JOHNS HOPKINS,BETTEGOWDA CHETAN;;POMPER MARTIN G;;FOSS CATHERINE;;VOGELSTEIN BERT;;KINZLER KENNETH;;ZHOU SHIBIN,,https://lens.org/074-591-207-696-343,Patent Application,no,0,0,22,22,0,A61K51/1241;;A61K51/1231;;A61K51/0491;;A61K51/1241;;A61K51/1231;;A61K51/0491,A61K49/00;;A61K51/00,,0,0,,,,INACTIVE
33,DK,T3,DK 1768704 T3,165-569-610-858-11X,2012-07-02,2012,DK 05788432 T,2005-06-20,US 58122204 P;;US 2005/0021888 W,2004-06-18,BILLEDDANNELSE AF INFEKTION MED FORBINDELSER DER BINDER TIL THYMIDINKINASE,"The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.",UNIV JOHNS HOPKINS,POMPER MARTIN G;;BETTEGOWDA CHETAN;;FOSS CATHERINE;;ZHOU SHIBIN;;KINZLER KENNETH;;VOGELSTEIN BERT,,https://lens.org/165-569-610-858-11X,Granted Patent,no,0,0,22,22,0,A61K51/1241;;A61K51/1231;;A61K51/0491;;A61K51/1241;;A61K51/1231;;A61K51/0491,A61K49/00,,0,0,,,,ACTIVE
34,EP,B1,EP 1768704 B1,021-873-328-496-842,2012-05-02,2012,EP 05788432 A,2005-06-20,US 2005/0021888 W;;US 58122204 P,2004-06-18,IMAGING INFECTION WITH COMPOUNDS THAT BIND TO THYMIDINE KINASE,"The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.",UNIV JOHNS HOPKINS,POMPER MARTIN G;;BETTEGOWDA CHETAN;;FOSS CATHERINE;;ZHOU SHIBIN;;KINZLER KENNETH;;VOGELSTEIN BERT,THE JOHNS HOPKINS UNIVERSITY (2012-01-18);;THE JOHN HOPKINS UNIVERSITY (2011-12-21),https://lens.org/021-873-328-496-842,Granted Patent,yes,0,0,22,22,0,A61K51/1241;;A61K51/1231;;A61K51/0491;;A61K51/1241;;A61K51/1231;;A61K51/0491,A61K49/00,,3,3,137-530-461-634-572;;051-434-145-979-44X;;133-124-946-804-307,10.1128/jb.185.9.2683-2686.2003;;12700245;;pmc154404;;11752416;;pmc64926;;10.1073/pnas.261606598;;6742789;;10.1002/ana.410150607,"CHAKRABARTY A.M.: ""Microorganisms and cancer: quest for a therapy."", May 2003, JOURNAL OF BACTERIOLOGY MAY 2003 LNKD- PUBMED:12700245, VOL. 185, NR. 9, PAGE(S) 2683 - 2686, ISSN: 0021-9193;;JAIN R.K. ET AL: ""Can engineered bacteria help control cancer?"", 18 December 2001, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 18 DEC 2001 LNKD- PUBMED:11752416, VOL. 98, NR. 26, PAGE(S) 14748 - 14750, ISSN: 0027-8424;;SAITO Y. ET AL: ""Diagnostic imaging of herpes simplex virus encephalitis using a radiolabeled antiviral drug: autoradiographic assessment in an animal model."", June 1984, ANNALS OF NEUROLOGY JUN 1984 LNKD- PUBMED:6742789, VOL. 15, NR. 6, PAGE(S) 548 - 558, ISSN: 0364-5134",ACTIVE
35,WO,A3,WO 2006/002142 A3,067-102-224-349-526,2006-05-04,2006,US 2005/0021888 W,2005-06-20,US 58122204 P,2004-06-18,IMAGING INFECTION WITH COMPOUNDS THAT BIND TO THYMIDINE KINASE,"The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.",UNIV JOHNS HOPKINS;;POMPER MARTIN G;;BETTEGOWDA CHETAN;;FOSS CATHERINE;;ZHOU SHIBIN;;KINZLER KENNETH;;VOGELSTEIN BERT,POMPER MARTIN G;;BETTEGOWDA CHETAN;;FOSS CATHERINE;;ZHOU SHIBIN;;KINZLER KENNETH;;VOGELSTEIN BERT,,https://lens.org/067-102-224-349-526,Search Report,yes,4,0,22,22,0,A61K51/1241;;A61K51/1231;;A61K51/0491;;A61K51/1241;;A61K51/1231;;A61K51/0491,A61K49/00;;A61K51/00,,4,4,076-872-930-898-431;;039-901-395-841-545;;057-506-930-709-101;;008-342-521-824-904,pmc545851;;10.1073/pnas.0408861102;;15653773;;14513292;;10.1007/s00259-003-1269-z;;10.1021/jm010922s;;11708929;;10.1021/jm020827z;;12408716,"BETTEGOWDA C. ET AL.: ""Imaging bacterial infections with radiolabelled 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodouracil"", PNAS, vol. 102, no. 4, 25 January 2005 (2005-01-25), pages 1145 - 1150, XP002356266;;DENG, W-P. ET AL.: ""Non-invasive in vivo imaging with radiolabelled FIAU for monitoring cancer gene therapy using herpes simplex virus type 1 kthymidine kinase and ganciclovir"", EUR. J. NUCL. MED. MOL. IMAGING, vol. 31, no. 1, January 2004 (2004-01-01), pages 99 - 109, XP002356281;;GOLANKIEWICZ B ET AL: ""FLUORESCENT TRICYCLIC ANALOGUES OF ACYCLOVIR AND GANCICLOVIR. A STRUCTURE-ANTIVIRAL ACTIVITY STUDY"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 44, 2001, pages 4284 - 4287, XP001119790, ISSN: 0022-2623;;GOSLINSKI T ET AL.: ""Synthesis and biological activity of strongly fluoroescent tricyclic analogues of acyclovir and ganciclovir"", J. MED. CHEM., vol. 45, no. 1, 2002, pages 5052 - 5057, XP002356282",PENDING
36,JP,A,JP 2013049673 A,111-281-085-037-361,2013-03-14,2013,JP 2012204156 A,2012-09-18,US 58122204 P,2004-06-18,IMAGING INFECTION WITH COMPOUND THAT BINDS TO THYMIDINE KINASE,"PROBLEM TO BE SOLVED: To provide an imaging agent for detecting bacterial infection in mammals.SOLUTION: There is provided the imaging agent containing a labeled nucleoside analog for detecting bacterial infection in mammals. The nucleotide analog is preferably selected from the group consisting of: 2'-fluoro-2'-deoxy-1-β-D-arabinofuranosyl-5-iodo-uracil (FIAU), 9-(4-fluoro-3-[hydroxymethyl]butyl)guanine (FHBG), 1-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)thymine (FMAU), and 2'-fluoro-2'-deoxy-1-β-D-arabinofuranosyl-5-ethyl-uracil (FEAU).",UNIV JOHNS HOPKINS,POMPER MARTIN G;;BETTEGOWDA CHETAN;;FOSS CATHERINE;;ZHOU SHIBIN;;KINZLER KENNETH;;VOGELSTEIN BERT,,https://lens.org/111-281-085-037-361,Patent Application,no,0,0,22,22,4,A61K51/1241;;A61K51/1231;;A61K51/0491;;A61K51/1241;;A61K51/1231;;A61K51/0491,A61K49/00;;A61K51/00;;G01T1/161,,4,0,,,"JPN6011031082; Ａｎｎａｌｓ ｏｆ Ｎｅｕｒｏｌｏｇｙ Ｖｏｌ．１５， Ｎｏ．６, 1984, ｐ．５４８-５５８;;JPN6011031084; Ｎａｔｕｒｅ Ｍｅｄｉｃｉｎｅ Ｖｏｌ．７， Ｎｏ．７, 2001, ｐ．８５９-８６３;;JPN6011031087; Ｊｏｕｒｎａｌ ｏｆ Ｇｅｎｅｒａｌ Ｍｉｃｒｏｂｉｏｌｏｇｙ Ｖｏｌ．１３０， Ｎｏ．７, 1984, ｐ．１８６３-１８７０;;JPN6011031089; Ｊｏｕｒｎａｌ ｏｆ Ｇｅｎｅｒａｌ Ｍｉｃｒｏｂｉｏｌｏｇｙ Ｖｏｌ．１３１， Ｎｏ．１１, 1985, ｐ．３０９１-３０９８",PENDING
37,EP,A2,EP 1768704 A2,159-426-448-229-140,2007-04-04,2007,EP 05788432 A,2005-06-20,US 2005/0021888 W;;US 58122204 P,2004-06-18,IMAGING INFECTION WITH COMPOUNDS THAT BIND TO THYMIDINE KINASE,"The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.",UNIV JOHNS HOPKINS,POMPER MARTIN G;;BETTEGOWDA CHETAN;;FOSS CATHERINE;;ZHOU SHIBIN;;KINZLER KENNETH;;VOGELSTEIN BERT,THE JOHNS HOPKINS UNIVERSITY (2012-01-18);;THE JOHN HOPKINS UNIVERSITY (2011-12-21),https://lens.org/159-426-448-229-140,Patent Application,yes,0,0,22,22,0,A61K51/1241;;A61K51/1231;;A61K51/0491;;A61K51/1241;;A61K51/1231;;A61K51/0491,A61K49/00,,0,0,,,,ACTIVE
38,AU,A1,AU 2005/258042 A1,018-138-717-700-158,2006-01-05,2006,AU 2005/258042 A,2005-06-20,US 58122204 P;;US 2005/0021888 W,2004-06-18,Imaging infection with compounds that bind to thymidine kinase,"The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.",UNIV JOHNS HOPKINS,FOSS CATHERINE;;POMPER MARTIN G;;KINZLER KENNETH;;BETTEGOWDA CHETAN;;VOGELSTEIN BERT;;ZHOU SHIBIN,,https://lens.org/018-138-717-700-158,Patent Application,no,0,0,22,22,0,A61K51/1241;;A61K51/1231;;A61K51/0491;;A61K51/1241;;A61K51/1231;;A61K51/0491,A61K49/00,,0,0,,,,INACTIVE
39,WO,A2,WO 2006/002142 A2,087-879-441-430-927,2006-01-05,2006,US 2005/0021888 W,2005-06-20,US 58122204 P,2004-06-18,IMAGING INFECTION WITH COMPOUNDS THAT BIND TO THYMIDINE KINASE,"The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.",UNIV JOHNS HOPKINS;;POMPER MARTIN G;;BETTEGOWDA CHETAN;;FOSS CATHERINE;;ZHOU SHIBIN;;KINZLER KENNETH;;VOGELSTEIN BERT,POMPER MARTIN G;;BETTEGOWDA CHETAN;;FOSS CATHERINE;;ZHOU SHIBIN;;KINZLER KENNETH;;VOGELSTEIN BERT,,https://lens.org/087-879-441-430-927,Patent Application,yes,3,4,22,22,0,A61K51/1241;;A61K51/1231;;A61K51/0491;;A61K51/1241;;A61K51/1231;;A61K51/0491,A61K49/00,,6,4,039-901-395-841-545;;057-506-930-709-101;;008-342-521-824-904;;133-124-946-804-307,14513292;;10.1007/s00259-003-1269-z;;10.1021/jm010922s;;11708929;;10.1021/jm020827z;;12408716;;6742789;;10.1002/ana.410150607,"DENG W.-P. ET AL.: ""Non-invasive in vivo imaging with radiolabelled FIAU for monitoring cancer gene therapy using herpes simplex virus type 1 k thymidine kinase and ganciclovir"", EUR. J. NUCL. MED. MOL. IMAGING, vol. 31, no. 1, January 2004 (2004-01-01), pages 99 - 109;;GOLANKIEWICZ B. ET AL.: ""Journal of Medicinal Chemistry"", vol. 44, 2001, AMERICAN CHEMICAL SOCIETY, article ""Fluorescent Tricyclic Analogues of Acyclovir and Ganciclovir. A Structure-Antiviral Activity Study"", pages: 4284 - 4287;;GOSLINSKI T. ET AL.: ""Synthesis and Biological Activity of Strongly Fluorescent Tricyclic Analogues of Acyclovir and Ganciclovir"", J. MED. CHEM., vol. 45, no. 1, 2002, pages 5052 - 5057;;SAITO Y. ET AL.: ""Diagnostic Imaging of Herpes Simplex Virus Encephalitis Using a Radiolabelled Antiviral Drug: Autoradiographic Assessment in an Animal Model"", ANN. NEUROL., vol. 15, 1984, pages 548 - 558;;BETTEGOWDA ET AL., PNAS, vol. 102, no. 1, 2005, pages 145 - 50;;""Remington's Pharmaceutical Sciences"", MACK PUBLISHING COMPANY",PENDING
40,US,A1,US 2009/0010844 A1,177-372-023-506-327,2009-01-08,2009,US 62960705 A,2005-06-20,US 62960705 A;;US 58122204 P;;US 2005/0021888 W,2004-06-18,Imaging Infection With Compounds That Bind to Thymidine Kinase,"The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.",UNIV JOHNS HOPKINS,POMPER MARTIN G;;BETTEGOWDA CHETAN;;FOSS CATHERINE;;ZHOU SHIBIN;;KINZLER KENNETH;;VOGELSTEIN BERT,THE JOHNS HOPKINS UNIVERSITY (2011-08-31),https://lens.org/177-372-023-506-327,Patent Application,yes,5,3,22,22,0,A61K51/1241;;A61K51/1231;;A61K51/0491;;A61K51/1241;;A61K51/1231;;A61K51/0491,A61K49/04;;A61K51/06;;A61K101/02,424/1.73;;424/9.2;;424/9.44,0,0,,,,ACTIVE
41,EP,B9,EP 1768704 B9,023-015-189-491-487,2013-01-02,2013,EP 05788432 A,2005-06-20,US 2005/0021888 W;;US 58122204 P,2004-06-18,IMAGING INFECTION WITH COMPOUNDS THAT BIND TO THYMIDINE KINASE,"The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.",UNIV JOHNS HOPKINS,POMPER MARTIN G;;BETTEGOWDA CHETAN;;FOSS CATHERINE;;ZHOU SHIBIN;;KINZLER KENNETH;;VOGELSTEIN BERT,THE JOHNS HOPKINS UNIVERSITY (2012-01-18);;THE JOHN HOPKINS UNIVERSITY (2011-12-21),https://lens.org/023-015-189-491-487,Amended Patent,yes,4,0,22,22,0,A61K51/1241;;A61K51/1231;;A61K51/0491;;A61K51/1241;;A61K51/1231;;A61K51/0491,A61K49/00,,7,0,,,"BETTEGOWDA C. ET AL.: ""Imaging bacterial infections with radiolabelled 1-(2'-deoxy-2'-fluoro-beta-D-arabinofurano syl)-5-iodouracil"" PNAS, vol. 102, no. 4, 25 January 2005 (2005-01-25), pages 1145-1150, XP002356266;;DENG, W-P. ET AL.: ""Non-invasive in vivo imaging with radiolabelled FIAU for monitoring cancer gene therapy using herpes simplex virus type 1 kthymidine kinase and ganciclovir"" EUR. J. NUCL. MED. MOL. IMAGING, vol. 31, no. 1, January 2004 (2004-01), pages 99-109, XP002356281;;GOLANKIEWICZ B ET AL: ""FLUORESCENT TRICYCLIC ANALOGUES OF ACYCLOVIR AND GANCICLOVIR. A STRUCTURE-ANTIVIRAL ACTIVITY STUDY"" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 44, 2001, pages 4284-4287, XP001119790 ISSN: 0022-2623;;GOSLINSKI T ET AL.: ""Synthesis and biological activity of strongly fluoroescent tricyclic analogues of acyclovir and ganciclovir"" J. MED. CHEM., vol. 45, no. 1, 2002, pages 5052-5057, XP002356282;;CHAKRABARTY A.M.: 'Microorganisms and cancer: quest for a therapy.', May 2003, JOURNAL OF BACTERIOLOGY MAY 2003 LNKD- PUBMED:12700245, VOL. 185, NR. 9, PAGE(S) 2683 - 2686, ISSN 0021-9193;;JAIN R.K. ET AL: 'Can engineered bacteria help control cancer?', 18 December 2001, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 18 DEC 2001 LNKD- PUBMED:11752416, VOL. 98, NR. 26, PAGE(S) 14748 - 14750, ISSN 0027-8424;;SAITO Y. ET AL: 'Diagnostic imaging of herpes simplex virus encephalitis using a radiolabeled antiviral drug: autoradiographic assessment in an animal model.', June 1984, ANNALS OF NEUROLOGY JUN 1984 LNKD- PUBMED:6742789, VOL. 15, NR. 6, PAGE(S) 548 - 558, ISSN 0364-5134",ACTIVE
42,EP,A4,EP 3322824 A4,040-310-218-682-679,2019-01-23,2019,EP 16825025 A,2016-07-12,US 201562192424 P;;US 2016/0041862 W,2015-07-14,DETECTION OF TUMOR-DERIVED DNA IN CEREBROSPINAL FLUID,,UNIV JOHNS HOPKINS,BETTEGOWDA CHETAN;;KINZLER KENNETH W;;VOGELSTEIN BERT;;WANG YUXUAN;;DIAZ LUIS;;PAPADOPOULOS NICKOLAS,,https://lens.org/040-310-218-682-679,Search Report,no,2,0,4,4,0,C12Q2600/156;;C12Q1/6886;;C12Q2600/156;;C12Q1/6886,C12Q1/6886,,3,2,057-077-509-106-056;;066-389-196-544-635,23881452;;10.1038/mtna.2013.28;;pmc3732870;;10.1158/1538-7445.am2015-620,"WALTER W CHEN ET AL: ""BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles"", MOLECULAR THERAPY-NUCLEIC ACIDS, vol. 2, 1 January 2013 (2013-01-01), pages e109, XP055532990, ISSN: 2162-2531, DOI: 10.1038/mtna.2013.28;;MELANIE GEPHART: ""Abstract 620: Monitoring leptomeningeal metastasis treatment response using tumor cell free DNA from cerebral spinal fluid | Proceedings: AACR 106th Annual Meeting 2015"", CANCER RESEARCH, 22 April 2015 (2015-04-22), XP055534376, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/75/15_Supplement/620> [retrieved on 20181214];;See also references of WO 2017011440A1",PENDING
43,AU,B2,AU 2005/258042 B2,106-308-854-667-138,2010-11-11,2010,AU 2005/258042 A,2005-06-20,US 58122204 P;;US 2005/0021888 W,2004-06-18,Imaging infection with compounds that bind to thymidine kinase,"The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.",UNIV JOHNS HOPKINS,FOSS CATHERINE;;POMPER MARTIN G;;KINZLER KENNETH;;BETTEGOWDA CHETAN;;VOGELSTEIN BERT;;ZHOU SHIBIN,,https://lens.org/106-308-854-667-138,Granted Patent,no,3,0,22,22,0,A61K51/1241;;A61K51/1231;;A61K51/0491;;A61K51/1241;;A61K51/1231;;A61K51/0491,A61K49/00,,0,0,,,,INACTIVE
44,AU,A1,AU 2017/203206 A1,109-589-074-085-922,2017-06-01,2017,AU 2017/203206 A,2017-05-12,AU 2017/203206 A;;AU 2013/338393 A;;US 201261719942 P;;US 2013/0065342 W,2012-10-29,Papanicolaou test for ovarian and endometrial cancers,"The recently developed liquid-based Papanicolaou (Pap) smear allows not only cytologic evaluation but also collection of DNA for detection of HPV, the causative agent of cervical cancer. We tested these samples to detect somatic mutations present in rare tumor cells 5 that might accumulate in the cervix once shed from endometrial and ovarian cancers. A panel of commonly mutated genes in endometrial and ovarian cancers was assembled and used to identify mutations in all 46 endometrial or cervical cancer tissue samples. We were able also able to identify the same mutations in the DNA from liquid Pap smears in 100% of endometrial cancers (24 of 24) and in 41% of ovarian cancers (9 of 22). We developed a sequence-based method to 10 query mutations in 12 genes in a single liquid Pap smear without prior knowledge of the tumor's genotype.",UNIV JOHNS HOPKINS,KINDE ISAAC;;KINZLER KENNETH W;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;DIAZ LUIS;;BETTEGOWDA CHETAN;;WANG YUXUAN,,https://lens.org/109-589-074-085-922,Patent Application,no,0,0,23,23,0,C12Q1/6886;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;C12Q1/6886;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q1/6851;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158,G01N33/574;;C12Q1/68;;G01N33/68,,0,0,,,,ACTIVE
45,ES,T3,ES 2886507 T3,024-454-080-088-476,2021-12-20,2021,ES 18193794 T,2013-10-17,US 201261719942 P,2012-10-29,Prueba de Papanicolaou para cánceres de ovario y de endometrio,"Procedimiento que comprende: poner a prueba una muestra de un sujeto humano para un cambio genético o epigenético en uno o más ácidos nucleicos mutados en una neoplasia o un cáncer de endometrio, trompas de Falopio u ovario, en el que la etapa de prueba se realiza aumentando la sensibilidad de instrumentos de secuenciación masiva en paralelo con una técnica de reducción de errores que incluye: (i) asignación de un identificador único (UID) a cada molécula modelo para formar moléculas modelo con código de barras; y (ii) secuenciación redundante de las moléculas modelo con código de barras, y en la que la muestra: (a) comprende células o fragmentos de endometrio, trompas de Falopio y/u ovario, y (b) es una muestra endocervical.",UNIV JOHNS HOPKINS,KINDE ISAAC;;KINZLER KENNETH;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;DIAZ LUIS;;BETTEGOWDA CHETAN;;WANG YUXUAN,,https://lens.org/024-454-080-088-476,Granted Patent,no,0,0,23,23,0,C12Q1/6886;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;C12Q1/6886;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q1/6851;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158,C12Q1/6886,,0,0,,,,ACTIVE
46,EP,A1,EP 3447495 A1,171-426-760-500-913,2019-02-27,2019,EP 18193794 A,2013-10-17,US 201261719942 P;;EP 13851273 A;;US 2013/0065342 W,2012-10-29,PAPANICOLAOU TEST FOR OVARIAN AND ENDOMETRIAL CANCERS,"The recently developed liquid-based Papanicolaou (Pap) smear allows not only cytologic evaluation but also collection of DNA for detection of HPV, the causative agent of cervical cancer. We tested these samples to detect somatic mutations present in rare tumor cells that might accumulate in the cervix once shed from endometrial and ovarian cancers. A panel of commonly mutated genes in endometrial and ovarian cancers was assembled and used to identify mutations in all 46 endometrial or cervical cancer tissue samples. We were able also able to identify the same mutations in the DNA from liquid Pap smears in 100% of endometrial cancers (24 of 24) and in 41% of ovarian cancers (9 of 22). We developed a sequence-based method to query mutations in 12 genes in a single liquid Pap smear without prior knowledge of the tumor's genotype.",UNIV JOHNS HOPKINS,KINDE ISAAC;;KINZLER KENNETH W;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;DIAZ LUIS;;BETTEGOWDA CHETAN;;WANG YUXUAN,,https://lens.org/171-426-760-500-913,Patent Application,yes,1,0,23,23,191,C12Q1/6886;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;C12Q1/6886;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q1/6851;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158,G01N33/574;;C12Q1/68;;G01N33/68,,52,47,008-893-435-882-252;;073-689-825-793-510;;040-265-210-951-520;;132-706-623-273-568;;015-608-990-439-67X;;145-193-038-744-016;;039-539-876-524-082;;064-852-228-426-035;;025-724-319-742-702;;083-594-170-632-636;;055-279-747-159-738;;023-055-679-554-969;;030-127-793-502-971;;099-378-356-189-825;;019-690-569-075-391;;077-134-947-165-690;;039-767-448-431-669;;023-866-085-896-346;;013-766-679-756-841;;025-090-666-694-854;;029-992-013-913-018;;014-072-831-490-33X;;018-849-226-711-208;;061-247-339-324-539;;075-365-727-231-866;;073-689-825-793-510;;032-718-950-332-134;;114-510-755-626-735;;036-706-039-016-917;;002-841-897-235-524;;038-254-580-060-877;;040-265-210-951-520;;132-706-623-273-568;;182-722-766-027-448;;089-020-090-771-471;;074-428-992-955-039;;004-003-508-190-140;;029-880-616-965-814;;023-026-304-398-119;;006-303-913-554-013;;124-678-289-264-889;;058-218-878-573-074;;009-005-505-313-388;;071-615-061-904-916;;040-798-594-126-918;;014-951-949-943-585;;033-734-224-976-468,10.1016/j.rigapp.2006.05.009;;pmc3163504;;10.1038/nature10166;;21720365;;10.1093/jnci/djs345;;pmc3692380;;22923510;;21586637;;pmc3111315;;10.1073/pnas.1105422108;;10.1111/j.1365-2303.2008.00621.x;;19207308;;10.1097/00001888-194307000-00029;;10.1093/annonc/mdp471;;20176693;;pmc2826099;;22752881;;10.1002/ijc.27711;;21351269;;10.1002/ijc.25516;;22261450;;10.1309/ajcplfbk1a2xjdqi;;10.3109/00016349109007922;;1785276;;10.1097/00004347-199301000-00005;;8418076;;10.7326/0003-4819-121-2-199407150-00009;;8017726;;10.1177/172460089801300411;;10228907;;21642681;;10.1001/jama.2011.766;;15738045;;10.1097/00006250-200503000-00049;;19305319;;10.1097/aog.0b013e31819cda77;;pmc2728067;;15756773;;10.1097/00006250-200212000-00045;;10.1016/s0029-7844(02)02630-3;;12468197;;17003399;;10.1001/jama.296.12.1507;;21537713;;10.1590/s0104-42302011000200024;;10.1016/j.ajog.2004.01.043;;15295350;;10.1097/01.aog.0000152350.10875.02;;15738014;;10.1097/01.aog.0000218705.87329.4a;;16738153;;10.1067/mob.2001.108995;;11174481;;pmc3163504;;10.1038/nature10166;;21720365;;20826764;;pmc3076894;;10.1126/science.1196333;;22102435;;pmc3503448;;10.1002/path.3967;;10.1093/nar/gkq929;;20952405;;pmc3013785;;10.1111/j.1399-0004.2008.01125.x;;19215248;;10.1158/0008-5472.can-05-2620;;16322209;;10.1093/jnci/djs345;;pmc3692380;;22923510;;21586637;;pmc3111315;;10.1073/pnas.1105422108;;18746585;;pmc1780413;;10.1038/nm1087;;15286780;;10.1016/s0889-8545(00)80018-2;;10857117;;10.1016/j.ygyno.2012.01.003;;22245711;;10.1200/jco.2002.20.5.1248;;10.1200/jco.20.5.1248;;11870167;;17942871;;10.1056/nejmoa071430;;17942872;;10.1056/nejmoa073204;;19367689;;10.1016/j.ijgo.2009.02.012;;17909045;;10.1158/0008-5472.can-07-0605;;10.1126/scitranslmed.3002543;;pmc3160649;;21775669;;pmc3260819;;21399237;;10.18632/oncotarget.235;;10547847;;10.1385/1-59259-192-2:365;;15087669;;10.1097/00000478-200404000-00009;;pmc2361201;;10.1038/sj.bjc.6603012;;16495918,"ELMASRY K ET AL: ""Genetic mutations in gynaecological cancers"", REVIEWS IN GYNAECOLOGICAL AND PERINATAL PRACTICE, ELSEVIER, KIDLINGTON, GB, vol. 6, no. 3-4, 1 September 2006 (2006-09-01), pages 115 - 125, XP024920562, ISSN: 1871-2320, [retrieved on 20060901], DOI: 10.1016/J.RIGAPP.2006.05.009;;D. BELL ET AL: ""Integrated genomic analyses of ovarian carcinoma"", NATURE, vol. 474, no. 7353, 1 June 2011 (2011-06-01), pages 609 - 615, XP055086944, ISSN: 0028-0836, DOI: 10.1038/nature10166;;E. KUHN ET AL: ""Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses"", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 104, no. 19, 23 August 2012 (2012-08-23), GB, pages 1503 - 1513, XP055275023, ISSN: 0027-8874, DOI: 10.1093/jnci/djs345;;I. KINDE ET AL: ""Detection and quantification of rare mutations with massively parallel sequencing"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 23, 17 May 2011 (2011-05-17), pages 9530 - 9535, XP055164202, ISSN: 0027-8424, DOI: 10.1073/pnas.1105422108;;C. PATEL ET AL: ""Endometrial carcinoma detected with SurePath liquid-based cervical cytology: comparison with conventional cytology"", CYTOPATHOLOGY, vol. 20, no. 6, 1 December 2009 (2009-12-01), GB, pages 380 - 387, XP055274130, ISSN: 0956-5507, DOI: 10.1111/j.1365-2303.2008.00621.x;;GEORGIOS PAPANICOLAOU, DIAGNOSIS OF UTERINE CANCER BY THE VAGINAL SMEAR, 1943;;M. ARBYN; A. ANTTILA; J. JORDAN; G. RONCO; U. SCHENCK; N. SEGNAN; H. WIENER; A. HERBERT; L. VON KARSA: ""European Guidelines for Quality Assurance in Cervical Cancer Screening"", ANN ONCOL, vol. 21, 2010, pages 448 - 458;;R. M. DEMAY: ""Practical principles of cytopathology."", 2010, ASCP PRESS, pages: 402;;F. BRAY; J. S. REN; E. MASUYER; J. FERLAY: ""Global estimates of cancer prevalence for 27 sites in the adult population in 2008"", INT J CANCER, 2012;;J. FERLAY; H.R. SHIN; F. BRAY; D. FORMAN; C. MATHERS; D.M. PARKIN: ""GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide"", IARC CANCERBASE, 2010;;S. B. SAMS; H. S. CURRENS; S. S. RAAB: ""Liquid-based Papanicolaou tests in endometrial carcinoma diagnosis. Performance, error root cause analysis, and quality improvement"", AM J CLIN PATHOL, vol. 137, 2012, pages 248 - 254;;P. SMITH; O. BAKOS; G. HEIMER; U. ULMSTEN: ""Transvaginal ultrasound for identifying endometrial abnormality"", ACTA OBSTET GYNECOL SCAND, vol. 70, 1991, pages 591 - 594;;H. MITCHELL; G. GILES; G. MEDLEY: ""Accuracy and survival benefit of cytological prediction of endometrial carcinoma on routine cervical smears"", INT J GYNECOL PATHOL, vol. 12, 1993, pages 34 - 40;;K. J. CARLSON; S. J. SKATES; D. E. SINGER: ""Screening for ovarian cancer"", ANN INTERN MED, vol. 121, 1994, pages 124 - 132;;H. MEDEN; A. FATTAHI-MEIBODI: ""CA 125 in benign gynecological conditions"", INT J BIOL MARKERS, vol. 13, 1998, pages 231 - 237, XP008003111;;S. S. BUYS; E. PARTRIDGE; A. BLACK; C. C. JOHNSON; L. LAMERATO; C. ISAACS; D. J. REDING; R. T. GREENLEE; L. A. YOKOCHI; B. KESSEL: ""Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial"", JAMA, vol. 305, 2011, pages 2295 - 2303;;""ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational diabetes mellitus"", OBSTET GYNECOL, vol. 105, 2005, pages 675 - 685;;E. PARTRIDGE; A. R. KREIMER; R. T. GREENLEE; C. WILLIAMS; J. L. XU; T. R. CHURCH; B. KESSEL; C. C. JOHNSON; J. L. WEISSFELD; C. IS: ""Results from four rounds of ovarian cancer screening in a randomized trial"", OBSTET GYNECOL, vol. 113, 2009, pages 775 - 782;;""Detailed guide: ovarian cancer — can ovarian cancer be found early?"", AMERICAN CANCER SOCIETY, Retrieved from the Internet <URL:http://www.cancer.org/Cancer/OvarianCancer/DetailedGuide/ovarian-cancer-detection>;;""Screening for ovarian cancer: recommendation statement. U.S. Preventive Services Task Force"", AM FAM PHYSICIAN, vol. 71, 2005, pages 759 - 762;;""ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer"", OBSTET GYNECOL, vol. 100, 2002, pages 1413 - 1416;;NATIONAL COMPREHENSIVE CANCER NETWORK PRACTICE GUIDELINES IN ONCOLOGY: OVARIAN CANCER AND GENETIC SCREENING, Retrieved from the Internet <URL:http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf>;;N. M. LINDOR; G. M. PETERSEN; D. W. HADLEY; A. Y. KINNEY; S. MIESFELDT; K. H. LU; P. LYNCH; W. BURKE; N. PRESS: ""Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review"", JAMA, vol. 296, 2006, pages 1507 - 1517;;J. P. MARQUES; L. B. COSTA; A. P. PINTO; A. F. LIMA; M. E. DUARTE; A. P. BARBOSA; P. L. MEDEIROS: ""Atypical glandular cells and cervical cancer: systematic review"", REV ASSOC MED BRAS, vol. 57, 2011, pages 234 - 238;;R. P. INSINGA; A. G. GLASS; B. B. RUSH: ""Diagnoses and outcomes in cervical cancer screening: a population-based study"", AM J OBSTET GYNECOL, vol. 191, 2004, pages 105 - 113, XP005690608, DOI: doi:10.1016/j.ajog.2004.01.043;;K. E. SHARPLESS; P. F. SCHNATZ; S. MANDAVILLI; J. F. GREENE; J. I. SOROSKY: ""Dysplasia associated with atypical glandular cells on cervical cytology"", OBSTET GYNECOL, vol. 105, 2005, pages 494 - 500;;C. P. DESIMONE; M. E. DAY; M. M. TOVAR; C. S. DIETRICH; M. L. EASTHAM; S. C. MODESITT: ""Rate of pathology from atypical glandular cell Pap tests classified by the Bethesda 2001 nomenclature"", OBSTET GYNECOL, vol. 107, 2006, pages 1285 - 1291;;C. S. GEIER; M. WILSON; W. CREASMAN: ""Clinical evaluation of atypical glandular cells of undetermined significance"", AM J OBSTET GYNECOL, vol. 184, 2001, pages 64 - 69, XP029484552, DOI: doi:10.1067/mob.2001.108995;;""Integrated genomic analyses of ovarian carcinoma"", NATURE, vol. 474, 2011, pages 609 - 615;;S. JONES; T. L. WANG; M. SHIH IE; T. L. MAO; K. NAKAYAMA; R. RODEN; R. GLAS; D. SLAMON; L. A. DIAZ, JR.; B. VOGELSTEIN: ""Frequent mutations of chromatin remodeling gene ARID 1 A in ovarian clear cell carcinoma"", SCIENCE, vol. 330, 2010, pages 228 - 231, XP055098629, DOI: doi:10.1126/science.1196333;;S. JONES; T. L. WANG; R. J. KURMAN; K. NAKAYAMA; V. E. VELCULESCU; B. VOGELSTEIN; K. W. KINZLER; N. PAPADOPOULOS; M. SHIH IE: ""Low-grade serous carcinomas of the ovary contain very few point mutations"", J PATHOL, vol. 226, 2012, pages 413 - 420;;S. A. FORBES; N. BINDAL; S. BAMFORD; C. COLE; C. Y. KOK; D. BEARE; M. JIA; R. SHEPHERD; K. LEUNG; A. MENZIES: ""COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer"", NUCLEIC ACIDS RES, vol. 39, 2011, pages D945 - 950;;E. BARROW; L. ROBINSON; W. ALDUAIJ; A. SHENTON; T. CLANCY; F. LALLOO; J. HILL; D. G. EVANS: ""Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations"", CLIN GENET, vol. 75, 2009, pages 141 - 149;;K. ODA; D. STOKOE; Y. TAKETANI; F. MCCORMICK: ""High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma"", CANCER RES, vol. 65, 2005, pages 10669 - 10673, XP055268548, DOI: doi:10.1158/0008-5472.CAN-05-2620;;E. KUHN; R. C. WU; B. GUAN; G. WU; J. ZHANG; Y. WANG; L. SONG; X. YUAN; L. WEI; R. B. RODEN: ""Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses"", J NATL CANCER INST, 2012;;I. KINDE; J. WU; N. PAPADOPOULOS; K. W. KINZLER; B. VOGELSTEIN: ""Detection and quantification of rare mutations with massively parallel sequencing"", PROC NATL ACAD SCI U S A, vol. 108, 2011, pages 9530 - 9535, XP055164202, DOI: doi:10.1073/pnas.1105422108;;H. F. TRAUT; G. N. PAPANICOLAOU: ""Cancer of the Uterus: The Vaginal Smear in Its Diagnosis"", CAL WEST MED, vol. 59, 1943, pages 121 - 122;;B. VOGELSTEIN; K. W. KINZLER: ""Cancer genes and the pathways they control"", NAT MED, vol. 10, 2004, pages 789 - 799, XP002552463, DOI: doi:10.1038/nm1087;;J. M. COOPER; M. L. ERICKSON: ""Endometrial sampling techniques in the diagnosis of abnormal uterine bleeding"", OBSTET GYNECOL CLIN NORTH AM, vol. 27, 2000, pages 235 - 244;;C. C. GUNDERSON; A. N. FADER; K. A. CARSON; R. E. BRISTOW: ""Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review"", GYNECOL ONCOL, vol. 125, 2012, pages 477 - 482;;R. E. BRISTOW; R. S. TOMACRUZ; D. K. ARMSTRONG; E. L. TRIMBLE; F. J. MONTZ: ""Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis"", J CLIN ONCOL, vol. 20, 2002, pages 1248 - 1259;;M. H. MAYRAND; E. DUARTE-FRANCO; I. RODRIGUES; S. D. WALTER; J. HANLEY; A. FERENCZY; S. RATNAM; F. COUTLEE; E. L. FRANCO: ""Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer"", NENGL J MED, vol. 357, 2007, pages 1579 - 1588;;P. NAUCLER; W. RYD; S. TORNBERG; A. STRAND; G. WADELL; K. ELFGREN; T. RADBERG; B. STRANDER; B. JOHANSSON; O. FORSLUND: ""Human papillomavirus and Papanicolaou tests to screen for cervical cancer"", N ENGL J MED, vol. 357, 2007, pages 1589 - 1597;;S. PECORELLI: ""Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium"", INT J GYNAECOL OBSTET, vol. 105, 2009, pages 103 - 104, XP026038230, DOI: doi:10.1016/j.ijgo.2009.02.012;;C. RAGO; D. L. HUSO; F. DIEHL; B. KARIM; G. LIU; N. PAPADOPOULOS; Y. SAMUELS; V. E. VELCULESCU; B. VOGELSTEIN; K. W. KINZLER: ""Serial assessment of human tumor burdens in mice by the analysis of circulating DNA"", CANCER RES, vol. 67, 2007, pages 9364 - 9370, XP055288572, DOI: doi:10.1158/0008-5472.CAN-07-0605;;J. WU; H. MATTHAEI; A. MAITRA; M. DAL MOLIN; L. D. WOOD; J. R. ESHLEMAN; M. GOGGINS; M. I. CANTO; R. D. SCHULICK; B. H. EDIL: ""Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development"", SCI TRANSL MED, vol. 3, 2011, pages 92ra66;;J. HE; J. WU; Y. JIAO; N. WAGNER-JOHNSTON; R. F. AMBINDER; L. A. DIAZ, JR.; K. W. KINZLER; B. VOGELSTEIN; N. PAPADOPOULOS: ""IgH gene rearrangements as plasma biomarkers in Non- Hodgkin's lymphoma patients"", ONCOTARGET, vol. 2, 2011, pages 178 - 185, XP055247543, DOI: doi:10.18632/oncotarget.235;;S. ROZEN; H. SKALETSKY: ""Primer3 on the WWW for general users and for biologist programmers"", METHODS MOL, vol. 132, 2000, pages 365 - 386, XP002949676;;N. HOWLADER; A.M. NOONE; M. KRAPCHO; N. NEYMAN; R. AMINOU; S. F. ALTEKRUSE; C.L. KOSARY; J. RUHL; Z. TATALOVICH; H. CHO: ""SEER Cancer Statistics Review"", 2012, NATIONAL CANCER INSTITUTE, pages: 1975 - 2009;;A. MALPICA; M. T. DEAVERS; K. LU; D. C. BODURKA; E. N. ATKINSON; D. M. GERSHENSON; E. G. SILVA: ""Grading ovarian serous carcinoma using a two-tier system"", AM J SURG PATHOL, vol. 28, 2004, pages 496 - 504;;L.A.G. RIES; J.L. YOUNG; G.E. KEEL; M.P. EISNER; Y.D. LIN; M-J. HORNER: ""Patient and Tumor Characteristics"", 2007, NIH PUB. NO. 07-6215. NATIONAL CANCER INSTITUTE, article ""SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988-2001"";;C. A. HAMILTON; M. K. CHEUNG; K. OSANN; L. CHEN; N. N. TENG; T. A. LONGACRE; M. A. POWELL; M. R. HENDRICKSON; D. S. KAPP; J. K. CH: ""Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers"", BR J CANCER, vol. 94, 2006, pages 642 - 646",ACTIVE
47,AU,B2,AU 2013/338393 B2,056-135-368-797-987,2017-05-11,2017,AU 2013/338393 A,2013-10-17,US 201261719942 P;;US 2013/0065342 W,2012-10-29,Papanicolaou test for ovarian and endometrial cancers,"The recently developed liquid-based Papanicolaou (Pap) smear allows not only cytologic evaluation but also collection of DNA for detection of HPV, the causative agent of cervical cancer. We tested these samples to detect somatic mutations present in rare tumor cells that might accumulate in the cervix once shed from endometrial and ovarian cancers. A panel of commonly mutated genes in endometrial and ovarian cancers was assembled and used to identify mutations in all 46 endometrial or cervical cancer tissue samples. We were able also able to identify the same mutations in the DNA from liquid Pap smears in 100% of endometrial cancers (24 of 24) and in 41% of ovarian cancers (9 of 22). We developed a sequence-based method to query mutations in 12 genes in a single liquid Pap smear without prior knowledge of the tumor's genotype.",UNIV JOHNS HOPKINS,KINDE ISAAC;;KINZLER KENNETH W;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;DIAZ LUIS;;BETTEGOWDA CHETAN;;WANG YUXUAN,,https://lens.org/056-135-368-797-987,Granted Patent,no,1,0,23,23,0,C12Q1/6886;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;C12Q1/6886;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q1/6851;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158,G01N33/574;;C12Q1/68;;G01N33/68,,1,1,083-594-170-632-636,22261450;;10.1309/ajcplfbk1a2xjdqi,"Sams et al (2012) Am J Clin Pathol, vol. 137, pps 248-254",ACTIVE
48,CN,A,CN 109457030 A,091-219-217-538-432,2019-03-12,2019,CN 201811009217 A,2013-10-17,US 201261719942 P;;CN 201380068411 A,2012-10-29,Papanicolaou test for ovarian and endometrial cancers,"The invention relates to papanicolaou test for ovarian and endometrial cancers. The recently developed liquid-based Papanicolaou (Pap) smear allows not only cytologic evaluation but also collection ofDNA for detection of HPV, the causative agent of cervical cancer. We tested these samples to detect somatic mutations present in rare tumor cells that might accumulate in the cervix once shed from endometrial and ovarian cancers. A panel of commonly mutated genes in endometrial and ovarian cancers was assembled and used to identify mutations in all 46 endometrial or cervical cancer tissue samples. We were able also able to identify the same mutations in the DNA from liquid Pap smears in 100% of endometrial cancers (24 of 24) and in 41% of ovarian cancers (9 of 22). We developed a sequence-based method to query mutations in 12 genes in a single liquid Pap smear without prior knowledge of the tumor's genotype.",UNIV JOHNS HOPKINS,KINDE ISAAC;;KINZLER KENNETH W;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;DIAZ LUIS;;BETTEGOWDA CHETAN;;WANG YUXUAN,,https://lens.org/091-219-217-538-432,Patent Application,no,4,0,23,23,0,C12Q1/6886;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;C12Q1/6886;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q1/6851;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158,C12Q1/6886;;G01N33/574,,8,0,,,"BYRON SA等: ""FGFR2 mutations are rare across histologic subtypes of ovarian cancer."", 《GYNECOL ONCOL》;;ROBERT J KURMAN等: ""Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm"", 《HUM PATHOL》;;ELISABETTA KUHN等: ""Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses"", 《J NATL CANCER INST》;;KATSUTOSHI ODA等: ""High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma"", 《CANCER RES》;;BRYAN T HENNESSY等: ""Ovarian cancer"", 《LANCET》;;OGECHI N IKEDIOBI等: ""Mutation analysis of 24 known cancer genes in the NCI-60 cell line set"", 《MOL CANCER THER》;;D G HUNTSMAN等: ""MLL2, the second human homolog of the Drosophila trithorax gene, maps to 19q13.1 and is amplified in solid tumor cell lines"", 《ONCOGENE》;;张梅娟: ""液基细胞学检查在宫颈癌和子宫内膜癌筛查中的应用研究"", 《中国优秀硕士学位论文全文数据库》",ACTIVE
49,CA,C,CA 2889937 C,153-313-956-100-096,2020-12-29,2020,CA 2889937 A,2013-10-17,US 201261719942 P;;US 2013/0065342 W,2012-10-29,PAPANICOLAOU TEST FOR OVARIAN AND ENDOMETRIAL CANCERS,"The recently developed liquid-based Papanicolaou (Pap) smear allows not only cytologic evaluation but also collection of DNA for detection of HPV, the causative agent of cervical cancer. We tested these samples to detect somatic mutations present in rare tumor cells that might accumulate in the cervix once shed from endometrial and ovarian cancers. A panel of commonly mutated genes in endometrial and ovarian cancers was assembled and used to identify mutations in all 46 endometrial or cervical cancer tissue samples. We were able also able to identify the same mutations in the DNA from liquid Pap smears in 100% of endometrial cancers (24 of 24) and in 41% of ovarian cancers (9 of 22). We developed a sequence-based method to query mutations in 12 genes in a single liquid Pap smear without prior knowledge of the tumor's genotype.",UNIV JOHNS HOPKINS,KINDE ISAAC;;KINZLER KENNETH W;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;DIAZ LUIS;;BETTEGOWDA CHETAN;;WANG YUXUAN,,https://lens.org/153-313-956-100-096,Granted Patent,no,0,0,23,23,0,C12Q1/6886;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;C12Q1/6886;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q1/6851;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158,G01N33/574;;G01N33/68,,0,0,,,,ACTIVE
50,ES,T3,ES 2701742 T3,047-991-415-332-265,2019-02-25,2019,ES 13851273 T,2013-10-17,US 201261719942 P;;US 2013/0065342 W,2012-10-29,Prueba de Papanicolaou para cánceres de ovario y de endometrio,"Procedimiento que comprende: poner a prueba una muestra líquida de frotis de Papanicolaou de un sujeto humano para un cambio genético o epigenético en uno o más ácidos nucleicos mutados en una neoplasia o un cáncer de endometrio, trompas de Falopio u ovario, en el que la etapa de prueba se realiza aumentando la sensibilidad de instrumentos de secuenciación masiva en paralelo con una técnica de reducción de errores que incluye: (i) asignación de un identificador único (UID) a cada molécula modelo para formar moléculas modelo con código de barras; y (ii) secuenciación redundante de las moléculas modelo con código de barras.",UNIV JOHNS HOPKINS,KINDE ISAAC;;KINZLER KENNETH W;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;DIAZ LUIS;;BETTEGOWDA CHETAN;;WANG YUXUAN,,https://lens.org/047-991-415-332-265,Granted Patent,no,0,0,23,23,0,C12Q1/6886;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;C12Q1/6886;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q1/6851;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158,C12Q1/6886,,0,0,,,,ACTIVE
51,EP,B1,EP 3447495 B1,167-986-693-159-815,2021-07-14,2021,EP 18193794 A,2013-10-17,US 201261719942 P;;EP 13851273 A;;US 2013/0065342 W,2012-10-29,PAPANICOLAOU TEST FOR OVARIAN AND ENDOMETRIAL CANCERS,,UNIV JOHNS HOPKINS,KINDE ISAAC;;KINZLER KENNETH W;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;DIAZ LUIS;;BETTEGOWDA CHETAN;;WANG YUXUAN,,https://lens.org/167-986-693-159-815,Granted Patent,yes,1,0,23,23,0,C12Q1/6886;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;C12Q1/6886;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q1/6851;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158,C12Q1/6886,,15,14,055-471-129-576-665;;039-102-640-839-852;;083-594-170-632-636;;032-498-479-258-208;;015-608-990-439-67X;;009-889-184-874-024;;087-623-144-467-812;;132-706-623-273-568;;122-846-871-942-187;;008-893-435-882-252;;073-689-825-793-510;;040-265-210-951-520;;012-006-900-263-969;;074-428-992-955-039,16684597;;10.1016/j.ejso.2006.03.034;;15159323;;10.1158/1055-9965.882.13.5;;22261450;;10.1309/ajcplfbk1a2xjdqi;;12478681;;10.1002/cncr.10761;;10.1111/j.1365-2303.2008.00621.x;;19207308;;10518134;;10.1159/000331294;;20715668;;10.1159/000325189;;21586637;;pmc3111315;;10.1073/pnas.1105422108;;9539251;;10.1093/jnci/90.7.540;;10.1016/j.rigapp.2006.05.009;;pmc3163504;;10.1038/nature10166;;21720365;;10.1093/jnci/djs345;;pmc3692380;;22923510;;22653804;;10.1002/path.4056;;pmc3939694;;10.1016/s0889-8545(00)80018-2;;10857117,"""Affymetrix Human Genome U133 Plus 2.0 Array"", GENE EXPRESSION OMNIBUS, 7 November 2003 (2003-11-07), XP002627319;;SHARMA, A. MENON, U.: ""Screening for gynaecological cancers"", EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, LONDON, GB, vol. 32, no. 8, 1 October 2006 (2006-10-01), GB , pages 818 - 824, XP005674908, ISSN: 0748-7983, DOI: 10.1016/j.ejso.2006.03.034;;FIEGL H, ET AL: ""Methylated DNA collected by tampons--a new tool to detect endometrial cancer."", CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION, AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 13, no. 5, 1 May 2004 (2004-05-01), pages 882 - 888, XP002330534, ISSN: 1055-9965;;SHARON B. SAMS, HEATHER S. CURRENS, STEPHEN S. RAAB: ""Liquid-Based Papanicolaou Tests in Endometrial Carcinoma Diagnosis"", AMERICAN JOURNAL OF CLINICAL PATHOLOGY, AMERICAN SOCIETY FOR CLINICAL PATHOLOGY, US, vol. 137, no. 2, 1 February 2012 (2012-02-01), US , pages 248 - 254, XP055254715, ISSN: 0002-9173, DOI: 10.1309/AJCPLFBK1A2XJDQI;;JOHN O. SCHORGE; M. HOSSEIN SABOORIAN; LINDA HYNAN; RAHEELA ASHFAQ: ""ThinPrep detection of cervical and endometrial adenocarcinoma"", CANCER, AMERICAN CANCER SOCIETY , PHILADELPHIA , PA, US, vol. 96, no. 6, 24 July 2002 (2002-07-24), US , pages 338 - 343, XP071039429, ISSN: 0008-543X, DOI: 10.1002/cncr.10761;;C. PATEL, A. ULLAL, M. ROBERTS, J. BRADY, P. BIRCH, J. N. BULMER, V. WADEHRA: ""Endometrial carcinoma detected with SurePath liquid-based cervical cytology: comparison with conventional cytology"", CYTOPATHOLOGY, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 20, no. 6, 1 December 2009 (2009-12-01), GB , pages 380 - 387, XP055274130, ISSN: 0956-5507, DOI: 10.1111/j.1365-2303.2008.00621.x;;GUPTA DILIP, BALSARA GULNAR: ""Extrauterine Malignancies"", ACTA CYTOLOGICA., vol. 43, no. 5, 1 January 1999 (1999-01-01), pages 806 - 813, XP055916829, ISSN: 0001-5547, DOI: 10.1159/000331294;;WANG HANGJUN, CHEN PATRICK C.: ""Primary Serous Peritoneal Carcinoma Presenting First on a Routine Papanicolaou Smear"", ACTA CYTOLOGICA., vol. 54, no. 4, 1 July 2010 (2010-07-01), pages 623 - 626, XP055916833, ISSN: 0001-5547, DOI: 10.1159/000325189;;I. KINDE, J. WU, N. PAPADOPOULOS, K. W. KINZLER, B. VOGELSTEIN: ""Detection and quantification of rare mutations with massively parallel sequencing"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 23, 7 June 2011 (2011-06-07), pages 9530 - 9535, XP055164202, ISSN: 00278424, DOI: 10.1073/pnas.1105422108;;AL-JEHANI RAJAI MUNIR, JEYARAJAH ARJUN RAVINDRAN, ORAM DAVID HOWARD, JACOBS IAN JEFFREY, HAGEN BJORN, HOGDALL ESTRID VILMA: ""Model for the Molecular Genetic Diagnosis of Endometrial Cancer Using K-ras Mutation Analysis"", JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIVERSITY PRESS, GB, vol. 90, no. 7, 1 April 1998 (1998-04-01), GB , pages 540 - 542, XP055916836, ISSN: 0027-8874, DOI: 10.1093/jnci/90.7.540;;ELMASRY, K. GAYTHER, S.A.: ""Genetic mutations in gynaecological cancers"", REVIEWS IN GYNAECOLOGICAL AND PERINATAL PRACTICE, ELSEVIER, KIDLINGTON, GB, vol. 6, no. 3-4, 1 September 2006 (2006-09-01), GB , pages 115 - 125, XP005625230, ISSN: 1871-2320, DOI: 10.1016/j.rigapp.2006.05.009;;D. BELL, A. BERCHUCK, M. BIRRER, J. CHIEN, D. W. CRAMER, F. DAO, R. DHIR, P. DISAIA, H. GABRA, P. GLENN, A. K. GODWIN, J. GROSS, L: ""Integrated genomic analyses of ovarian carcinoma"", NATURE, ¬MACMILLAN JOURNALS LTD., ETC.|, vol. 474, no. 7353, 1 June 2011 (2011-06-01), pages 609 - 615, XP055086944, ISSN: 00280836, DOI: 10.1038/nature10166;;E. KUHN, R.-C. WU, B. GUAN, G. WU, J. ZHANG, Y. WANG, L. SONG, X. YUAN, L. WEI, R. B. S. RODEN, K.-T. KUO, K. NAKAYAMA, B. CLARKE,: ""Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses"", JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIVERSITY PRESS, GB, vol. 104, no. 19, 3 October 2012 (2012-10-03), GB , pages 1503 - 1513, XP055274877, ISSN: 0027-8874, DOI: 10.1093/jnci/djs345;;MELISSA K MCCONECHY, JIARUI DING, MAGGIE CU CHEANG, KIMBERLY C WIEGAND, JANINE SENZ, ALICIA A TONE, WINNIE YANG, LEAH M PRENTICE, : ""Use of mutation profiles to refine the classification of endometrial carcinomas"", THE JOURNAL OF PATHOLOGY, LONGMAN, HOBOKEN, USA, vol. 228, no. 1, 1 January 2012 (2012-01-01), Hoboken, USA, pages 20 - 30, XP055319701, ISSN: 0022-3417, DOI: 10.1002/path.4056;;COOPER JAY M., ERICKSON MARVIN L.: ""Endometrial sampling techniques in the diagnosis of abnormal uterine bleeding"", OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA., W.B. SAUNDERS CO., PHILADELPHIA, PA., US, vol. 27, no. 2, 1 June 2000 (2000-06-01), PHILADELPHIA, PA., US , pages 235 - 244, XP055916839, ISSN: 0889-8545, DOI: 10.1016/S0889-8545(00)80018-2",ACTIVE
52,CN,A,CN 105683391 A,191-271-637-144-61X,2016-06-15,2016,CN 201480019547 A,2014-02-18,US 201361765909 P;;US 201361766857 P;;US 201361772249 P;;US 2014/0016906 W,2013-02-18,Tert promoter mutations in gliomas and subset of tumors,"We surveyed 1230 tumors of 60 different types and found that tumors could be divided into types with low (<15%) and high (>=15%) frequencies of TERT promoter mutations. The nine TERT-high tumor types almost always originated in tissues with relatively low rates of self renewal, including melanomas, liposarcomas, hepatocellular carcinomas, urothelial carcinomas, squamous cell carcinomas of the tongue, medulloblastomas, and subtypes of gliomas (including 83% of primary glioblastoma, the most common brain tumor type). TERT and ATRX mutations were mutually exclusive, suggesting that these two genetic mechanisms confer equivalent selective growth advantages. In addition to their implications for understanding the relationship between telomeres and tumorigenesis, TERT mutations provide a biomarker for the early detection of urinary tract and liver tumors and aid in the classification and prognostication of brain tumors.",UNIV DUKE;;UNIV JOHNS HOPKINS,H YAN;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;KINZLER KENNETH W;;Y JIAO;;BETTEGOWDA CHETAN;;BIGNER DARELL D,,https://lens.org/191-271-637-144-61X,Patent Application,no,2,0,17,24,0,C12Q2600/112;;C12Q2600/156;;C12Q1/6886;;C12Q2600/156;;C12Q2600/112;;C12Q1/6886,C12Q1/68;;C12N15/12,,1,1,003-113-655-474-830,10.1126/science.1229259;;pmc4423787;;23348506,"FRANKLIN W. HUANG ET AL: ""Highly Recurrent TERT Promoter Mutations in Human Melanoma"", 《SCIENCE》",PENDING
53,AU,A1,AU 2019/202900 A1,039-131-284-645-340,2019-05-16,2019,AU 2019/202900 A,2019-04-24,AU 2019/202900 A;;AU 2017/203206 A;;AU 2013/338393 A;;US 201261719942 P;;US 2013/0065342 W,2012-10-29,Papanicolaou test for ovarian and endometrial cancers,"The recently developed liquid-based Papanicolaou (Pap) smear allows not only cytologic evaluation but also collection of DNA for detection of HPV, the causative agent of cervical cancer. We tested these samples to detect somatic mutations present in rare tumor cells 5 that might accumulate in the cervix once shed from endometrial and ovarian cancers. A panel of commonly mutated genes in endometrial and ovarian cancers was assembled and used to identify mutations in all 46 endometrial or cervical cancer tissue samples. We were able also able to identify the same mutations in the DNA from liquid Pap smears in 100% of endometrial cancers (24 of 24) and in 41% of ovarian cancers (9 of 22). We developed a sequence-based method to 0 query mutations in 12 genes in a single liquid Pap smear without prior knowledge of the tumor's genotype.",UNIV JOHNS HOPKINS,KINDE ISAAC;;KINZLER KENNETH W;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;DIAZ LUIS;;BETTEGOWDA CHETAN;;WANG YUXUAN,,https://lens.org/039-131-284-645-340,Patent Application,no,0,0,23,23,0,C12Q1/6886;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;C12Q1/6886;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q1/6851;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158,G01N33/574;;C12Q1/68;;G01N33/68,,0,0,,,,DISCONTINUED
54,US,A1,US 2023/0250483 A1,072-886-946-880-350,2023-08-10,2023,US 202218050809 A,2022-10-28,US 202218050809 A;;US 201514439041 A;;US 2013/0065342 W;;US 201261719942 P,2012-10-29,PAPANICOLAOU TEST FOR OVARIAN AND ENDOMETRIAL CANCERS,"The recently developed liquid-based Papanicolaou (Pap) smear allows not only cytologic evaluation but also collection of DNA for detection of HPV, the causative agent of cervical cancer. We tested these samples to detect somatic mutations present in rare tumor cells that might accumulate in the cervix once shed from endometrial and ovarian cancers. A panel of commonly mutated genes in endometrial and ovarian cancers was assembled and used to identify mutations in all 46 endometrial or cervical cancer tissue samples. We were able also able to identify the same mutations in the DNA from liquid Pap smears in 100% of endometrial cancers (24 of 24) and in 41% of ovarian cancers (9 of 22). We developed a sequence-based method to query mutations in 12 genes in a single liquid Pap smear without prior knowledge of the tumor's genotype.",UNIV JOHNS HOPKINS,KINDE ISAAC;;KINZLER KENNETH W;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;DIAZ LUIS;;BETTEGOWDA CHETAN;;WANG YUXUAN,,https://lens.org/072-886-946-880-350,Patent Application,yes,0,0,23,23,0,C12Q1/6886;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;C12Q1/6886;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q1/6851;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158,C12Q1/6886;;G01N33/574,,0,0,,,,PENDING
55,EP,A4,EP 2912468 A4,168-679-656-647-189,2016-06-29,2016,EP 13851273 A,2013-10-17,US 201261719942 P;;US 2013/0065342 W,2012-10-29,PAPANICOLAOU TEST FOR OVARIAN AND ENDOMETRIAL CANCERS,,UNIV JOHNS HOPKINS,KINDE ISAAC;;KINZLER KENNETH W;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;DIAZ LUIS;;BETTEGOWDA CHETAN;;WANG YUXUAN,,https://lens.org/168-679-656-647-189,Search Report,no,1,0,23,23,0,C12Q1/6886;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;C12Q1/6886;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q1/6851;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158,G01N33/574;;C12Q1/68;;G01N33/68,,9,6,008-893-435-882-252;;073-689-825-793-510;;040-265-210-951-520;;132-706-623-273-568;;050-445-845-886-911;;015-608-990-439-67X,10.1016/j.rigapp.2006.05.009;;pmc3163504;;10.1038/nature10166;;21720365;;10.1093/jnci/djs345;;pmc3692380;;22923510;;21586637;;pmc3111315;;10.1073/pnas.1105422108;;23303603;;10.1126/scitranslmed.3004952;;pmc3757513;;10.1111/j.1365-2303.2008.00621.x;;19207308,"ELMASRY K ET AL: ""Genetic mutations in gynaecological cancers"", REVIEWS IN GYNAECOLOGICAL AND PERINATAL PRACTICE, ELSEVIER, KIDLINGTON, GB, vol. 6, no. 3-4, 1 September 2006 (2006-09-01), pages 115 - 125, XP024920562, ISSN: 1871-2320, [retrieved on 20060901], DOI: 10.1016/J.RIGAPP.2006.05.009;;D. BELL ET AL: ""Integrated genomic analyses of ovarian carcinoma"", NATURE, vol. 474, no. 7353, 1 June 2011 (2011-06-01), pages 609 - 615, XP055086944, ISSN: 0028-0836, DOI: 10.1038/nature10166;;E. KUHN ET AL: ""Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses"", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 104, no. 19, 23 August 2012 (2012-08-23), GB, pages 1503 - 1513, XP055275023, ISSN: 0027-8874, DOI: 10.1093/jnci/djs345;;I. KINDE ET AL: ""Detection and quantification of rare mutations with massively parallel sequencing"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 23, 17 May 2011 (2011-05-17), pages 9530 - 9535, XP055164202, ISSN: 0027-8424, DOI: 10.1073/pnas.1105422108;;KINDE ISAAC ET AL: ""Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers"", SCIENCE TRANSLATIONAL MEDICINE, vol. 5, no. 167, 9 January 2013 (2013-01-09), pages 72 - 81, XP009181744, ISSN: 1946-6242, [retrieved on 20130109];;ERNANI F P ET AL: ""Agilent's SureSelect Target Enrichment System: Bringing Cost and Process Efficiency to Next-Generation Sequencing"", 16 March 2009 (2009-03-16), pages 1 - 8, XP002613060, Retrieved from the Internet <URL:http://www.chem.agilent.com/Library/brochures/5990-3532en_lo%20CMS.pdf> [retrieved on 20101203];;""Affymetrix Human Genome U133 Plus 2.0 Array"", GENE EXPRESSION OMNIBUS, 7 November 2003 (2003-11-07), XP002627319;;C. PATEL ET AL: ""Endometrial carcinoma detected with SurePath liquid-based cervical cytology: comparison with conventional cytology"", CYTOPATHOLOGY, vol. 20, no. 6, 1 December 2009 (2009-12-01), GB, pages 380 - 387, XP055274130, ISSN: 0956-5507, DOI: 10.1111/j.1365-2303.2008.00621.x;;See also references of WO 2014070462A1",ACTIVE
56,EP,A4,EP 2734644 A4,131-537-587-251-837,2015-03-18,2015,EP 12814956 A,2012-07-18,US 201161509366 P;;US 2012/0047211 W,2011-07-19,OLIGODENDROGLIOMA DRIVER GENES,,UNIV JOHNS HOPKINS;;UNIV DUKE,VOGELSTEIN BERT;;KINZLER KENNETH W;;BETTEGOWDA CHETAN;;AGRAWAL NISHANT;;BIGNER DARELL;;YAN HAI;;MCLENDON ROGER,,https://lens.org/131-537-587-251-837,Search Report,no,2,0,11,11,0,C12Q1/6886;;C12Q1/6886;;C12Q2600/106;;C12Q2600/106;;C12Q2600/112;;C12Q2600/112;;C12Q2600/118;;C12Q2600/118;;C12Q2600/156;;C12Q2600/156;;C12Q2600/158;;C12Q2600/158,C12Q1/68,,3,2,040-988-224-915-933;;101-030-760-689-875,pmc2820383;;19228619;;10.1056/nejmoa0808710;;10.1007/s11060-004-4598-2;;15981098,"YAN HAI ET AL: ""IDH1 and IDH2 mutations in gliomas"", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 360, no. 8, 19 February 2009 (2009-02-19), pages 765 - 773, XP002538459, ISSN: 1533-4406, DOI: 10.1056/NEJMOA0808710;;CHING-JUNG LEE ET AL: ""CIC, a gene involved in cerebellar development and ErbB signaling, is significantly expressed in medulloblastomas"", JOURNAL OF NEURO-ONCOLOGY, KLUWER ACADEMIC PUBLISHERS, BO, vol. 73, no. 2, 1 June 2005 (2005-06-01), pages 101 - 108, XP019260683, ISSN: 1573-7373;;See also references of WO 2013012927A2",ACTIVE
57,WO,A1,WO 2014/070462 A1,011-475-332-514-170,2014-05-08,2014,US 2013/0065342 W,2013-10-17,US 201261719942 P,2012-10-29,PAPANICOLAOU TEST FOR OVARIAN AND ENDOMETRIAL CANCERS,"The recently developed liquid-based Papanicolaou (Pap) smear allows not only cytologic evaluation but also collection of DNA for detection of HPV, the causative agent of cervical cancer. We tested these samples to detect somatic mutations present in rare tumor cells that might accumulate in the cervix once shed from endometrial and ovarian cancers. A panel of commonly mutated genes in endometrial and ovarian cancers was assembled and used to identify mutations in all 46 endometrial or cervical cancer tissue samples. We were able also able to identify the same mutations in the DNA from liquid Pap smears in 100% of endometrial cancers (24 of 24) and in 41% of ovarian cancers (9 of 22). We developed a sequence-based method to query mutations in 12 genes in a single liquid Pap smear without prior knowledge of the tumor's genotype.",UNIV JOHNS HOPKINS,KINDE ISAAC;;KINZLER KENNETH W;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;DIAZ LUIS;;BETTEGOWDA CHETAN;;WANG YUXUAN,,https://lens.org/011-475-332-514-170,Patent Application,yes,5,1,23,23,191,C12Q1/6886;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;C12Q1/6886;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q1/6851;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158,G01N33/574;;C12Q1/68;;G01N33/68,,4,3,083-594-170-632-636;;044-825-849-210-860;;050-445-845-886-911,22261450;;10.1309/ajcplfbk1a2xjdqi;;22355468;;pmc3280068;;10.3802/jgo.2012.23.1.53;;23303603;;10.1126/scitranslmed.3004952;;pmc3757513,"SAMS ET AL.: ""Liquid-based Papanicolaou tests in endometrial carcinoma diagnosis. Performance, error root cause analysis, and quality improvement"", AMERICAN JOURNAL OF CLINICAL PATHOLOGY, vol. 137, no. 2, 28 February 2012 (2012-02-28), pages 248 - 254, XP055254715;;SUH ET AL.: ""Major clinical research advances in gynecologic cancer in 2011"", JOURNAL OF GYNECOLOGIC ONCOLOGY, vol. 23, no. 1, 9 January 2012 (2012-01-09), pages 53 - 64, XP055254719;;KINDE ET AL.: ""Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers"", SCIENCE TRANSLATIONAL MEDICINE, vol. 5, no. ISSUE, 9 January 2013 (2013-01-09), pages 1 - 10, XP009181744;;See also references of EP 2912468A4",PENDING
58,CN,A,CN 104956225 A,064-273-452-801-251,2015-09-30,2015,CN 201380068411 A,2013-10-17,US 2013/0065342 W;;US 201261719942 P,2012-10-29,Papanicolaou test for ovarian and endometrial cancers,"The recently developed liquid-based Papanicolaou (Pap) smear allows not only cytologic evaluation but also collection of DNA for detection of HPV, the causative agent of cervical cancer. We tested these samples to detect somatic mutations present in rare tumor cells that might accumulate in the cervix once shed from endometrial and ovarian cancers. A panel of commonly mutated genes in endometrial and ovarian cancers was assembled and used to identify mutations in all 46 endometrial or cervical cancer tissue samples. We were able also able to identify the same mutations in the DNA from liquid Pap smears in 100% of endometrial cancers (24 of 24) and in 41% of ovarian cancers (9 of 22). The invention developes a sequence-based method to query mutations in 12 genes in a single liquid Pap smear without prior knowledge of the tumor's genotype.",UNIV JOHNS HOPKINS,KINDE ISAAC;;KINZLER KENNETH W;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;DIAZ LUIS;;BETTEGOWDA CHETAN;;WANG YUXUAN,,https://lens.org/064-273-452-801-251,Patent Application,no,4,2,23,23,0,C12Q1/6886;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;C12Q1/6886;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q1/6851;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158,G01N33/574;;C12Q1/68;;G01N33/68,,8,7,040-265-210-951-520;;038-254-580-060-877;;093-024-626-361-802;;018-637-759-472-487;;040-160-952-206-473;;062-567-465-716-049;;006-412-712-975-703,10.1093/jnci/djs345;;pmc3692380;;22923510;;10.1158/0008-5472.can-05-2620;;16322209;;10.1016/j.ygyno.2009.12.002;;20106510;;21683865;;pmc3148026;;10.1016/j.humpath.2011.03.003;;10.1016/s0140-6736(09)61338-6;;19793610;;pmc2705832;;10.1158/1535-7163.mct-06-0433;;17088437;;10.1038/sj.onc.1203291;;10637508,"ELISABETTA KUHN ET AL.: ""Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses"", 《J NATL CANCER INST》;;张梅娟: ""液基细胞学检查在宫颈癌和子宫内膜癌筛查中的应用研究"", 《中国优秀硕士学位论文全文数据库》;;KATSUTOSHI ODA ET AL.: ""High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma"", 《CANCER RES》;;SARA A. BYRON ET AL.: ""FGFR2 mutations are rare across histologic subtypes of ovarian cancer"", 《GYNECOLOGIC ONCOLOGY》;;ROBERT J. KURMAN MD ET AL.: ""Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm"", 《HUMAN PATHOLOGY》;;BRYAN T HENNESSY ET AL.: ""Ovarian cancer"", 《LANCET》;;OGECHI N. IKEDIOBI ET AL.: ""Mutation analysis of 24 known cancer genes in the NCI-60 cell line set"", 《MOLECULAR CANCER THERAPEUTICS》;;DAVID G HUNTSMAN ET AL.: ""MLL2, the second human homolog of the Drosophila trithorax gene, maps to 19q13.1 and is ampli®ed in solid tumor cell lines"", 《ONCOGENE》",ACTIVE
59,US,A1,US 2015/0292027 A1,069-354-794-511-277,2015-10-15,2015,US 201314439041 A,2013-10-17,US 201314439041 A;;US 201261719942 P;;US 2013/0065342 W,2012-10-29,PAPANICOLAOU TEST FOR OVARIAN AND ENDOMETRIAL CANCERS,"The recently developed liquid-based Papanicolaou (Pap) smear allows not only cytologic evaluation but also collection of DNA for detection of HPV, the causative agent of cervical cancer. We tested these samples to detect somatic mutations present in rare tumor cells that might accumulate in the cervix once shed from endometrial and ovarian cancers. A panel of commonly mutated genes in endometrial and ovarian cancers was assembled and used to identify mutations in all 46 endometrial or cervical cancer tissue samples. We were able also able to identify the same mutations in the DNA from liquid Pap smears in 100% of endometrial cancers (24 of 24) and in 41% of ovarian cancers (9 of 22). We developed a sequence-based method to query mutations in 12 genes in a single liquid Pap smear without prior knowledge of the tumor's genotype.",UNIV JOHNS HOPKINS,KINDE ISAAC;;KINZLER KENNETH W;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;DIAZ LUIS;;BETTEGOWDA CHETAN;;WANG YUXUAN,THE JOHNS HOPKINS UNIVERSITY (2012-11-15),https://lens.org/069-354-794-511-277,Patent Application,yes,1,2,23,23,191,C12Q1/6886;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;C12Q1/6886;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q1/6851;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158,C12Q1/68,,13,10,055-471-129-576-665;;132-706-623-273-568;;040-265-210-951-520;;040-850-907-515-494;;095-905-459-658-707;;011-674-727-534-32X;;125-465-676-122-407;;042-343-147-653-937;;012-695-424-683-618;;032-498-479-258-208,16684597;;10.1016/j.ejso.2006.03.034;;21586637;;pmc3111315;;10.1073/pnas.1105422108;;10.1093/jnci/djs345;;pmc3692380;;22923510;;12439748;;10.1038/sj.onc.1205924;;10545015;;10.1023/a:1006611220434;;12183400;;14648662;;10.1002/path.1474;;10.1158/0008-5472.can-07-1320;;17909001;;pmc3745022;;10.1038/ng.117;;18408720;;12478681;;10.1002/cncr.10761,"Sharma and Menon. EJSO; 2006; Vol 32: pp 818-824. (Year: 2006);;Kinde et al. PNAS; 2011; 108: 9530-9535. (Year: 2011);;McConechy et al. J Path; 2012; 228: 20-30 and Supplementary Tables 1-2. (Year: 2012);;Kuhn et al. J Natl Cancer Inst. 2012 August; 104:1503–1513. (Year: 2012);;Moreno-Bueno et al. Oncogene; 2002; 21: 7981 – 7990. (Year: 2002);;Dokianakis et al. Clinical & Experimental Metastasis; 1999; 17: 293–297. (Year: 1999);;Walsh et al. PNAS; 2011 108; 44: p 1-6 (Epub 2011 Oct 17). (Year: 2011);;Spruck et al. CANCER RESEARCH; 2002; 62, 4535–4539. (Year: 2002);;Cassia et al. Pathol 2003; 201: 589–595. (Year: 2003);;Akhoondi et al. Cancer Res; 2007; 67: (19): 9006-9012. (Year: 2007);;Qiu (Nature Genetics, May 2008, Vol 40, pp 650-655);;The Cancer Genome Atlas Research Network (Nature, June 2011, Vol 474, pp 609-616);;Schorge (Cancer (Cancer Cytopathol) 2002; 96:338-43)",ACTIVE
60,PL,T3,PL 2912468 T3,039-324-067-288-616,2019-04-30,2019,PL 13851273 T,2013-10-17,US 201261719942 P;;EP 13851273 A;;US 2013/0065342 W,2012-10-29,PAPANICOLAOU TEST FOR OVARIAN AND ENDOMETRIAL CANCERS,,UNIV JOHNS HOPKINS,KINDE ISAAC;;KINZLER KENNETH W;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;DIAZ LUIS;;BETTEGOWDA CHETAN;;WANG YUXUAN,,https://lens.org/039-324-067-288-616,Patent Application,no,0,0,23,23,0,C12Q1/6886;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;C12Q1/6886;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q1/6851;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158,C12Q1/6886,,0,0,,,,PENDING
61,EP,B1,EP 2912468 B1,090-428-425-630-131,2018-09-12,2018,EP 13851273 A,2013-10-17,US 201261719942 P;;US 2013/0065342 W,2012-10-29,PAPANICOLAOU TEST FOR OVARIAN AND ENDOMETRIAL CANCERS,,UNIV JOHNS HOPKINS,KINDE ISAAC;;KINZLER KENNETH W;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;DIAZ LUIS;;BETTEGOWDA CHETAN;;WANG YUXUAN,,https://lens.org/090-428-425-630-131,Granted Patent,yes,0,0,23,23,0,C12Q1/6886;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;C12Q1/6886;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q1/6851;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158,C12Q1/6886,,1,1,000-390-246-825-296,10.1016/j.ygyno.2007.01.045;;17360030,"KANG S ET AL: ""Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma"", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 105, no. 3, 1 June 2007 (2007-06-01), pages 662 - 666, XP025347371, ISSN: 0090-8258, [retrieved on 20070601], DOI: 10.1016/J.YGYNO.2007.01.045",ACTIVE
62,US,B2,US 11525163 B2,144-926-807-122-035,2022-12-13,2022,US 201314439041 A,2013-10-17,US 201314439041 A;;US 201261719942 P;;US 2013/0065342 W,2012-10-29,Papanicolaou test for ovarian and endometrial cancers,"The recently developed liquid-based Papanicolaou (Pap) smear allows not only cytologic evaluation but also collection of DNA for detection of HPV, the causative agent of cervical cancer. We tested these samples to detect somatic mutations present in rare tumor cells that might accumulate in the cervix once shed from endometrial and ovarian cancers. A panel of commonly mutated genes in endometrial and ovarian cancers was assembled and used to identify mutations in all 46 endometrial or cervical cancer tissue samples. We were able also able to identify the same mutations in the DNA from liquid Pap smears in 100% of endometrial cancers (24 of 24) and in 41% of ovarian cancers (9 of 22). We developed a sequence-based method to query mutations in 12 genes in a single liquid Pap smear without prior knowledge of the tumor's genotype.",UNIV JOHNS HOPKINS,KINDE ISAAC;;KINZLER KENNETH W;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;DIAZ LUIS;;BETTEGOWDA CHETAN;;WANG YUXUAN,THE JOHNS HOPKINS UNIVERSITY (2012-11-15),https://lens.org/144-926-807-122-035,Granted Patent,yes,336,0,23,23,191,C12Q1/6886;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;C12Q1/6886;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q1/6851;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158,C12Q1/68;;C12Q1/6851;;C12Q1/6886;;G01N33/574,,762,673,012-695-424-683-618;;073-689-825-793-510;;032-498-479-258-208;;055-471-129-576-665;;012-006-900-263-969;;095-905-459-658-707;;040-948-781-748-051;;055-471-129-576-665;;132-706-623-273-568;;095-905-459-658-707;;012-006-900-263-969;;012-006-900-263-969;;012-006-900-263-969;;132-706-623-273-568;;040-265-210-951-520;;040-265-210-951-520;;040-850-907-515-494;;005-102-024-526-621;;055-471-129-576-665;;132-706-623-273-568;;040-265-210-951-520;;040-850-907-515-494;;095-905-459-658-707;;011-674-727-534-32X;;125-465-676-122-407;;042-343-147-653-937;;083-594-170-632-636;;044-825-849-210-860;;050-445-845-886-911;;000-390-246-825-296;;062-567-465-716-049;;040-160-952-206-473;;093-024-626-361-802;;018-637-759-472-487;;006-412-712-975-703;;008-893-435-882-252;;073-689-825-793-510;;040-265-210-951-520;;132-706-623-273-568;;038-254-580-060-877;;014-951-949-943-585;;013-766-679-756-841;;077-134-947-165-690;;089-020-090-771-471;;033-734-224-976-468;;004-003-508-190-140;;061-247-339-324-539;;058-218-878-573-074;;075-365-727-231-866;;002-841-897-235-524;;040-265-210-951-520;;039-767-448-431-669;;064-852-228-426-035;;099-378-356-189-825;;023-055-679-554-969;;182-722-766-027-448;;132-706-623-273-568;;073-689-825-793-510;;071-615-061-904-916;;009-005-505-313-388;;074-428-992-955-039;;029-992-013-913-018;;030-127-793-502-971;;039-539-876-524-082;;023-026-304-398-119;;025-090-666-694-854;;006-303-913-554-013;;055-279-747-159-738;;029-880-616-965-814;;014-072-831-490-33X;;036-706-039-016-917;;083-594-170-632-636;;032-718-950-332-134;;114-510-755-626-735;;124-678-289-264-889;;040-798-594-126-918;;019-690-569-075-391;;023-866-085-896-346;;018-849-226-711-208;;015-608-990-439-67X;;006-363-295-027-340;;031-742-261-837-86X;;055-973-480-022-686;;017-055-400-864-20X;;080-185-165-497-576;;011-086-772-474-089;;082-057-478-967-176;;085-333-946-613-019;;024-097-835-709-718;;000-354-035-412-581;;008-842-998-017-326;;016-750-535-011-560;;037-154-266-421-983;;001-116-982-141-786;;016-292-994-688-700;;032-834-664-063-269;;133-524-944-589-415;;016-559-071-195-721;;056-940-693-165-088;;147-609-684-040-629;;012-082-585-020-725;;019-458-142-456-578;;026-414-906-566-910;;031-301-052-925-421;;056-640-863-663-481;;020-574-020-858-249;;046-851-781-674-969;;028-295-436-013-281;;043-690-933-215-304;;011-347-353-177-787;;075-299-640-402-914;;099-514-099-427-995;;138-885-092-562-559;;019-335-980-182-22X;;039-664-421-720-071;;051-832-867-260-895;;096-560-257-359-528;;013-581-942-268-634;;116-503-575-188-587;;072-052-867-054-682;;021-990-400-696-746;;036-671-697-849-198;;038-040-632-602-487;;085-109-849-355-023;;105-017-745-541-847;;059-752-029-061-96X;;113-574-757-756-599;;001-979-525-651-67X;;065-120-242-142-752;;093-805-594-476-171;;106-205-124-270-196;;011-749-656-485-594;;078-585-629-084-94X;;002-607-574-944-363;;003-615-850-168-222;;114-057-754-570-845;;081-701-381-607-199;;038-433-413-202-077;;033-702-901-050-86X;;021-426-036-383-999;;136-812-738-351-735;;036-084-868-306-571;;172-165-897-982-70X;;033-921-724-184-84X;;047-624-889-602-402;;047-624-889-602-402;;036-495-506-050-384;;036-495-506-050-384;;038-883-924-811-884;;025-607-704-150-727;;071-351-654-127-263;;059-786-079-109-47X;;078-519-579-236-486;;070-822-895-969-113;;030-275-384-700-023;;065-723-200-789-454;;048-341-126-148-340;;156-871-873-075-855;;087-631-463-354-25X;;041-898-023-916-267;;039-949-677-071-780;;050-467-197-254-760;;052-293-237-973-256;;027-566-458-736-70X;;083-926-915-990-672;;083-354-835-640-225;;008-820-407-084-993;;010-509-060-333-910;;049-017-522-554-561;;071-703-689-437-671;;037-544-106-793-239;;078-813-580-836-734;;041-328-439-315-145;;001-072-634-824-124;;129-126-905-184-089;;018-565-258-437-405;;024-293-290-200-302;;003-583-771-008-999;;048-341-126-148-340;;007-730-712-196-101;;048-374-714-867-49X;;040-728-750-737-670;;018-378-714-407-135;;099-199-452-094-873;;150-674-681-753-526;;023-906-808-359-450;;001-014-734-590-999;;010-884-356-367-145;;119-323-918-170-655;;129-596-554-836-212;;007-393-976-173-814;;009-304-930-029-468;;061-119-112-507-860;;084-985-863-763-385;;130-959-200-769-476;;038-359-323-499-097;;012-593-580-956-182;;026-901-428-389-363;;071-853-342-448-623;;043-708-611-146-273;;014-516-426-346-320;;006-609-949-922-131;;054-861-307-966-672;;006-960-435-136-406;;119-710-320-524-578;;027-637-887-931-488;;062-886-477-069-983;;023-669-182-038-332;;014-064-720-770-558;;031-956-357-487-482;;016-168-594-013-175;;044-971-595-106-937;;026-942-136-598-324;;062-938-122-645-517;;017-454-308-976-151;;156-956-275-102-510;;115-202-796-599-464;;096-373-867-837-01X;;099-647-484-412-430;;059-813-431-055-732;;017-668-431-644-199;;029-769-329-170-255;;018-266-090-124-316;;089-396-943-130-314;;029-698-150-050-83X;;140-987-997-983-664;;091-567-143-131-04X;;069-305-646-999-88X;;092-723-912-505-084;;011-867-431-282-216;;048-192-976-278-313;;006-439-781-976-304;;077-670-062-152-330;;007-131-306-715-418;;054-267-533-248-060;;035-420-135-483-670;;054-658-462-484-530;;024-067-588-342-826;;007-266-411-937-862;;033-734-224-976-468;;051-646-155-580-517;;063-326-774-228-398;;105-794-863-306-553;;036-636-463-546-377;;058-930-724-843-296;;001-257-678-454-728;;040-734-824-975-331;;033-576-656-573-530;;037-733-624-411-002;;000-309-382-655-286;;007-894-265-616-653;;020-510-078-953-684;;022-294-448-149-829;;084-155-344-960-632;;078-159-095-937-394;;137-629-232-369-55X;;052-761-492-826-661;;068-948-392-185-298;;064-793-211-225-432;;092-077-271-687-194;;003-113-655-474-830;;131-477-679-188-503;;009-255-177-983-404;;067-999-346-813-277;;027-205-423-780-651;;020-466-599-003-371;;090-460-004-972-58X;;045-815-944-855-138;;124-051-282-483-801;;010-408-992-432-262;;048-515-855-723-576;;097-599-195-567-528;;067-279-734-601-895;;099-836-350-683-334;;010-901-966-518-774;;028-351-399-333-625;;035-969-407-810-822;;142-731-954-079-847;;019-392-813-016-049;;069-785-693-151-14X;;026-133-517-782-096;;021-084-744-501-098;;084-439-208-872-958;;065-120-242-142-752;;010-405-659-512-88X;;003-032-472-378-884;;023-718-453-511-995;;120-949-662-159-689;;123-892-011-860-062;;045-019-971-777-350;;054-905-501-264-705;;037-886-106-753-659;;050-017-194-820-562;;089-905-844-556-988;;010-132-033-750-586;;034-878-648-984-276;;007-705-019-774-503;;132-706-623-273-568;;006-236-160-573-465;;025-840-222-373-734;;003-017-862-253-264;;011-628-940-743-668;;070-201-389-594-193;;075-138-341-209-754;;033-649-068-782-285;;089-352-123-140-053;;034-391-682-606-362;;008-995-433-622-913;;003-690-004-532-670;;045-432-831-497-575;;050-107-892-827-672;;056-932-303-534-897;;054-067-144-892-059;;007-621-536-610-576;;097-932-949-866-433;;019-444-382-756-302;;003-246-077-292-726;;040-925-877-368-73X;;043-335-945-580-708;;026-956-426-574-053;;015-556-476-096-772;;016-160-452-471-764;;051-581-086-311-393;;169-884-162-436-663;;104-691-433-278-742;;089-804-744-587-493;;027-164-783-410-891;;078-050-590-241-846;;052-723-289-234-233;;031-188-304-250-896;;093-807-259-218-035;;039-596-960-561-848;;025-741-371-124-201;;007-668-424-494-396;;047-553-481-300-229;;000-532-481-960-755;;029-216-799-606-340;;075-984-822-444-459;;070-395-916-503-627;;065-739-869-740-595;;047-476-423-045-622;;061-394-951-377-581;;129-384-033-700-710;;015-532-667-412-751;;041-326-190-111-120;;046-498-163-865-691;;117-647-737-953-317;;037-838-508-451-905;;045-842-300-730-771;;074-300-521-713-735;;106-963-272-110-824;;069-809-834-106-187;;083-127-512-770-295;;018-648-913-613-131;;034-382-770-254-542;;019-748-972-939-689;;019-062-024-928-027;;015-592-423-936-895;;107-231-120-080-980;;015-874-518-951-444;;005-605-207-436-375;;033-238-535-950-924;;068-432-851-494-149;;058-471-014-568-197;;105-487-325-716-301;;031-184-545-167-681;;013-685-395-320-945;;068-636-480-520-065;;035-874-511-846-241;;134-006-420-612-959;;194-661-447-414-888;;061-975-254-893-551;;032-388-761-157-163;;100-799-317-040-867;;015-246-544-130-191;;086-453-645-603-91X;;015-649-583-844-628;;021-225-809-309-141;;042-778-669-684-645;;109-383-610-398-751;;028-356-902-083-380;;021-685-997-966-620;;077-907-585-995-735;;000-904-340-234-631;;027-747-239-565-595;;084-581-823-149-611;;072-175-594-135-718;;009-489-455-736-887;;060-640-745-804-751;;023-823-146-793-739;;010-331-336-398-665;;043-062-786-780-145;;023-506-990-594-226;;040-315-860-012-413;;019-829-643-933-993;;049-386-380-825-242;;020-536-191-728-361;;022-187-353-707-193;;037-560-741-850-669;;053-299-051-785-154;;017-847-593-419-510;;070-240-453-226-929;;004-707-461-928-149;;001-176-959-270-170;;092-197-413-890-187;;045-849-276-279-598;;045-623-729-340-346;;122-329-957-618-980;;138-248-709-082-781;;024-525-327-049-053;;005-062-322-756-376;;137-740-045-010-07X;;069-970-853-729-540;;004-614-692-603-824;;108-485-290-526-654;;012-127-573-268-260;;030-600-693-038-05X;;012-124-917-930-227;;079-561-256-871-536;;047-082-475-859-773;;056-627-051-319-056;;022-529-160-972-801;;027-880-918-100-338;;100-326-886-906-165;;082-940-218-821-341;;010-633-036-381-97X;;061-084-746-125-840;;026-470-399-924-758;;057-249-429-500-764;;010-152-833-378-258;;000-350-016-926-597;;002-809-590-586-530;;069-067-441-341-258;;012-416-187-818-122;;034-740-122-565-593;;068-477-111-353-913;;055-705-251-460-059;;028-357-155-918-325;;010-038-648-122-112;;062-905-907-703-093;;086-692-162-062-424;;114-585-058-782-886;;038-944-728-272-47X;;018-844-896-174-656;;023-856-944-731-840;;101-517-537-467-705;;166-366-554-482-264;;113-653-136-719-512;;036-995-052-294-798;;021-802-673-755-413;;048-531-036-139-018;;169-098-790-016-696;;108-108-380-591-915;;120-949-039-770-128;;019-376-351-948-115;;107-084-986-741-885;;135-473-933-144-993;;003-021-671-130-685;;022-674-739-446-924;;099-713-428-514-021;;099-590-635-251-167;;007-496-221-857-304;;006-511-842-258-511;;001-700-260-897-699;;035-078-103-181-255;;166-184-779-496-109;;047-350-339-866-109;;084-818-113-171-534;;040-088-132-103-483;;032-633-325-458-994;;026-315-603-754-419;;015-054-478-685-490;;106-922-552-667-802;;029-142-032-583-498;;008-761-741-014-547;;050-037-658-433-244;;011-188-537-102-979;;147-460-029-041-227;;059-177-855-761-441;;154-552-531-660-295;;027-162-949-401-292;;018-802-017-876-024;;156-506-639-841-528;;091-716-150-608-922;;102-918-508-945-089;;070-283-999-199-571;;003-385-211-334-449;;026-825-236-221-046;;010-904-041-654-903;;017-864-956-796-572;;079-572-351-996-824;;046-831-938-719-654;;005-715-467-738-713;;021-581-441-202-186;;010-817-538-531-057;;015-487-968-291-068;;072-843-847-297-848;;010-260-218-932-155;;001-823-251-674-389;;033-465-588-969-178;;028-648-416-934-463;;043-717-905-731-800;;017-752-417-327-009;;097-567-234-089-615;;072-219-875-937-954;;081-474-855-819-920;;001-351-991-581-433;;058-805-630-437-913;;004-023-312-700-266;;002-339-148-765-727;;018-097-950-298-638;;097-141-257-138-856;;054-192-828-540-428;;055-838-594-227-75X;;017-476-623-295-193;;121-232-395-485-161;;048-120-341-468-874;;022-019-320-183-28X;;045-297-861-500-262;;002-926-644-422-025;;030-791-090-371-587;;048-886-823-415-782;;140-144-389-806-773;;042-780-839-743-736;;095-397-545-288-345;;066-468-363-673-22X;;098-244-197-260-558;;009-346-364-845-481;;020-153-118-315-407;;028-316-886-997-759;;011-388-588-342-979;;018-820-980-344-359;;019-380-851-108-00X;;053-015-865-592-960;;189-890-119-460-840;;145-103-056-668-705;;007-049-429-982-011;;137-676-907-941-238;;037-726-617-964-316;;162-114-937-122-390;;018-890-084-693-247;;048-731-740-298-182;;046-278-331-743-622;;046-455-546-163-320;;066-483-437-179-52X;;130-688-830-807-113;;015-176-953-211-370;;010-791-672-524-98X;;069-933-813-979-606;;019-818-039-901-115;;109-593-283-545-771;;000-410-465-176-551;;140-412-611-485-746;;079-352-137-663-063;;028-370-251-005-83X;;095-424-803-840-94X;;034-816-108-525-067;;055-974-350-507-014;;118-291-757-777-762;;048-409-287-285-643;;032-988-090-568-488;;040-074-459-454-755;;004-884-678-898-590;;051-425-933-870-758;;025-845-246-862-762;;046-928-584-934-947;;058-908-500-628-211;;002-305-624-069-664;;087-397-629-837-989;;001-447-332-772-638;;007-484-806-914-230;;005-353-293-536-98X;;070-340-818-332-205;;005-135-888-924-193;;044-151-997-135-163;;109-436-845-685-92X;;061-452-112-388-004;;045-345-822-429-954;;016-368-180-560-853;;114-510-755-626-735;;057-454-562-508-450;;057-215-247-883-957;;043-941-460-892-092;;032-252-559-040-305;;139-096-809-399-037;;002-436-130-957-709;;056-973-005-744-379;;038-203-486-527-901;;041-192-748-557-260;;066-777-191-605-798;;079-687-146-421-837;;023-162-321-997-54X;;001-431-879-214-457;;099-126-277-725-780;;120-641-182-729-178;;006-631-066-782-295;;035-626-761-138-253;;081-874-171-800-834;;011-729-107-009-351;;056-906-981-798-104;;093-475-597-860-540;;075-300-952-942-608;;007-068-027-932-998;;008-682-199-957-338;;076-254-297-138-905;;014-663-040-609-79X;;008-828-288-946-381;;029-803-191-220-024;;016-777-485-780-942;;067-122-879-346-957;;039-577-491-853-974;;022-372-643-613-464;;051-350-006-601-932;;077-426-527-150-745;;005-047-966-450-799;;028-775-642-383-649;;021-516-444-530-037;;014-872-150-577-224;;113-492-184-800-281;;007-773-862-619-835;;045-816-348-564-507;;033-410-673-309-66X;;072-108-116-581-270;;008-226-269-872-067;;036-210-824-876-745;;138-014-059-711-678;;014-597-215-205-226;;119-079-400-373-253;;039-029-824-780-041;;118-503-879-107-347;;072-695-174-001-94X;;118-632-276-477-745;;003-289-172-143-171;;044-611-856-177-401;;033-465-588-969-178;;096-560-257-359-528;;080-342-351-333-205;;002-730-938-989-946;;029-171-584-059-881;;141-778-341-829-539;;073-765-541-698-695;;005-135-888-924-193;;062-062-248-718-327;;062-062-248-718-327;;062-109-326-659-082;;033-200-901-189-634;;056-160-192-809-140;;047-312-129-403-125;;011-166-815-883-094;;132-070-367-283-415;;132-706-623-273-568;;038-216-767-939-171;;031-832-132-614-669;;064-393-798-265-368;;113-982-589-595-53X;;042-075-918-940-005;;041-732-349-226-637;;049-466-305-849-578;;052-422-871-439-42X;;046-131-469-555-433;;077-292-538-037-683;;106-050-590-853-029;;075-428-588-773-811;;006-811-377-029-557;;081-476-724-605-091;;032-552-584-055-351;;125-012-797-581-309;;060-434-632-994-184;;012-006-900-263-969;;025-255-111-526-841;;122-846-871-942-187;;009-889-184-874-024;;087-623-144-467-812,pmc3745022;;10.1038/ng.117;;18408720;;pmc3163504;;10.1038/nature10166;;21720365;;12478681;;10.1002/cncr.10761;;16684597;;10.1016/j.ejso.2006.03.034;;22653804;;10.1002/path.4056;;pmc3939694;;10545015;;10.1023/a:1006611220434;;10.1073/pnas.1115052108;;pmc3207658;;22006311;;16684597;;10.1016/j.ejso.2006.03.034;;21586637;;pmc3111315;;10.1073/pnas.1105422108;;10545015;;10.1023/a:1006611220434;;22653804;;10.1002/path.4056;;pmc3939694;;22653804;;10.1002/path.4056;;pmc3939694;;22653804;;10.1002/path.4056;;pmc3939694;;21586637;;pmc3111315;;10.1073/pnas.1105422108;;10.1093/jnci/djs345;;pmc3692380;;22923510;;10.1093/jnci/djs345;;pmc3692380;;22923510;;12439748;;10.1038/sj.onc.1205924;;10.1016/j.ccr.2004.05.029;;15193256;;16684597;;10.1016/j.ejso.2006.03.034;;21586637;;pmc3111315;;10.1073/pnas.1105422108;;10.1093/jnci/djs345;;pmc3692380;;22923510;;12439748;;10.1038/sj.onc.1205924;;10545015;;10.1023/a:1006611220434;;12183400;;14648662;;10.1002/path.1474;;10.1158/0008-5472.can-07-1320;;17909001;;22261450;;10.1309/ajcplfbk1a2xjdqi;;22355468;;pmc3280068;;10.3802/jgo.2012.23.1.53;;23303603;;10.1126/scitranslmed.3004952;;pmc3757513;;10.1016/j.ygyno.2007.01.045;;17360030;;pmc2705832;;10.1158/1535-7163.mct-06-0433;;17088437;;10.1016/s0140-6736(09)61338-6;;19793610;;10.1016/j.ygyno.2009.12.002;;20106510;;21683865;;pmc3148026;;10.1016/j.humpath.2011.03.003;;10.1038/sj.onc.1203291;;10637508;;10.1016/j.rigapp.2006.05.009;;pmc3163504;;10.1038/nature10166;;21720365;;10.1093/jnci/djs345;;pmc3692380;;22923510;;21586637;;pmc3111315;;10.1073/pnas.1105422108;;10.1158/0008-5472.can-05-2620;;16322209;;15087669;;10.1097/00000478-200404000-00009;;10.1097/00006250-200212000-00045;;10.1016/s0029-7844(02)02630-3;;12468197;;15738045;;10.1097/00006250-200503000-00049;;10.1038/nm1087;;15286780;;pmc2361201;;10.1038/sj.bjc.6603012;;16495918;;10.1016/j.ygyno.2012.01.003;;22245711;;10.1097/01.aog.0000218705.87329.4a;;16738153;;17909045;;10.1158/0008-5472.can-07-0605;;10.1067/mob.2001.108995;;11174481;;10.1111/j.1399-0004.2008.01125.x;;19215248;;10.1093/jnci/djs345;;pmc3692380;;22923510;;19305319;;10.1097/aog.0b013e31819cda77;;pmc2728067;;22752881;;10.1002/ijc.27711;;10.1177/172460089801300411;;10228907;;10.1097/00004347-199301000-00005;;8418076;;18746585;;pmc1780413;;21586637;;pmc3111315;;10.1073/pnas.1105422108;;pmc3163504;;10.1038/nature10166;;21720365;;pmc3260819;;21399237;;10.18632/oncotarget.235;;10.1126/scitranslmed.3002543;;pmc3160649;;21775669;;10.1016/s0889-8545(00)80018-2;;10857117;;21537713;;10.1590/s0104-42302011000200024;;10.7326/0003-4819-121-2-199407150-00009;;8017726;;10.1093/annonc/mdp471;;20176693;;pmc2826099;;17942871;;10.1056/nejmoa071430;;17003399;;10.1001/jama.296.12.1507;;17942872;;10.1056/nejmoa073204;;10.3109/00016349109007922;;1785276;;10.1200/jco.2002.20.5.1248;;10.1200/jco.20.5.1248;;11870167;;10.1016/j.ajog.2004.01.043;;15295350;;10.1093/nar/gkq929;;20952405;;pmc3013785;;22261450;;10.1309/ajcplfbk1a2xjdqi;;20826764;;pmc3076894;;10.1126/science.1196333;;22102435;;pmc3503448;;10.1002/path.3967;;19367689;;10.1016/j.ijgo.2009.02.012;;10547847;;10.1385/1-59259-192-2:365;;21642681;;10.1001/jama.2011.766;;15756773;;10.1097/01.aog.0000152350.10875.02;;15738014;;10.1111/j.1365-2303.2008.00621.x;;19207308;;28445469;;pmc5812436;;10.1038/nature22364;;10.1080/14737140.2016.1192466;;27210216;;12204533;;10.1016/s1535-6108(02)00097-1;;17934467;;10.1038/nmeth1111;;10.1146/annurev.genet.24.1.305;;10.1146/annurev.ge.24.120190.001513;;2088171;;22210467;;pmc3495058;;10.1016/j.ygyno.2011.12.444;;19188670;;10.1200/jco.2009.21.9170;;pmc5611666;;27163957;;10.1097/sla.0000000000001763;;10.1016/j.eururo.2013.08.052;;24018021;;21483804;;10.1371/journal.pgen.1001356;;pmc3069107;;24744574;;10.3748/wjg.v20.i14.3804;;pmc3983438;;10.1200/jco.2008.20.6771;;19451431;;pmc5555376;;28489996;;10.1056/nejmoa1614814;;28177521;;10.1002/bjs.10471;;10.1016/j.eururo.2016.06.010;;27370177;;16166284;;10.1158/0008-5472.can-04-1198;;pmc4314462;;25467404;;10.1016/s1470-2045(14)71123-4;;10.1016/s0140-6736(10)60893-8;;20609468;;26796987;;10.1097/cad.0000000000000336;;10.1038/nrurol.2016.252;;27958391;;pmc5045300;;10.3332/ecancer.2016.675;;27729940;;22750976;;10.1097/mpa.0b013e318258cd9c;;pmc2911110;;10.1186/gb-2010-11-6-r62;;20565776;;10.1016/s0140-6736(10)61121-x;;10.3410/f.5004956.4936054;;20728210;;24875752;;10.1016/j.cca.2014.05.012;;28196593;;10.1016/j.ccell.2017.01.002;;8044798;;27233050;;10.1097/pap.0000000000000118;;1551596;;10.1016/0378-1119(92)90299-5;;27493615;;10.1159/000447284;;pmc4960359;;22149875;;10.1056/nejmoa1113216;;pmc5705202;;10.1016/j.breast.2017.06.024;;28694015;;10.2144/000112890;;18476841;;10.6004/jnccn.2017.0036;;28275037;;10.1073/pnas.0710052104;;pmc2148413;;18077431;;pmc1361723;;10.1101/gr.4452906;;16365382;;10.1126/scitranslmed.3007094;;24553385;;pmc4017867;;10.1038/nature11547;;pmc3530898;;23103869;;15782221;;10.1038/nmeth751;;10.1371/journal.pone.0000197;;pmc1797623;;17299583;;pmc2819115;;20161664;;10.1126/scitranslmed.3000540;;pmc3691570;;23805382;;10.7554/elife.00747;;10.1056/nejmoa1200694;;pmc3563263;;22658128;;10.1200/jco.2004.22.90140.2004;;10.18632/oncotarget.12386;;27705932;;pmc5346680;;18043132;;10.1097/cad.0b013e3282f077b3;;9875137;;10.1002/(sici)1096-9896(199809)186:1<31::aid-path146>3.0.co;2-f;;24476821;;10.1038/nature12965;;pmc3962515;;pmc3704730;;23636398;;10.1038/nature12113;;10.1093/jnci/djw266;;28376157;;pmc5441297;;21490082;;10.1093/nar/gkr217;;pmc3130290;;19880759;;10.1373/clinchem.2003.024893;;14709639;;pmc5423782;;28416139;;10.1016/j.molmed.2017.03.002;;10.1016/j.gastro.2005.05.007;;16083707;;10.1053/j.gastro.2005.05.007;;pmc2377196;;pmc3361449;;22493262;;10.1073/pnas.1119920109;;pmc5353939;;28344886;;10.1080/2162402x.2016.1273302;;27693088;;10.1016/j.jcma.2016.08.005;;28040359;;10.1016/j.eururo.2016.12.008;;10.2144/02331md03;;12139240;;34598952;;10.1158/2159-8290.cd-21-1070;;10.1073/pnas.0810641105;;pmc2600580;;19073917;;10.1101/gr.1878804;;pmc314296;;14707179;;10.1056/nejmcp0901926;;19587342;;10.1073/pnas.1704961114;;28874546;;pmc5617273;;10.1073/pnas.1704961114;;28874546;;pmc5617273;;29348365;;10.1126/science.aar3247;;pmc6080308;;29348365;;10.1126/science.aar3247;;pmc6080308;;10.1016/0027-5107(94)90320-4;;7506357;;28803919;;10.1016/j.stem.2017.07.010;;pmc5591073;;10.1016/j.critrevonc.2017.02.022;;28325261;;10.1007/bf00994018;;23303777;;10.1093/nar/gks1443;;pmc3616734;;10.1016/j.humpath.2016.02.009;;pmc5561423;;26980028;;10.1038/nmeth.1251;;18794863;;pmc3171277;;29061138;;10.1186/s12885-017-3693-7;;pmc5654013;;10.1371/journal.pone.0194268;;pmc5856340;;29547636;;16938544;;10.1016/s0076-6879(06)10001-4;;pmc2823079;;20145119;;10.1158/0008-5472.can-09-1640;;10.1016/j.yuro.2013.07.019;;23822788;;10.1056/nejmc1306040;;23822789;;23822790;;10.1093/genetics/118.2.181;;pmc1203272;;3282984;;15077197;;pmc1181988;;10.1086/420796;;24633422;;10.1007/s00268-014-2485-3;;10.1038/ng1296-457;;8944026;;7866999;;9815967;;pmc2820386;;18602395;;10.1053/j.gastro.2008.05.039;;16258065;;pmc1283450;;10.1073/pnas.0507904102;;23801650;;pmc3800248;;10.1002/cncy.21327;;22366594;;pmc3330705;;10.1016/j.ygyno.2012.02.019;;10.1097/igc.0b013e31825736fd;;22694911;;18660515;;pmc2532726;;10.1093/nar/gkn425;;pmc4084760;;10.1002/sim.6027;;24132938;;29432176;;10.1073/pnas.1717846115;;pmc5828610;;10.1073/pnas.1133470100;;pmc166396;;12857956;;17634482;;10.1200/jco.2006.07.2066;;19252504;;10.1038/nmeth.1307;;pmc2776647;;10.1371/journal.pone.0194268;;pmc5856340;;29547636;;20981092;;pmc3042601;;10.1038/nature09534;;10.3816/ccc.2009.n.014;;pmc3449297;;19739269;;19423501;;10.1086/514228;;9498432;;pmc1801337;;7825587;;10.1093/nar/18.13.3739;;2374708;;pmc331072;;10.1097/00006676-200404000-00004;;15084963;;pmc4876680;;27274308;;10.2147/bctt.s83146;;19023044;;10.1126/science.1162986;;pmc3271178;;10.1158/0008-5472.can-11-2507;;22144471;;25719388;;10.1586/14737159.2015.1019477;;10.1016/j.cllc.2017.02.001;;28416123;;10.1016/j.cytogfr.2006.09.010;;17113338;;10.1007/s10555-014-9547-8;;pmc4776756;;25736266;;pmc4316672;;10.1097/aog.0000000000000484;;25437714;;18604217;;pmc2978646;;10.1038/nmeth.1230;;28251493;;10.1007/s11912-017-0577-6;;29796909;;10.1007/s10620-018-5128-y;;10.26226/morressier.59a6b34ad462b80290b555dc;;23907406;;pmc3809091;;10.1007/s10637-013-0003-3;;10.2217/pgs.09.172;;20350138;;pmc2562413;;10.1073/pnas.0808319105;;18838674;;27959613;;10.1056/nejmoa1607303;;10.1016/j.ajog.2005.01.041;;15846205;;10.1056/nejmoa0900212;;19553641;;10.1093/nar/gkw1121;;27899578;;pmc5210583;;22649089;;10.1126/scitranslmed.3003726;;12735818;;10.18637/jss.v033.i01;;pmc2929880;;20808728;;10.1097/mpa.0b013e31829628f4;;24048457;;21472713;;10.1002/cncr.25701;;pmc3062960;;10.2325/jbcs.13.272;;16929121;;pmc5448652;;10.1111/cas.13210;;28231414;;10.1101/gr.074906.107;;pmc3807531;;19339662;;10.5493/wjem.v2.i5.86;;24520539;;pmc3905586;;26735340;;10.18632/oncotarget.6808;;pmc4868723;;10.1371/journal.pone.0016332;;21298110;;pmc3027657;;17328495;;10.1159/000325682;;10.1016/s1470-2045(11)70214-5;;21862407;;10.1186/s13045-018-0643-z;;30064463;;pmc6069963;;25426838;;pmc4290021;;10.1056/nejmoa1409405;;10.1056/nejmx120044;;10.1016/j.bios.2010.07.106;;20729058;;pmc2946430;;10.1097/00006676-199807000-00012;;9667526;;10.1016/s1470-2045(11)70333-3;;22257524;;20530278;;10.1200/jco.2009.26.4481;;10.1007/978-1-4939-7778-9_26;;29717459;;18458039;;10.1200/jco.2007.14.0590;;pmc5601780;;28938684;;10.18632/oncotarget.16336;;pmc4461726;;10.1155/2015/149014;;26106599;;pmc3477150;;23094052;;10.1371/journal.pone.0047469;;10.1245/s10434-016-5763-5;;28074325;;21368825;;pmc3074107;;10.1038/nature09805;;10.1016/0027-5107(92)90186-6;;1373828;;23238808;;10.1002/em.21756;;18398148;;10.1200/jco.2007.13.7679;;22692591;;10.1007/s00216-012-6162-9;;18367109;;10.1016/j.urolonc.2007.06.002;;pmc5209689;;28051182;;10.1038/srep39999;;10.1126/science.2270482;;2270482;;10.1200/jco.2015.62.3397;;26351349;;07661930;;10.1056/nejm199503303321302;;7661930;;pmc2361201;;10.1038/sj.bjc.6603012;;16495918;;pmc5385631;;28400999;;10.1200/jco.2007.14.2364;;17954709;;pmc3176451;;10.1038/nature08802;;20200521;;10.1200/jco.2005.23.16_suppl.lba3;;10.3410/f.727089161.793539631;;27932067;;pmc5476941;;10.1016/s1470-2045(16)30624-6;;24689646;;10.1586/14737159.2014.905203;;pmc5528374;;22356776;;10.1016/j.molonc.2012.01.010;;pmc10662965;;18815398;;10.1056/nejmra0802714;;pmc2773433;;10.1038/nmeth.1343;;19543287;;pmc2848820;;20081835;;10.1038/nmeth.1416;;10.1101/gr.147686.112;;pmc3638140;;23382536;;10.1126/scitranslmed.3006200;;pmc3973132;;23926200;;10.1101/gr.095190.109;;pmc2752124;;19581485;;10.1073/pnas.1602025113;;pmc4932958;;27303044;;14522891;;23348503;;10.1126/science.1230062;;23568031;;10.1038/labinvest.2013.54;;10.1093/carcin/bgq045;;pmc2864414;;20176654;;pmc2584031;;18945373;;10.1186/1749-8546-3-13;;20660336;;10.1309/ajcp3bzy4yafntrg;;10.1126/science.1229259;;pmc4423787;;23348506;;pmc5554367;;10.1038/nature22079;;28397821;;11283592;;10.1038/86730;;pmc6354672;;10.1093/annonc/mdx008;;28168303;;10.1038/srep45557;;pmc5377334;;28367990;;24035680;;10.1016/j.eururo.2013.08.057;;15175435;;10.1056/nejmoa032691;;10952771;;10.1054/bjoc.2000.1339;;pmc2363529;;10.1002/pmic.200701167;;18528842;;10.1093/nar/gng015;;pmc150247;;12582260;;10.1158/0008-5472.sabcs11-p3-16-05;;10228758;;pmc3250168;;10.1073/pnas.1110064108;;22135472;;10.1016/s1470-2045(10)70268-0;;21147030;;11245480;;25426837;;pmc4306669;;10.1056/nejmoa1408617;;10.1371/journal.pone.0031968;;pmc3282791;;22363777;;10.1016/j.ymed.2012.08.030;;21252315;;10.1126/science.1200609;;pmc3144496;;10.1126/science.1164368;;18772397;;pmc2848990;;pmc3894624;;17320506;;10.1016/j.cell.2007.01.029;;26437032;;10.1038/ng.3414;;10.1073/pnas.1617032114;;28096363;;pmc5293050;;pmc3704730;;23636398;;10.1038/nature12113;;pmc3927368;;24132290;;10.1038/nature12634;;21502498;;10.1073/pnas.1017300108;;pmc3088633;;pmc6057749;;25366685;;10.1200/jco.2014.56.2728;;19733894;;10.1016/j.humpath.2009.06.011;;pmc4271547;;25299156;;10.1038/nprot.2014.170;;pmc3325357;;22079405;;10.1016/j.mad.2011.10.009;;pmc298472;;2594764;;10.1073/pnas.86.23.9253;;pmc4458739;;10.1089/aid.2014.0031;;25748056;;10.1016/s0022-5347(05)67916-5;;10.1097/00005392-200002000-00031;;10647670;;10.1016/j.forsciint.2005.11.017;;16360294;;23530248;;pmc3625331;;10.3410/f.718015949.793477772;;10.1073/pnas.1303607110;;14731128;;10.1111/j.1440-1746.2004.03219.x;;10.1093/carcin/bgi237;;16219636;;21586637;;pmc3111315;;10.1073/pnas.1105422108;;10.1371/journal.pone.0041162;;22815955;;pmc3399813;;pmc3966102;;10.1158/0008-5472.can-13-2498;;24121487;;10.1038/nmeth.1778;;10.1038/npre.2011.5903.1;;22101854;;10.1111/j.1525-1438.2007.01035.x;;17645503;;16452222;;10.1158/0008-5472.can-05-1182;;10.1158/1055-9965.487.13.3;;15006928;;10.3389/fonc.2014.00204;;pmc4127527;;25157335;;10.1038/nbt.1716;;pmc3139991;;21113165;;pmc4709065;;10.1371/journal.pone.0146638;;26752634;;pmc2664327;;10.1038/nmeth.1311;;19287394;;21431776;;10.1007/978-1-61779-089-8_18;;16149882;;10.1586/14737159.5.5.809;;pmc2654379;;18955147;;10.1016/j.ymeth.2008.10.005;;pmc4889384;;10.1073/pnas.1601311113;;27152024;;10.3892/ijo.23.1.41;;12792774;;10.4103/0975-7406.92726;;pmc3283953;;22368395;;29182103;;10.1177/1010428317740296;;29072129;;10.1177/1010428317736643;;pmc4272528;;10.1186/s13059-014-0530-z;;25608559;;10.6026/97320630013202;;28729763;;pmc5512859;;3988773;;10.1016/s0021-9258(18)89090-1;;10.1016/j.sjbs.2014.09.017;;pmc5562385;;28855814;;10.1016/j.ajpath.2015.11.011;;27012190;;pmc5808151;;pmc3989371;;10.1158/1541-7786.mcr-13-0614;;24478461;;19347274;;10.1007/978-1-60327-530-9_6;;10.1016/s0084-4071(10)79492-6;;10.1093/bjaceaccp/mkn041;;10.1038/nmeth.1923;;22388286;;pmc3322381;;10.1007/s10544-011-9602-y;;22069079;;pmc3299890;;10.1007/978-0-387-77498-5_28;;pmc4085574;;10.1158/0008-5472.can-14-0734;;24924775;;15882252;;10.1111/j.1523-1755.2005.00365.x;;10.7326/0003-4819-145-4-200608150-00004;;16908915;;19491263;;10.1158/0008-5472.can-08-4652;;pmc2918393;;pmc3798632;;22863985;;10.2188/jea.je20120003;;10.1038/nm1708;;18408729;;10.1016/j.eururo.2008.01.054;;18243496;;18243511;;10.1016/j.eururo.2008.01.055;;10.1093/bioinformatics/btu356;;24974202;;pmc4271055;;21167051;;10.1186/1471-2164-11-712;;pmc3022918;;18678846;;10.7326/0003-4819-149-3-200808050-00009;;20722160;;10.1016/j.urolonc.2008.12.008;;19181545;;10.1016/j.yexcr.2010.02.036;;20211618;;16258432;;10.1038/sj.bjc.6690427;;pmc2362303;;10360661;;14740499;;10.2144/04361dd03;;27829567;;10.1016/j.bios.2016.10.054;;26268938;;10.1186/s12916-015-0425-1;;pmc4535298;;17060676;;10.1200/jco.2006.08.2644;;pmc4664477;;10.1126/science.aab1785;;26430121;;pmc2704963;;19597549;;10.1371/journal.pone.0006229;;10.1016/s0090-4295(02)02136-2;;12559279;;28469485;;pmc5345949;;10.1177/1179299x16684640;;10.4137/bcbcr.s12443;;pmc5214808;;28096680;;22148227;;10.1021/nn204361s;;pmc1209226;;10.1093/genetics/28.6.491;;17247100;;10.1038/sj.onc.1206349;;12730682;;pmc3244274;;20304628;;10.1016/j.ejca.2010.02.047;;pmc5564444;;10.1016/j.neuron.2014.06.034;;25033177;;28092682;;10.1038/ng.3764;;pmc5663439;;10.2174/138920207781386924;;pmc2430687;;18645599;;12362277;;10.1038/sj.onc.1205564;;10.3233/cbm-150518;;26406418;;pmc3700422;;10.1158/0008-5472.can-11-3909;;22549947;;10.1038/nbt.1710;;pmc3579223;;21113166;;17955361;;10.1007/s10528-007-9114-x;;pmc3069686;;17582071;;10.1056/nejmoa067710;;pmc3219767;;22147957;;23385285;;10.1097/igc.0b013e31828566f1;;25964255;;pmc4463475;;10.1200/jco.2014.59.4945;;pmc3218867;;21527027;;10.1186/gb-2011-12-4-r41;;10.1038/nrg2626;;19997069;;10.1097/gim.0b013e318145b25b;;17873645;;10.1200/jco.2007.25.18_suppl.1115;;15459281;;pmc521679;;10.1093/nar/gnh132;;25589628;;pmc4391639;;10.1158/1078-0432.ccr-13-3474;;pmc3195294;;10.1155/2011/343582;;22084684;;18242356;;10.1016/j.urology.2007.08.031;;12730373;;10.1073/pnas.0936399100;;pmc156303;;20670950;;10.1158/1078-0432.ccr-10-0548;;pmc1770948;;17256055;;10.1172/jci30062;;26935559;;10.1016/j.eururo.2016.02.029;;15607417;;10.1016/j.ygeno.2004.10.005;;18295319;;10.1016/j.ygyno.2008.01.009;;10.1200/jco.2008.26.15_suppl.1027;;7847642;;10.7326/0003-4819-122-5-199503010-00001;;10.1073/pnas.82.9.2895;;pmc397673;;2986144;;17084511;;10.1016/j.eururo.2006.10.044;;10.1016/j.ygyno.2007.10.017;;18061248;;10.1097/grf.0b013e318218c755;;21508697;;22964825;;10.7326/0003-4819-157-11-201212040-00539;;pmc5189938;;10.1371/journal.pmed.1002206;;28027320;;21822318;;21107323;;pmc3143360;;10.1038/nature09626;;11149048;;10.1016/j.ucl.2015.08.006;;26614029;;10.3109/00313021003779145;;20438413;;10.1097/pap.0b013e3182863f80;;23574774;;22158597;;10.1038/nrurol.2011.193;;4531152;;9155557;;pmc1195761;;10.1136/sti.73.1.54;;10.1007/s00428-016-2001-2;;27520411;;pmc5561427;;10.2217/fon.11.135;;22149035;;pmc3312922;;24938522;;10.1158/1078-0432.ccr-14-0365;;pmc4181906;;10.1158/2326-6066.cir-13-0126;;24535937;;pmc3925074;;18408757;;10.1038/onc.2008.113;;17138901;;10.1126/science.1131370;;10.1056/nejmoa041588;;15591335;;pmc2095802;;17932070;;10.1093/nar/gkm760;;10.1038/nrc3239;;pmc4856023;;22437870;;10.1007/3-540-30683-8_443;;28514751;;pmc5522104;;10.18632/oncotarget.17463;;7632227;;07632227;;10.1126/science.7632227;;10.1200/jco.2007.13.5392;;18065730;;24070238;;10.1186/gm492;;pmc3978886;;28814544;;10.1126/scitranslmed.aan2415;;pmc6714979;;19010901;;10.1158/0008-5472.can-08-1776;;10.1056/nejmoa052306;;16236737;;15920524;;10.1038/ng1569;;10.1056/nejmsb1616281;;28355509;;pmc4137876;;25147725;;10.1260/2040-2295.3.4.503;;10.1016/j.bbadis.2009.02.011;;19264125;;10.1038/nmeth.1270;;19034268;;pmc2610436;;10.1002/0471142905.hg1802s62;;pmc3849550;;10.1002/0471142905.hg1802s80;;19582764;;10.1002/0471142905.hg1802s79;;10.1158/0008-5472.can-14-0155;;24840647;;24878357;;10.3109/10408363.2014.914888;;2915370;;10.1093/jnci/81.5.341;;10.1200/jco.2008.26.15_suppl.3529;;28434516;;10.1016/j.jtho.2016.12.027;;10.1126/science.1186802;;pmc3037280;;20220176;;28597078;;10.1007/s00428-017-2164-5;;16236738;;10.1056/nejmoa052122;;10.1200/jco.2006.07.8170;;17557949;;pmc6295668;;10.1126/science.aaa4967;;25838374;;10.1186/1471-2105-9-431;;pmc2575221;;18851737;;26188393;;10.1016/j.eururo.2015.06.044;;25427124;;25427125;;10.1056/nejmc1412266;;25427123;;10.1200/jco.2007.12.8637;;17947727;;10.1016/s1470-2045(13)70240-7;;23810788;;10.3410/f.718052087.793482487;;10.3410/f.718052087.793484800;;pmc5504330;;28573829;;10.1002/cam4.1107;;8015077;;10.1016/s0022-5347(17)32745-3;;7677935;;10.1093/jnci/85.1.53;;7751883;;10.1200/jco.1995.13.6.1384;;23319948;;10.1155/2012/709049;;pmc3540796;;10.1016/s0022-5347(06)00576-3;;16753364;;pmc5497352;;28676103;;10.1186/s12916-017-0885-6;;pmc3437896;;10.1073/pnas.1208715109;;22853953;;16507944;;10.1097/01.aog.0000202401.29145.68;;20164060;;pmc2877986;;10.1074/mcp.m900419-mcp200;;pmc3280870;;22271573;;10.1084/jem.20111117;;10749116;;24030752;;10.1038/modpathol.2013.167;;28474297;;10.1007/s40265-017-0752-y;;26100816;;10.1245/s10434-015-4610-4;;pmc4688202;;10.1002/ijc.25651;;20824703;;10.4172/2157-2518.s1-005;;20886219;;10.1007/s00345-010-0594-7;;10.1002/uog.12270;;22911637;;23881923;;10.1158/1078-0432.ccr-13-1391;;pmc6485449;;10.1016/j.mito.2009.09.004;;pmc5040184;;19788937;;10.1097/pdm.0b013e31818cbdb2;;19214113;;10.1038/nmeth713;;15782177;;10.1093/carcin/bgq239;;21076057;;pmc3026845;;25642631;;10.1038/ng.3202;;9353179;;10.1126/science.278.5340.1054;;2024123;;10.1126/science.2024123;;28055103;;10.3322/caac.21387;;28252003;;10.1038/nrclinonc.2017.14;;12771727;;10.1097/01.ju.0000066842.45464.cc;;28378010;;10.1016/j.gore.2017.03.007;;pmc5369329;;24552892;;10.1097/igc.0000000000000073;;10.1007/s00345-016-1928-x;;27604375;;28276230;;10.1056/nejmc1615559;;28273022;;10.3390/cancers9010008;;10.1016/j.cell.2005.04.028;;16009139;;26253305;;10.1053/j.gastro.2015.07.041;;pmc4782782;;29557778;;10.7554/elife.32143;;pmc5860864;;25931582;;pmc4624443;;10.1182/blood-2015-03-631747;;26515115;;pmc4647555;;10.1101/gad.269498.115;;19360079;;pmc2821689;;10.1038/nature07943;;10.1002/pmic.200700199;;17549799;;10.1002/ijc.30133;;27062469;;28387913;;10.1200/jco.2007.25.18_suppl.3520;;9865743;;pmc5392345;;28061466;;10.18632/oncotarget.14501;;9258625;;10.1002/(sici)1097-0339(199708)17:2<153::aid-dc13>3.0.co;2-f;;10.1038/nature11632;;pmc3498066;;23128226;;pmc1356122;;10.1101/gr.3825705;;16339382;;26035703;;pmc4506388;;10.1038/bjc.2015.202;;pmc3280224;;10.1371/journal.pone.0031597;;22355378;;10.1371/journal.pone.0001281;;pmc2093996;;18060075;;14600122;;pmc1770101;;10.1136/jcp.56.11.805;;22787200;;10.1158/1055-9965.epi-12-0138-t;;pmc3437007;;2847780;;10.1021/bi00416a027;;10.1126/science.1260825;;25554788;;pmc4446723;;10.1073/pnas.1221068110;;pmc3568331;;23345422;;10.3748/wjg.v21.i37.10573;;pmc4588079;;26457017;;3942423;;10.1097/00000658-198601000-00013;;pmc1251042;;26030518;;10.1056/nejmoa1505270;;10.1016/s0140-6736(10)60892-6;;20609467;;25613900;;10.1126/science.1260419;;21041413;;10.1101/gr.109157.110;;pmc2989997;;16817944;;10.1186/bcr1510;;pmc1557735;;1863986;;10.1016/0009-8981(91)90247-a;;10.1080/14712598.2017.1309389;;28335643;;10.1016/j.gde.2014.04.002;;25282114;;pmc5480293;;10430926;;pmc17763;;10.1073/pnas.96.16.9236;;26559569;;10.1056/nejmp1508811;;25719666;;pmc4523082;;10.1038/nature14169;;16199623;;10.1097/01.aog.0000172423.64995.6f;;10.1126/scitranslmed.aaa8507;;26109104;;pmc4587492;;10.1073/pnas.1511694112;;26195750;;pmc4534284;;pmc5601676;;10.18632/oncotarget.17272;;28938580;;10.1126/scitranslmed.aap8793;;29563323;;pmc6320220;;27101364;;pmc4887204;;10.7554/elife.13879;;10.1016/j.cancergen.2012.06.005;;22867995;;pmc5238783;;28000852;;10.3892/ijo.2016.3811;;28881675;;10.18632/oncotarget.18305;;pmc5584276;;10.18632/oncotarget.2660;;25474136;;pmc4322995;;pmc4822694;;10.1586/14789450.2016.1122529;;26581546;;30064438;;10.1186/s12943-018-0860-7;;pmc6069835;;10.1093/nar/gkn133;;18385155;;pmc2396435;;10.1016/j.cgh.2014.10.015;;25424572;;pmc5019545;;10.1021/pr025506q;;12645900;;10.1093/ajcp/114.3.412;;10989642;;10.1038/nrc1697;;16110317;;17283152;;10.1158/0008-5472.can-06-2101;;pmc4313872;;10.1038/nm.3733;;25326804;;pmc6085584;;30045829;;10.1016/j.ebiom.2018.06.026;;pmc5404666;;28438180;;10.1186/s13045-017-0467-2;;22991414;;pmc3500447;;10.1158/1078-0432.ccr-12-1215;;10.1016/j.urolonc.2014.06.008;;25037483;;11992840;;10.1016/s0090-4295(02)01529-7;;28410303;;10.1097/ppo.0000000000000255;;pmc4996934;;27546487;;10.1038/ncomms12484;;10.1378/chest.12-1917;;23287985;;10.26355/eurrev_201808_15616;;30070314;;29509247;;10.26355/eurrev_201802_14381;;10.1021/tx3000889;;22515372;;pmc3536064;;10.1038/ng.2760;;24071852;;pmc3966983;;10.1006/gyno.2001.6400;;11606097;;29137182;;pmc5704173;;10.1002/path.4975;;28925567;;pmc6019974;;29963195;;10.3892/ol.2018.8700;;29762832;;10.26355/eurrev_201804_14819;;30070313;;10.26355/eurrev_201808_15617;;10.1002/cncy.21716;;27019161;;10.1016/j.ygyno.2009.05.019;;19501894;;9488584;;10.1242/dev.001131;;17928417;;10.1002/pd.2150;;19003785;;10.1093/annonc/mdx083;;28327984;;24013103;;10.1515/cclm-2013-0151;;10.1089/thy.2013.0403;;24295088;;23780408;;pmc3864404;;10.1002/path.4230;;6310399;;10.1056/nejm198310133091503;;pmc4878148;;10.1038/nature14969;;26416732;;10.1038/nrc4019;;26493647;;pmc4892184;;10.1016/j.ajog.2005.05.005;;16260202;;10.1097/01.aog.0000187892.78392.3f;;16319259;;10.1016/s0016-5107(97)70149-4;;9165320;;10.1038/labinvest.3700103;;15077125;;10.1016/s0010-7824(02)00353-0;;12384202;;pmc4880836;;10.1186/s40661-015-0008-z;;27231561;;10.1016/j.ygyno.2013.12.009;;24333842;;pmc3932113;;14522897;;10.1038/nature00766;;12068308;;16790114;;10.1016/s1472-6483(10)61192-3;;pmc4522327;;10.1016/j.ygyno.2015.06.005;;26050923;;16502175;;10.1007/s00270-005-0167-0;;pmc2893622;;10.2353/jmoldx.2010.090200;;20413681;;10.1111/j.1572-0241.2003.08666.x;;10.1016/s0002-9270(03)01699-x;;14687813;;10.1093/jnci/dju410;;25628372;;10.1016/j.ejca.2012.12.027;;23485231;;10.1111/j.1572-0241.2003.07530.x;;12873573;;10.1016/s0002-9270(03)00359-9;;pmc3961140;;22930283;;10.1002/cncr.27782;;10.1158/2159-8290.cd-13-1014;;pmc4433544;;24801577;;12907095;;10.1016/s0029-7844(03)00480-0;;12839961;;16885660;;10.1097/00003081-200609000-00013;;10.1158/1538-7445.am2016-ct104;;10.1073/pnas.0712345105;;pmc2393770;;18337506;;22102435;;pmc3503448;;10.1002/path.3967;;pmc4442685;;25877891;;10.1126/scitranslmed.aaa7161;;19746182;;pmc2739011;;10.1155/2010/932371;;10.1056/nejmoa020119;;12023992;;23273873;;10.1016/j.ejso.2012.12.003;;10.1097/01.pas.0000213335.40358.47;;17255760;;23268721;;10.1186/1559-0275-9-14;;pmc3552982;;10.1186/1559-0275-10-4;;23557354;;pmc3637236;;21990067;;10.1002/path.3023;;pmc4782784;;20154587;;10.1097/pas.0b013e3181cf3d79;;pmc2841791;;10.1097/aog.0b013e3182783c2f;;23232752;;17117391;;10.1002/path.2091;;10.1200/jco.2008.18.1107;;pmc2652087;;18854563;;10.1148/radiol.10100213;;pmc6939954;;20505067;;16053388;;10.1089/thy.2005.15.708;;10439003;;10.1016/s0015-0282(99)00207-1;;17270244;;10.1016/j.humpath.2006.11.010;;10.1159/000328368;;11726122;;10.1016/j.ygyno.2006.05.029;;16806438;;10.1016/j.ajog.2014.01.003;;24412119;;26181193;;10.1001/jamaoncol.2015.1618;;pmc4935931;;16434898;;10.1097/01.pas.0000180854.28831.77;;24316306;;pmc3991859;;10.1016/j.ygyno.2013.11.030;;8355950;;10.1038/nature12065;;23563269;;24705333;;pmc4016134;;10.1038/nm.3519;;25575893;;10.1136/gutjnl-2014-307475;;23937438;;10.1146/annurev-pathol-020712-163949;;pmc4593588;;26436540;;10.1371/journal.pcbi.1004416;;pmc3791619;;10.1097/aog.0b013e3181a11c64;;19384117;;10.1038/nature14410;;26017449;;10.1097/aog.0b013e318298def5;;23969786;;26669862;;10.1158/0008-5472.can-15-1382;;pmc4703449;;10.1016/j.ccr.2013.10.013;;pmc3917315;;24332043;;12893227;;10.1016/s0090-8258(03)00365-2;;10.1002/path.1000;;11745677;;12023993;;10.1056/nejmoa012158;;10.1038/modpathol.2010.119;;20562848;;10.1016/j.ygyno.2007.11.013;;18155273;;14983501;;10.1002/cncr.20080;;10.1016/j.ygyno.2010.11.016;;pmc4843123;;21146201;;10.3322/caac.21254;;25559415;;12644542;;10.1093/jnci/95.6.484;;10.1158/1538-7445.am2015-2839;;10.1007/s00270-013-0823-8;;24366313;;pmc4095747;;24549645;;10.1002/path.4252;;23878203;;10.12809/hkmj133972;;21606739;;10.1097/aog.0b013e31821b5118;;10.1002/cncr.22594;;17373668;;pmc3749880;;23539594;;10.1126/science.1235122;;17561170;;10.1016/j.juro.2007.03.131;;22158988;;pmc3248495;;10.1073/pnas.1118046108;;pmc3148940;;20981102;;10.1038/nature09515;;10.1016/j.ejogrb.2013.08.003;;24017961;;10.1101/sqb.1999.64.71;;11232339;;16817944;;10.1186/bcr1510;;pmc1557735;;10.1126/scitranslmed.3007094;;24553385;;pmc4017867;;23598174;;10.1016/s1470-2045(13)70110-4;;15269313;;10.1056/nejmoa033025;;10.1158/2159-8290.cd-16-0607;;pmc5164915;;27856443;;10.1002/pd.3921;;22692721;;10.1038/ng.448;;pmc3562712;;19767754;;10.1158/2159-8290.cd-13-1014;;pmc4433544;;24801577;;18264105;;pmc3439997;;10.1038/nmeth.1184;;18264105;;pmc3439997;;10.1038/nmeth.1184;;30410101;;10.1038/s41576-018-0071-5;;10.1093/nar/21.9.2284;;10.1007/978-1-4939-2553-7_10;;17923760;;pmc2694379;;10.3346/jkms.2007.22.s.s79;;10.1093/oxfordjournals.jbchem.a134606;;6323394;;10.1016/j.gie.2008.07.033;;19152896;;21586637;;pmc3111315;;10.1073/pnas.1105422108;;pmc3641759;;23197571;;10.1126/scitranslmed.3004742;;22829749;;pmc3398667;;10.1155/2012/251364;;27018799;;10.1038/nbt.3520;;pmc4907374;;19842214;;10.1002/humu.21122;;10.1038/s41598-019-41215-z;;pmc6423013;;30886209;;26248467;;10.1186/s12864-015-1806-8;;pmc4528782;;pmc3481703;;23113152;;18846087;;10.1038/nbt1486;;10.1200/jco.2007.14.5482;;18332469;;10.2214/ajr.171.6.9843295;;9843295;;10.1038/nmeth.f.248;;pmc2703445;;19349981;;25108476;;10.1016/j.tig.2014.07.001;;28078112;;pmc5177568;;10.21037/jgo.2016.11.02;;10.1038/s41568-018-0076-6;;30420765;;26015395;;pmc4652990;;10.18632/oncotarget.4040;;10.14744/ejmo.2017.22931;;25309068;;pmc4188889;;10.3748/wjg.v20.i37.13325;;22653804;;10.1002/path.4056;;pmc3939694;;pmc5777224;;29346214;;10.1097/mpa.0000000000000973;;9539251;;10.1093/jnci/90.7.540;;10518134;;10.1159/000331294;;20715668;;10.1159/000325189,"Qiu (Nature Genetics, May 2008, vol. 40, pp. 650-655).;;The Cancer Genome Atlas Research Network (Nature, Jun. 2011, vol. 474, pp. 609-616).;;Schorge (Cancer (Cancer Cytopathol) 2002; 96:338-43).;;Sharma (EJSO 2006, vol. 32, pp. 818-824).;;McConechy (J Path 2012; 228:20-30 and supplementary table, pp. 1-11).;;Dokianakis (Clin & Exp. Metastasis 17: 293-297, 1999).;;Walsh et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. PNAS; 2011 108; 44: p. 1-6.(Epub Oct. 17, 2017) (Year: 2011).;;Sharma and Menon. Screening for gynaecological cancers. EJSO; 2006; vol. 32: p. 818-824. (Year: 2006).;;Kinde et al. Detection and quantification of rare mutations with massively parallel sequencing. PNAS; 2011; 108: 9530-9535. (Year: 2011).;;Dokianakis et al. Ras gene activation in malignant cells of human ovarian carcinoma peritoneal fluids. Clinical & Experimental Metastasis; 1999; 17: 293-297. (Year: 1999).;;McConechy et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Path; 2012; 228: 20-30. (Year: 2012).;;McConechy et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Path; 2012; 228: 20-30. Supplemental Table 1. (Year: 2012).;;McConechy et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Path; 2012; 228: 20-30. Supplemental Table 2. (Year: 2012).;;Kinde et al. PNAS; 2011; 108:9530-9535 cited on IDS. (Year: 2011).;;Kuhn et al. Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses. J Natl Cancer Inst. 2012; 104:1503-1513. (Year: 2012).;;Kuhn et al. Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses. J Natl Cancer Inst. 2012; 104:1503-1513. Supplemental Table 2. (Year: 2012).;;Moreno-Bueno et al. Abnormalities of the APC/b-catenin pathway in endometrial cancer. Oncogene; 2002; 21: 7981-7990. (Year: 2002).;;Ellenson and Wu. Focus on endometrial and cervical cancer. Cancer Cell; 2004; 5; p. 533-538. (Year: 2004).;;Sharma and Menon. EJSO; 2006; vol. 32: pp. 818-824. (Year: 2006).;;Kinde et al. PNAS; 2011; 108: 9530-9535. (Year: 2011).;;McConechy et al. J Path; 2012; 228: 20-30 and Supplementary Tables 1-2. (Year: 2012).;;Kuhn et al. J Natl Cancer Inst. Aug. 2012; 104:1503-1513. (Year: 2012).;;Moreno-Bueno et al. Oncogene; 2002; 21: 7981-7990. (Year: 2002).;;Dokianakis et al. Clinical & Experimental Metastasis; 1999; 17: 293-297. (Year: 1999).;;Walsh et al. PNAS; 2011 108; 44: p. 1-6 (Epub Oct. 17, 2017). (Year: 2011).;;Spruck et al. Cancer Research; 2002; 62, 4535-4539. (Year: 2002).;;Cassia et al. Pathol 2003; 201: 589-595. (Year: 2003).;;Akhoondi et al. Cancer Res; 2007; 67: (19): 9006-9012. (Year: 2007).;;Sams et al., ‘Liquid-based Papanicolaou tests in endometrial carcinoma diagnosis. Performance, error root cause analysis, and quality improvement’ American Journal of Clinical Pathology, vol. 137, No. 2, pp. 248-254 (Feb. 28, 2012).;;SUH et al., ‘Major clinical research advances in gynecologic cancer in 2011’ Journal of Gynecologic Oncology, vol. 23, No. 1, pp. 53-64 (Jan. 9, 2012).;;Kinde et al., ‘Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers’ Science Translational Medicine. vol. 5, Issue 167, Article No. 164ra, pp. 1-10 (Jan. 9, 2013).;;International Search Report and Written Opinion for PCT/US2013/065342, dated Apr. 1, 2014.;;European Office Action issued in related European Application No. 13851273.6, dated Apr. 19, 2017.;;Kang et al., “Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma,” Gynecology Oncology, 105 (2007) 662-666.;;Chinese Office Action dated Mar. 3, 2017 in related Chinese Application No. 201380068411.8.;;Ikediobi et al., “Mutation analysis of 24 known cancer genes in the NCI-60 cell line set,” Molecular Cancer Therapeutics, 5(11), Nov. 2006.;;Hennessy et al., “Ovarian cancer,” Lancet, vol. 374, Oct. 17, 2009.;;Byron et al., “FGFR2 mutations are rare across histologic subtypes of ovarian cancer,” Gynecologic Oncology 117 (2010), 125-129.;;Kurman et al., “Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-Shifting the paradigm,” Human Pathology (2011) 42, 918-931.;;Huntsman et al. “MLL2, the second human homolog of the Drosophila trithorax gene, maps to 19q13.1 and is amplified in solid tumor cell lines,” Oncogene (1999), 18, 7975-7984.;;International Search Report and Writen Opinion for PCT/US2013/065342, dated Apr. 1, 2014.;;Extended European Search Report issued in related European Application No. 13851273.6, dated Jun. 1, 2016.;;Elmasry et al., “Genetic mutations in gynaecological cancers,” Reviews in Gynaecological and Preinatal Practice, vol. 6, No. 3-4, Sep. 1, 2006, pp. 115-125.;;Bell et al., “Integrated genomic analyses of ovarian carcinoma,” Nature, vol. 474, No. 7353, Jun. 1, 2011, pp. 609-615.;;Kuhn et al, “Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses,” Journal of the National Cancer Institute, vol. 104, No. 19, Aug. 23, 2012, pp. 1503-1513.;;Kinde et al., “Detection and quantification of rare mutations with massively parallel sequencing,” PNAS, vol. 108, No. 23, May 17, 2011, pp. 9530-9535.;;Ernani et al, “Agilent's SureSelect Target Enrichment System: Brining Cost and Process Efficiency to Next-Generation Sequencing,” Agilent Technologies—Product Notes, Mar. 16, 2009, pp. 1-8.;;Japanese Office Action issued in related Japanese Application No. 201380068411.8, dated Apr. 19, 2016.;;Zhang, “Study of Use of Liquid-based Cytologic Test in Cervical Cancer and Endometrial Carcinoma Screening,” China Master Dissertations Full-text Database, 2005, No. 8, pp. 4-28.;;Oda et al., “High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma,” Cancer Research, vol. 65, No. 23, Dec. 1, 2005, pp. 10669-10673.;;Malpica et al., “Grading ovarian serous carcinoma using a two-tier system,” Am J Surg Pathol 28, 496-504 (2004).;;ACOG Committee Opinion: No. 280, Dec. 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer, Obstet Gynecol 100, 1413-1416 (2002).;;ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. No. 60, Mar. 2005, Pregestational diabetes mellitus. Obstet Gynecol 1 05, 675-685 (2005).;;American Cancer Society. Detailed guide: ovarian cancer—can ovarian cancer be found early? (Available at http://www.cancer.org/Cancer/OvarianCancer/DetailedGuide/ovariancancer-detection).;;Vogelstein et al., Cancer genes and the pathways they control. Nat ˜Med 10, 789-799 (2004).;;Hamilton et al., Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 94, 642-646 (2006).;;Gunderson et al., “Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review,” Gynecol Oncol 125, 477-482 (2012).;;DeSimone et al., Rate of pathology from atypical glandular cell Pap tests classified by the Bethesda 2001 nomenclature. Obstet Gynecol 107, 1285-1291 (2006).;;Rago, et al., Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res 67, 9364-9370 (2007).;;Geier et al., Clinical evaluation of atypical glandular cells of undetermined significance. Am J Obstet Gynecol 184, 64-69 (2001).;;Barrow et al., Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 75, 141-149 (2009).;;Kuhn et al., Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses. J Natl Cancer Inst, (2012).;;Partridge et al., Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 113, 775-782 (2009).;;Bray et al., Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer, (2012).;;Meden et al., CA 125 in benign gynecological conditions. Int J Biol Alarkers 13, 231-237 (1998).;;Mitchell et al., Accuracy and survival benefit of cytological prediction of endometrial carcinoma on routine cervical smears. Int J Gynecol Pathol 12, 34-40 (1993).;;Traut et al., Cancer of the Uterus: The Vaginal Smear in Its Diagnosis. Cal West J\!fed 59, 121-122 (1943).;;Kinde et al., Detection andquantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci US A 108, 9530-9535 (2011).;;Bell et al., Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).;;International Preliminary Report on Patentability issued in PCT/US2013/065342, dated May 5, 2015, 7 pages.;;He et al., IgH gene rearrangements as plasma biomarkers in Non-Hodgkin's lymphoma patients. Oncotarget2, 178-185 (2011).;;Wu et al., Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Afed 3, 92ra66 (2011).;;Cooper et al., Endometrial sampling techniques in the diagnosis of abnormal uterine bleeding. Obstet Gynecol Clin North Am 27, 235-244 (2000).;;Marques et al., Atypical glandular cells and cervical cancer: systematic review. Rev Assoc Af ed Bras 57, 234-238 (2011).;;Carlson et al., Screening for ovarian cancer. Ann Intern Afrd 121, 124-132 (1994).;;Ries et al., SEER Survival Afonograph: Cancer Survival Among Adults: US SEER Program, 1988-2001, Patient and Tumor Characteristics (NIH Pub. No. 07-6215. National Cancer Institute, Bethesda, MD, 2007).;;Arbyn et al., European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition—summary document. Ann Oncol 21, 448-458 (2010).;;Mayrand et al., Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357, 1579-1588 (2007).;;Howlader et al., SEER Cancer Statistics Review, 1975-2009 (National Cancer Institute.Bethesda, MD, 2012).;;Lindor et al.,Press, Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JA,HA 296, 1507-1517 (2006).;;Naucler et al.,Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J 1\fed 357, 1589-1597 (2007).;;Smith et al.,Transvaginal ultrasound for identifying endometrial abnormality. Acta Obstet Gynecol Scand 70, 591-594 (1991).;;Bristow et al., Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20, 1248-1259 (2002).;;Insinga et al., Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol 191, 105-113 (2004).20.;;Forbes et al., COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39, D945-950 (2011).;;Sams et al.., Liquid-based Papanicolaou tests in endometrial carcinoma diagnosis. Performance, error root cause analysis, and quality improvement. Am J Clin Pathol 137, 248-254 (2012).;;Jones et al., Papadopoulos, Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330, 228-231 (2010).;;Jones et al., Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol 226, 413-420 (2012).;;Pecorelli, Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105, 103-104 (2009).;;Rozen et al.,Primer3 on the WWW for general users and for biologist programmers. Methods Afol Biol 132, 365-386 (2000).;;Buys et al., Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305, 2295-2303 (2011).;;Screening for ovarian cancer: recommendation statement. U.S. Preventive Services Task Force. Am Fam Physician 71, 759-762 (2005).;;Sharpless et al., Dysplasia associated with atypical glandular cells on cervical cytology. Obstet Gynecol 1 05, 494-500 (2005).;;Extended European Search Report in Application No. 18193794.7, dated Dec. 19, 2018.;;Patel et al., “Endometrial carcinoma detected with SurePath liquid-based cervical cytology: comparison with conventional cytology”, CYTOPATHOLOGY, vol. 20, No. 6, pp. 380-387, 2009.;;“Consensus sequence” (online) Oct. 4, 2011 <https://en.wikipedia.org/w/index.php?title=Consensus_sequence&oldid=423354064>.;;“Polymerase chain reaction” (online) 2011, <https://web.archive.org/web/20110203140027/https:en.wikipedia.org/wiki/Polymerase>.;;Abbosh et al., “Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution”, Nature 545: 446-451, 2017.;;Abdel-Rahman, “Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis.”, Expert Rev Anticancer Ther 16(8): 885-91, 2016.;;Agus et al., “Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth”, Cancer Cell 2: 127-137, 2002.;;Albert et al., “Direct selection of human genomic loci by microarray hybridization”, Nat. Methods 4: 903-905, 2007.;;Albertini et al., “In vivo somatic mutations in humans: measurement and analysis.”, Annu Rev Genet 24: 305-326, 1990.;;AlHilli et al., “Incidence and factors associated with synchronous ovarian and endometrial cancer: a population-based case-control study.”, Gynecologic oncology 125: 109-113, 2012.;;Allegra et al., “American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.”, J. Clin. Oncol. 27: 2091-2096, 2009.;;Allen et al., “Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma.”, Ann Surg 265(1): 185-191, 2017.;;Allory et al., “Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome”, Eur Urol 65: 360-366, 2014.;;Alvarez et al., “Widespread Hypomethylation Occurs Early and Synergizes with Gene Amplification during Esophageal Carcinogenesis”, PLOS Genetics, vol. 7, issue 3, e1001356, 1-14 pages, 2011.;;Alvarez-Chaver et al., “Proteomics for discovery of candidate colorectal cancer biomarkers”, World J. Gastroenterol. 20(14): 3804-3 824, 2014.;;Andre et al., “Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.”, J Clin Oncol 27(19): 3109-3116, 2009.;;Anglesio et al., “Cancer-Associated Mutations in Endometriosis without Cancer”, N Engl J Med 376: 1835-1848, 2017.;;Ansari et al.,“Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma”, Br J Surg 104(5): 600-607, 2017.;;Antoni et al., “Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.”, Eur Urol, 71(1), 96-108, 2017.;;Araten et al., A quantitative measurement of the human somatic mutation rate., Cancer Res 65: 8111-8117, 2005.;;Arnold et al., “Global burden of cancer attributable to high body-mass index in 2012: a population-based study.”, The Lancet. Oncology 16, 36-46, 2015.;;Audeh et al., “Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.”, Lancet 376: 245-251, 2010.;;Awada et al., “An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors”, Anticancer Drugs 27(4): 342-8, 2016.;;Baard et al., Diagnostic dilemmas in patients with upper tract urothelial carcinoma., Nat Rev Urol, 14(3), 181-191, 2017.;;Baehner, “The analytical validation of the Oncotype DX Recurrence Score assay”, Ecancermedicalscience 10: 675, 2016.;;Bahuva et al., “Morphologic abnormalities are poorly predictive of visceral pain in chronic pancreatitis.”, Pancreas 42(1): 6-10, 2013.;;Bainbridge et al., “Whole exome capture in solution with 3 Gbp of data” Genome Biology, 11(6): R62, 2010.;;Bang et al., “Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial”, Lancet 376: 687-697, 2010.;;Bansal et al., “Low-and high-grade bladder cancer appraisal via serum-based proteomics approach,”, Clin Chim Acta 436: 97-103, 2014.;;Bardelli et al., “Liquid Biopsies, What We Do Not Know (Yet)”, Cell Press, 31, 172-179, 2017.;;Baretton et al., “Inerphase Cytogenetic Analysis of Prostatic Carcinomas by Use of Nonisotopic in Situ Hybridization”, Cancer Research 54, 4472-4480, 1994.;;Barkan et al., “The Paris System for Reporting Urinary Cytology: The Quest to Develop a Standardized Terminology,”, Adv AnatPathol 23:193-201, 2016.;;Barnes, “The fidelity of Taq polymerase catalyzing PCR is improved by an N-terminal deletion”, Gene 112:29-35, 1992.;;Barroso-Sousa et al., “Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer”, Breast Care 11(3): 167-173, 2016.;;Baselga et al., “Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer”, N Engl J Med 366: 109-119, 2012.;;Beddowes et al., “Predicting treatment resistance and relapse through circulating DNA.”, Breast 34(Suppl 1): S3 1-S35, 2017.;;Bell et al., “A simple way to treat PCR products prior to sequencing using ExoSAP-IT” BioTechniques, 2008.;;Benson et al., “Colon Cancer, Version 1.2017”, NCCN, vol. 15, No. 3, 370-398, 2017.;;Beroukhim et al., “Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma”, Proceedings of the National Academy of Sciences, 104: 20007-20012, 2007.;;Bertone et al., “Design optimization methods for genomic DNA tiling arrays”, Genome Res 16(2): 271-281, 2006.;;Bettegowda et al., “Detection of Circulating Tumor DNA in Early-and Late-Stage Human Malignancies”, Science translational medicine 6(224): 224ra224, 2014.;;Biankin et al., “Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.”, Nature 491(7424): 399-405, 2012.;;Bielas et al., “Quantification of random genomic mutations.”, Nat. Methods, 2: 285-290, 2005.;;Binladen et al., “The Use of Coded PCR Primers Enables High-Throughput Sequencing of Multiple Homolog Amplification Products by 454 Parallel Sequencing” PLoS One, 9 pages, Feb. 14, 2007.;;Boyd et al., “Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing.”, Science Trans lat. Med., vol. 1, 12ra23, Supplementary material, pp. 1-30, 2009.;;Bozic et al., “Evolutionary dynamics of cancer in response to targeted combination therapy”, Elife 2: e00747, 2013.;;Brahmer et al., “Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.”, N Engl J Med, 366(26): 2455-65, 2012.;;Burris et al., “Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days”, J. Clin. Oncol. 22: 128, 2004.;;Calvez-Kelm et al., “KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control”, ONCOTARGET, vol. 7, No. 48, 2016.;;Camidge et al., “A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors”, Anticancer Drugs 19: 77-84, 2008.;;Campbell et al., “No difference in stem cell somatic mutation between the background mucosa of right-and left-sided sporadic colorectal carcinomas.”, J Pathol 186: 31-35, 1998.;;Cancer Genome Atlas Research Network, “Comprehensive molecular characterization of urothelial bladder carcinoma.”, Nature 507: 315-322, 2014.;;Cancer Genome Atlas Research, “Integrated genomic characterization of endometrial carcinoma.”, Nature 497: 67-73, 2013.;;Capello et al., “Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.”, J Natl Cancer Inst 109(4), 2017.;;Casbon et al., “A method for counting PCR template molecules with application to next-generation sequencing,” Nucleic Acids Research, 1-8, 2011.;;Chai et al., Field effect in cancer-an update. Ann Clin Lab Sci 39: 331-337, 2009.;;Chan et al., “Size Distributions of Maternal and Fetal DNA in Maternal Plasma”, Clinical chemistry 50: 88-92, 2004.;;Chan, “Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Recommendations for a public health approach”, Second Edition, BOOK, 2016.;;Chang et al., “CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond”, Trends Mol Med 23(5): 430-450, 2017.;;Chari et al., “Probability of pancreatic cancer following diabetes: a population based study”. Gastroenterology 129(2): 504-511, 2005.;;Chen et al., “Aristolochic acid-associated urothelial cancer in Taiwan”, Proc Natl Acad Sci US A, 109(21): 8241-8246, 2012.;;Chen et al., “CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy”, Oncoimmunology 6(2): e1273302, 2016.;;Chen, “Immune checkpoint inhibitors for nonsmall cell lung cancer treatment”, J. Chin Med Assoc 80(1): 7-14, 2017.;;Cheng et al., “TERT Promoter Mutations Occur Frequently in Urothelial Papilloma and Papillary Urothelial Neoplasm of Low Malignant Potential.”, Eur Urol 71 :497-498, 2017.;;Chetverina et al., “Molecular colony diagnostics: detection and quantitation of viral nucleic acids by in-gel PCR.”, Biotechniques 33: 150-152, 154, 156, 2002.;;Cheung et al., “High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.”, Cancer Discov 1, 170-185, 2011.;;Chiu et al., “Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma”, Proc Natl Acad Sci US A 105: 20458-20463, 2008.;;Chu et al., J. Clin. Oncol. 22:14S, abstr 2078, 2004.;;Chung et al., “A whole-genome mouse BAC microarray with 1-Mb resolution for analysis of DNA copy number changes by array comparative genomic hybridization.”, Genome Res. 14(1): 188-196, 2004.;;Clarke-Pearson, “Clinical Practice, Screening for ovarian cancer.”, N Engl J Med., 361(2): 170-177, 2009.;;Cohen et al., “Combined biomarker-based liquid biopsy for the earlier detection of pancreatic cancers”. Proceedings of the National Academy of Sciences of the United States of America, vol. 114, No. 38, pp. 10202-102075, Sep. 2017.;;Cohen et al., “Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers”, PNAS, vol. 114, No. 38, 10202-10207, 2017.;;Cohen et al., “Detection and localization of surgically resectable cancers with a multi-analyte blood test”, Science, 359(6378): 926-930, 2018.;;Cohen et al., “Detection and localization of surgically resectable cancers with a multi-analyte liquid biopsy”, Science, 82 pages, 2017.;;Cole et al., “Working paper No. 3 Somatic mutant frequency, mutation rates and mutational spectra in the human population in vivo”, Mutat Res 304: 33-105, 1994.;;Coombs et al., “Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes”, Cell Stem Cell 21(3): 374-382, 2017.;;Corona et al., “CDK4/6 inhibitors in HER2-positive breast cancer”, Cri Rev Oncol Hematol 112: 208-214, 2017.;;Cortes et al., “Support-Vector Networks”, Machine learning 20: 273-297, 1995.;;Costello et al., “Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation.”, Nucleic acids research 41: e67, 2013.;;Cowan et al., “Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder.”, Hum Pathol., 53: 8-13, 2016.;;Craig et al., “Identification of genetic variants using bar-coded multiplexed sequencing.”, Nat Methods 5: 887-893, 2008.;;Cree et al., “The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review”, BMC Cancer, 17: 697, 1-17, 2017.;;D'Souza et al., “Tumor characterization by ultrasound-release of multiple protein and microRNA biomarkers, preclinical and clinical evidence”, PLOS ONE, 1-17 pages, 2018.;;Dalma-Weiszhausz et al., “The affymetrix GeneChip platform: an overview.”, Methods Enzymol. 410: 3-28, 2006.;;Darragh et al., “Tumor Detection by Imaging Proteolytic Activity”, Cancer Res 70: 1505-12, 2010.;;Davis et al., “Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline.”, J Urol 188: 2473-2481, 2012.;;Dawson et al., “Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer”, N Engl J Med 368(13): 1199-1209, 2013.;;De Boer et al., “An in vitro assay for frameshift mutations: hotspots for deletions of 1 bp by Klenow-fragment polymerase share a consensus DNA sequence.”, Genetics 118: 181-191, 1988.;;De Vos et al., “Novel PMS2 Pseudogenes Can Conceal Recessive Mutations Causing a Distinctive Childhood Cancer Syndrome”, American journal of human genetic, 74: 954-964, 2004.;;Demeure et al., “Whole-genome Sequencing of an Aggressive BRAF Wild-type Papillary Thyroid Cancer Identified EML4—ALK Translocation as a Therapeutic Target”, World J Surg., 38: 1296-305, 2014.;;DeRisi et al., “Use of a cDNA microarray to analyse gene expression patterns in human cancer.”, Nat. Genet. 14: 457-460, 1996.;;Di Renzo et al., “Expression of the MetfHepatocyte Growth Factor Receptor in Human Pancreatic Cancer”, Cancer Res 55(5): 1129-1138, 1995.;;Di Renzo et al., “Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer,”, Clin Cancer Res 1(2): 147-154, 1995.;;Diehl et al., “Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients.” Gastroenterology 135: 489-498, 2008.;;Diehl et al., “Detection and quantification of mutations in the plasma of patients with colorectal tumors”, Proceedings of the National Academy of Sciences of the United States of America, 102: 16368-16373, 2005.;;Dimashkieh et al., “Evaluation of UroVysion and Cytology for Bladder Cancer Detection”, Cancer Cytopathol 121: 591-597, 2013.;;Dizon et al., “A Phase II Evaluation of Belinostat and Carboplatin in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study”, Gynecol. Oncol. 125(2): 367-371, 2012.;;Dizon et al., “Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer”, Int J. Gynecol. Cancer 23(3): 533-539, 2012.;;Dohm et al., “Substantial biases in ultrashort read data sets from high-throughput DNA sequencing.”, Nucleic Acids Res 36:el05, 2008.;;Dong et al., “Combining markers with and without the limit of detection.”, Stat Med 33(8): 1307-1320, 2014.;;Douville et al., “Detection of aneuploidy in patients with cancer through amplification of long interspersed nucleotide elements (LINEs)”, PNAS, vol. 115, No. 8, 1871-1876, 2018.;;Dressman et al., Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci US A 100(15): 8817-8822, 2003.;;Drevis et al., “Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors”, 25: 3045-2054, 2007.;;Druley et al., “Quantification of rare allelic variants from pooled genomic DNA.”, Nat Methods 6: 263-265, 2009.;;D'Souza et al., “Tumor characterization by ultrasound-release of multiple protein and microRNA biomarkers, preclinical and clinical evidence”, PLos One, 13: e0194268, 2018.;;Durbin et al., “A map of human genome variation from population-scale sequencing.”, Nature 467:1061-1073, 2010.;;Dy et al., “Long-Term Survivors of Metastatic Colorectal Cancer Treated with Systemic Chemotherapy Alone: A North Central Cancer Treatment Group Review of 3811 Patients, N0144”, Clin Colorectal Cancer 8(2): 88-93, 2009.;;Eastman et al., “Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076,”, J Infect Dis 177:557-564, 1998.;;Easton et al., “Breast and Ovarian Cancer Incidence in BRCA I-Mutation Carriers”, Am. J. Hum. Genet. 56: 265-271, 1995.;;Eckert et al., “High fidelity DNA synthesis by the Thermus aquaticus DNA polymerase.”, Nucleic Acids Res 18: 3739-3744, 1990.;;Egawa et al., “Clinicopathological aspects of small pancreatic cancer. Pancreas”, 28(3): 235-240, 2004.;;Ehab et al., “Profile of palbociclib in the treatment of metastatic breast cancer”, Breast Cancer 8: 83-91, 2016.;;Eid et al., “Real-time DNA sequencing from single polymerase molecules”, Science 323: 133-138, 2009.;;Eliassen et al., “Urinary Estrogens and Estrogen Metabolites and Subsequent Risk of Breast Cancer among Premenopausal Women”, Cancer Research, vol. 72, issue 3, 696-706, 2012.;;Ellinger et al., “Epigenetic biomarkers in the blood of patients with urological malignancies”, Expert Rev Mal Diagn 15: 505-516, 2015.;;Ellis et al., “Immune Checkpoint Inhibitors for Patients With Advanced NoneSmall-Cell Lung Cancer: A Systematic Review”, Clin Lung Cancer pii: S1525-7304(17)30043-8, 2017.;;El-Tanani et al., “The regulation and role of osteopontin in malignant transformation and cancer.”, Cytokine Growth Factor Rev 17(6): 463-474, 2006.;;Elzek et al., “Proteomics of ovarian cancer: functional insights and clinical applications”, Cancer Metastasis Rev., 34(1): 83-96, 2015.;;Erickson et al., “Detection of somatic TP53 mutations in tampons of patients with highgrade serous ovarian cancer.”, Obstetrics and gynecology 124, 881-885, 2014.;;Erlich et al., “Alta-Cyclic: a self-optimizing base caller for next-generation sequencing.”, Nat Methods 5: 679-682, 2008.;;Ethier et al., “Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer”, Curr Oncol Rep 19(3): 15, 2017.;;Extended European Search Report issued in related European Application No. 12772013.4, dated Sep. 17, 2014.;;Extended European Search Report issued in related European Application No. 17154750.8, dated Aug. 17, 2017.;;Faias et al., “Clinical Impact of KRAS and GNAS Analysis Added to CEA and Cytology in Pancreatic Cystic Fluid Obtained by EUS-FNA”, Digestive Diseases and Sciences, vol. 63, No. 9, pp. 2351-2361, 2018.;;Falchook et al., “Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies”, Investig. New Drugs 31(5): 1192-1200, 2013.;;Falzoi et al., “Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry”, Pharmacogenomics 11: 559-571, 2010.;;Fan et al., “Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood.”, Proc Natl Acad Sci US A 105: 16266-16271, 2008.;;Finn et al., “Palbociclib and Letrozole in Advanced Breast Cancer”, N Eng J Med 375: 1925-1936, 2016.;;Fishman et al., “The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer,”, Am J Obstet Gynecol 192, 1214-1221; discussion 1221-1212, 2005.;;Fong et al., “Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.”, N Engl J Med 361: 123-134, 2009.;;Forbes et al., “COSMIC: somatic cancer genetics at high-resolution”, Nucleic Acids Res 45: D777-D783, 2017.;;Forshew et al., “Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA”, Sci Transl Med; 4: 136ra68, 2012.;;Fradet et al., “Performance characteristics of a new monoclonal antibody test forbladder cancer: ImmunoCyt trade mark.”, Can J Urol 4: 400-405, 1997 ABSTRACT. et al.",ACTIVE
63,US,A1,US 2015/0361507 A1,026-271-034-353-356,2015-12-17,2015,US 201414765692 A,2014-02-18,US 201414765692 A;;US 201361765909 P;;US 201361766857 P;;US 201361772249 P;;US 2014/0016906 W,2013-02-18,TERT PROMOTER MUTATIONS IN GLIOMAS AND A SUBSET OF TUMORS,"We surveyed 1,230 tumors of 60 different types and found that tumors could be divided into types with low (<15%) and high (≧15%) frequencies of TERT promoter mutations. The nine TERT-high tumor types almost always originated in tissues with relatively low rates of self renewal, including melanomas, liposarcomas, hepatocellular carcinomas, urothelial carcinomas, squamous cell carcinomas of the tongue, medulloblastomas, and subtypes of gliomas (including 83% of primary glioblastoma, the most common brain tumor type). TERT and ATRX mutations were mutually exclusive, suggesting that these two genetic mechanisms confer equivalent selective growth advantages. In addition to their implications for understanding the relationship between telomeres and tumorigenesis, TERT mutations provide a biomarker for the early detection of urinary tract and liver tumors and aid in the classification and prognostication of brain tumors.",UNIV DUKE;;UNIV JOHNS HOPKINS,YAN HAI;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;KINZLER KENNETH W;;JIAO YUCHEN;;BETTEGOWDA CHETAN;;BIGNER DARELL D,DUKE UNIVERSITY (2013-04-24);;THE JOHNS HOPKINS UNIVERSITY (2013-05-13),https://lens.org/026-271-034-353-356,Patent Application,yes,0,0,17,24,3,C12Q2600/112;;C12Q2600/156;;C12Q1/6886;;C12Q2600/156;;C12Q2600/112;;C12Q1/6886,C12Q1/68,,1,1,048-015-888-162-479,10.1093/neuonc/nos284;;pmc3635509;;23161787,"Di Stefano (Neuro-Oncology, 15(5): 542-547, 2013)",ACTIVE
64,AU,B2,AU 2017/203206 B2,039-127-516-866-205,2019-01-24,2019,AU 2017/203206 A,2017-05-12,AU 2017/203206 A;;AU 2013/338393 A;;US 201261719942 P;;US 2013/0065342 W,2012-10-29,Papanicolaou test for ovarian and endometrial cancers,"The recently developed liquid-based Papanicolaou (Pap) smear allows not only cytologic evaluation but also collection of DNA for detection of HPV, the causative agent of cervical cancer. We tested these samples to detect somatic mutations present in rare tumor cells 5 that might accumulate in the cervix once shed from endometrial and ovarian cancers. A panel of commonly mutated genes in endometrial and ovarian cancers was assembled and used to identify mutations in all 46 endometrial or cervical cancer tissue samples. We were able also able to identify the same mutations in the DNA from liquid Pap smears in 100% of endometrial cancers (24 of 24) and in 41% of ovarian cancers (9 of 22). We developed a sequence-based method to 10 query mutations in 12 genes in a single liquid Pap smear without prior knowledge of the tumor's genotype.",UNIV JOHNS HOPKINS,KINDE ISAAC;;KINZLER KENNETH W;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;DIAZ LUIS;;BETTEGOWDA CHETAN;;WANG YUXUAN,,https://lens.org/039-127-516-866-205,Granted Patent,no,0,0,23,23,0,C12Q1/6886;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;C12Q1/6886;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q1/6851;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158,G01N33/574;;C12Q1/68;;G01N33/68,,2,0,,,"ERNANI, F.P., ET AL., ""Agilent's SureSelect Target Enrichment System: Bringing Cost and Process Efficiency to Next-Generation Sequencing"", 2009, pp 1-8, AGILENT TECHNOLOGIES;;""Affymetrix Human Genome U133 Plus 2.0 Array"", Public on 07 November 2003, GENE EXPRESSION OMNIBUS<URL: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL570>[Retrieved from the internet 22 January 2018]",ACTIVE
65,CA,A1,CA 2889937 A1,101-972-119-641-090,2014-05-08,2014,CA 2889937 A,2013-10-17,US 201261719942 P;;US 2013/0065342 W,2012-10-29,PAPANICOLAOU TEST FOR OVARIAN AND ENDOMETRIAL CANCERS,"The recently developed liquid-based Papanicolaou (Pap) smear allows not only cytologic evaluation but also collection of DNA for detection of HPV, the causative agent of cervical cancer. We tested these samples to detect somatic mutations present in rare tumor cells that might accumulate in the cervix once shed from endometrial and ovarian cancers. A panel of commonly mutated genes in endometrial and ovarian cancers was assembled and used to identify mutations in all 46 endometrial or cervical cancer tissue samples. We were able also able to identify the same mutations in the DNA from liquid Pap smears in 100% of endometrial cancers (24 of 24) and in 41% of ovarian cancers (9 of 22). We developed a sequence-based method to query mutations in 12 genes in a single liquid Pap smear without prior knowledge of the tumor's genotype.",UNIV JOHNS HOPKINS,KINDE ISAAC;;KINZLER KENNETH W;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;DIAZ LUIS;;BETTEGOWDA CHETAN;;WANG YUXUAN,,https://lens.org/101-972-119-641-090,Patent Application,no,0,0,23,23,0,C12Q1/6886;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;C12Q1/6886;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q1/6851;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158,G01N33/574;;C12Q1/68;;G01N33/68,,0,0,,,,ACTIVE
66,AU,A1,AU 2013/338393 A1,106-923-093-230-98X,2015-05-21,2015,AU 2013/338393 A,2013-10-17,US 201261719942 P;;US 2013/0065342 W,2012-10-29,Papanicolaou test for ovarian and endometrial cancers,"The recently developed liquid-based Papanicolaou (Pap) smear allows not only cytologic evaluation but also collection of DNA for detection of HPV, the causative agent of cervical cancer. We tested these samples to detect somatic mutations present in rare tumor cells that might accumulate in the cervix once shed from endometrial and ovarian cancers. A panel of commonly mutated genes in endometrial and ovarian cancers was assembled and used to identify mutations in all 46 endometrial or cervical cancer tissue samples. We were able also able to identify the same mutations in the DNA from liquid Pap smears in 100% of endometrial cancers (24 of 24) and in 41% of ovarian cancers (9 of 22). We developed a sequence-based method to query mutations in 12 genes in a single liquid Pap smear without prior knowledge of the tumor's genotype.",UNIV JOHNS HOPKINS,KINDE ISAAC;;KINZLER KENNETH W;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;DIAZ LUIS;;BETTEGOWDA CHETAN;;WANG YUXUAN,,https://lens.org/106-923-093-230-98X,Patent Application,no,0,0,23,23,0,C12Q1/6886;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;C12Q1/6886;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q1/6851;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158,G01N33/574;;C12Q1/68;;G01N33/68,,0,0,,,,ACTIVE
67,EP,A1,EP 2912468 A1,172-673-947-892-106,2015-09-02,2015,EP 13851273 A,2013-10-17,US 201261719942 P;;US 2013/0065342 W,2012-10-29,PAPANICOLAOU TEST FOR OVARIAN AND ENDOMETRIAL CANCERS,,UNIV JOHNS HOPKINS,KINDE ISAAC;;KINZLER KENNETH W;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;DIAZ LUIS;;BETTEGOWDA CHETAN;;WANG YUXUAN,,https://lens.org/172-673-947-892-106,Patent Application,yes,0,0,23,23,191,C12Q1/6886;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q2600/16;;C12Q1/6886;;C12Q2600/16;;G01N33/57442;;G01N33/57449;;C12Q2600/154;;C12Q1/6851;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158,G01N33/574;;C12Q1/68;;G01N33/68,,0,0,,,,ACTIVE
68,EP,A4,EP 2956556 A4,031-526-991-615-63X,2016-10-12,2016,EP 14751900 A,2014-02-18,US 201361765909 P;;US 201361766857 P;;US 201361772249 P;;US 2014/0016906 W,2013-02-18,TERT PROMOTER MUTATIONS IN GLIOMAS AND A SUBSET OF TUMORS,,UNIV DUKE;;UNIV JOHNS HOPKINS,YAN HAI;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;KINZLER KENNETH W;;JIAO YUCHEN;;BETTEGOWDA CHETAN;;BIGNER DARELL D,,https://lens.org/031-526-991-615-63X,Search Report,no,0,0,17,24,0,C12Q2600/112;;C12Q2600/156;;C12Q1/6886;;C12Q2600/156;;C12Q2600/112;;C12Q1/6886,C12Q1/68;;C12N15/12,,1,1,011-757-015-197-891,10.1016/s0168-8278(10)60887-2,"PARK J Y ET AL: ""886 HTERT PROMOTER GENE POLYMORPHISM AND THE RISK OF HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH CHRONIC HEPATITIS B"", JOURNAL OF HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 52, 1 April 2010 (2010-04-01), pages S345, XP026998784, ISSN: 0168-8278, [retrieved on 20100401]",ACTIVE
69,WO,A1,WO 2014/127359 A1,151-432-515-320-631,2014-08-21,2014,US 2014/0016906 W,2014-02-18,US 201361765909 P;;US 201361766857 P;;US 201361772249 P,2013-02-18,TERT PROMOTER MUTATIONS IN GLIOMAS AND A SUBSET OF TUMORS,"We surveyed 1,230 tumors of 60 different types and found that tumors could be divided into types with low (<15%) and high (≥15%) frequencies of TERT promoter mutations. The nine TERT-high tumor types almost always originated in tissues with relatively low rates of self renewal, including melanomas, liposarcomas, hepatocellular carcinomas, urothelial carcinomas, squamous cell carcinomas of the tongue, medulloblastomas, and subtypes of gliomas (including 83% of primary glioblastoma, the most common brain tumor type). TERT and ATRX mutations were mutually exclusive, suggesting that these two genetic mechanisms confer equivalent selective growth advantages. In addition to their implications for understanding the relationship between telomeres and tumorigenesis, TERT mutations provide a biomarker for the early detection of urinary tract and liver tumors and aid in the classification and prognostication of brain tumors.",UNIV DUKE;;UNIV JOHNS HOPKINS,YAN HAI;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;KINZLER KENNETH W;;JIAO YUCHEN;;BETTEGOWDA CHETAN;;BIGNER DARELL D,,https://lens.org/151-432-515-320-631,Patent Application,yes,1,9,17,24,3,C12Q2600/112;;C12Q2600/156;;C12Q1/6886;;C12Q2600/156;;C12Q2600/112;;C12Q1/6886,C12Q1/68;;C12N15/12,,21,20,003-113-655-474-830;;137-629-232-369-55X;;003-166-392-538-562;;040-988-224-915-933;;010-132-033-750-586;;038-932-572-979-55X;;003-113-655-474-830;;036-336-793-184-01X;;035-453-694-694-248;;092-805-696-098-697;;043-096-694-231-750;;078-169-002-114-751;;050-009-006-022-10X;;015-711-835-021-543;;025-180-991-800-058;;056-474-208-008-279;;019-392-813-016-049;;004-875-695-978-483;;111-018-449-235-636;;016-902-039-368-405,10.1126/science.1229259;;pmc4423787;;23348506;;23348503;;10.1126/science.1230062;;20373057;;10.1007/s12032-010-9506-3;;pmc2820383;;19228619;;10.1056/nejmoa0808710;;23530248;;pmc3625331;;10.3410/f.718015949.793477772;;10.1073/pnas.1303607110;;10.1007/s00401-013-1141-6;;23764841;;10.1126/science.1229259;;pmc4423787;;23348506;;10.1152/physrev.00026.2007;;18391173;;12097303;;10.1074/jbc.274.19.13085;;10224060;;9837921;;10.1074/jbc.273.50.33436;;7605428;;10.1126/science.7605428;;9282118;;10.1016/s0959-8049(97)00062-2;;8808676;;10.1016/s1074-7613(00)80316-7;;pmc2360127;;10.1038/sj.bjc.6603671;;17353922;;10.1046/j.1432-0436.2002.690412.x;;11841477;;21252315;;10.1126/science.1200609;;pmc3144496;;pmc3174141;;10.1126/science.1207313;;21719641;;10.1038/nrg2763;;20351727;;pmc3181356;;10.1016/j.ajpath.2011.06.018;;21888887,"HUANG ET AL.: ""Highly recurrent TERT promoter mutations in human melanoma"", SCIENCE, vol. 339, no. 6122, 24 January 2013 (2013-01-24), pages 957 - 959, XP055109644;;HORN ET AL.: ""TERT promoter mutations in familial and sporadic melanoma"", SCIENCE, vol. 339, no. 6122, 24 January 2013 (2013-01-24), pages 959 - 961, XP055110024;;KHEIROLLAHI ET AL.: ""Alterations of telomere length in human brain tumors"", MEDICAL ONCOLOGY, vol. 28, no. 3, 2011, pages 864 - 870, XP019937672;;YAN ET AL.: ""IDH1 and IDH2 mutations in gliomas"", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 360, no. 8, 2009, pages 765 - 773, XP002538459;;KILLELA ET AL.: ""TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal"", PNAS, vol. 110, no. 15, 25 March 2013 (2013-03-25), pages 6021 - 6026, XP055110090;;ARITA ET AL.: ""Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss"", ACTA NEUROPATHOLOGICA, vol. 126, no. 2, 14 June 2013 (2013-06-14), pages 267 - 276, XP055218001;;HUANG ET AL., SCIENCE, vol. 339, no. 6122, pages 957 - 959;;AUBERT G; LANSDORP PM, TELOMERES AND AGING. PHYSIOL REV., vol. 88, no. 2, 2008, pages 557 - 579;;AKIYAMA M ET AL.: ""Cytokines modulate telomerase activity in a human multiple myeloma cell line"", CANCER RES., vol. 62, no. 13, 2002, pages 3876 - 3882;;KANG SS; KWON T; KWON DY; DO SI: ""Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit"", J BIOL CHEM., vol. 274, no. 19, 1999, pages 13085 - 13090;;LI H; ZHAO L; YANG Z; FUNDER JW; LIU JP: ""Telomerase is controlled by protein kinase Calpha in human breast cancer cells"", J BIOL CHEM., vol. 273, no. 50, 1998, pages 33436 - 33442;;KIM NW ET AL.: ""Specific association of human telomerase activity with immortal cells and cancer"", SCIENCE, vol. 266, no. 5193, 1994, pages 2011 - 2015, XP002138759, DOI: doi:10.1126/science.7605428;;SHAY JW; BACCHETTI S: ""A survey of telomerase activity in human cancer"", EUR J CANCER, vol. 33, no. 5, 1997, pages 787 - 791, XP004282534, DOI: doi:10.1016/S0959-8049(97)00062-2;;MORRISON SJ; PROWSE KR; HO P; WEISSMAN IL: ""Telomerase activity in hematopoietic cells is associated with self-renewal potential"", IMMUNITY, vol. 5, no. 3, 1996, pages 207 - 216;;HIYAMA E; HIYAMA K: ""Telomere and telomerase in stem cells"", BR J CANCER, vol. 96, no. 7, 2007, pages 1020 - 1024, XP055061521, DOI: doi:10.1038/sj.bjc.6603671;;FORSYTH NR; WRIGHT WE; SHAY JW: ""Telomerase and differentiation in multicellular organisms: Turn it off, turn it on, and turn it off again"", DIFFERENTIATION, vol. 69, no. 4-5, 2002, pages 188 - 197, XP026792136;;JIAO Y ET AL.: ""DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors"", SCIENCE, vol. 331, no. 6021, 2011, pages 1199 - 1203, XP055166205, DOI: doi:10.1126/science.1200609;;HEAPHY CM ET AL.: ""Altered telomeres in tumors with ATRX and DAXX mutations"", SCIENCE, vol. 333, no. 6041, 2011, pages 425, XP055140966, DOI: doi:10.1126/science.1207313;;CESARE AJ; REDDEL RR: ""Alternative lengthening of telomeres: Models, mechanisms and implications"", NAT REV GENET., vol. 11, no. 5, 2010, pages 319 - 330, XP055166193, DOI: doi:10.1038/nrg2763;;HEAPHY CM ET AL.: ""Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes"", AM J PATHOL., vol. 179, no. 4, 2011, pages 1608 - 1615;;See also references of EP 2956556A4",PENDING
70,SG,A,SG 11201506446Y A,171-378-923-493-735,2015-09-29,2015,SG 11201506446Y A,2014-02-18,US 201361765909 P;;US 201361766857 P;;US 201361772249 P;;US 2014/0016906 W,2013-02-18,TERT PROMOTER MUTATIONS IN GLIOMAS AND A SUBSET OF TUMORS,,UNIV DUKE;;UNIV JOHNS HOPKINS,HAI YAN;;BERT VOGELSTEIN;;NIKOLAS PAPADOPOULOS;;KENNETH W KINZLER;;YUCHEN JIAO;;CHETAN BETTEGOWDA;;DARELL D BIGNER,,https://lens.org/171-378-923-493-735,Unknown,no,0,0,17,24,0,C12Q2600/112;;C12Q2600/156;;C12Q1/6886;;C12Q2600/156;;C12Q2600/112;;C12Q1/6886,C12Q1/68;;C12N15/12,,0,0,,,,PENDING
71,KR,A,KR 20150132181 A,020-144-280-040-777,2015-11-25,2015,KR 20157025695 A,2014-02-18,US 201361765909 P;;US 201361766857 P;;US 201361772249 P;;US 2014/0016906 W,2013-02-18,TERT PROMOTER MUTATIONS IN GLIOMAS AND A SUBSET OF TUMORS,"본 발명자는 60개 다른 유형의 1,230개의 종양을 조사하고 낮은(<15%) 및 높은(≥15%) 빈도의프로모터 돌연변이를 갖는 유형으로 나뉜다는 것을 발견하였다. 9개의 TERT-높은 종양 유형은 거의 항상 상대적으로 낮은 속도로 자기 재생되는, 흑색종, 지방육종, 간세포암, 요로상피암, 혀의 편평세포암, 수모세포종, 및 신경교종(83%의 1차 교모세포종, 가장 일반적인 종양 유형을 포함하는)의 아류형을 포함하는 조직에서 시작되었다.및돌연변이는 상호 배타적이므로, 이들 2개의 유전적 메커니즘은 동등한 선택적인 성장 이점을 부여함을 나타낸다. 텔로미어와 종양 형성간의 관계를 이해하는 의미에 더하여,돌연변이는 요로 및 간 종양의 조기 검출을 위한 바이오마커(biomarker)를 제공하며 뇌 종양의 분류 및 예측을 돕는다.",UNIV DUKE;;UNIV JOHNS HOPKINS,YAN HAI;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;KINZLER KENNETH W;;JIAO YUCHEN;;BETTEGOWDA CHETAN;;BIGNER DARELL D,,https://lens.org/020-144-280-040-777,Patent Application,no,0,1,17,24,6,C12Q2600/112;;C12Q2600/156;;C12Q1/6886;;C12Q2600/156;;C12Q2600/112;;C12Q1/6886,,,0,0,,,,ACTIVE
72,EP,A1,EP 2956556 A1,065-368-965-811-98X,2015-12-23,2015,EP 14751900 A,2014-02-18,US 201361765909 P;;US 201361766857 P;;US 201361772249 P;;US 2014/0016906 W,2013-02-18,TERT PROMOTER MUTATIONS IN GLIOMAS AND A SUBSET OF TUMORS,,UNIV DUKE;;UNIV JOHNS HOPKINS,YAN HAI;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;KINZLER KENNETH W;;JIAO YUCHEN;;BETTEGOWDA CHETAN;;BIGNER DARELL D,,https://lens.org/065-368-965-811-98X,Patent Application,yes,0,0,17,24,3,C12Q2600/112;;C12Q2600/156;;C12Q1/6886;;C12Q2600/156;;C12Q2600/112;;C12Q1/6886,C12Q1/68;;C12N15/12,,0,0,,,,ACTIVE
73,US,B2,US 10619217 B2,126-199-984-318-476,2020-04-14,2020,US 201715834886 A,2017-12-07,US 201715834886 A;;US 201414233296 A;;US 2012/0047211 W;;US 201161509366 P,2011-07-19,Oligodendroglioma drive genes,"Oligodendrogliomas are the second most common malignant brain tumor in adults. These tumors often contain a chromosomal abnormality involving a pericentromeric fusion of chromosomes 1 and 19, resulting in losses of the entire short arm of the former and the long arm of the latter. To identify the molecular genetic basis for this alteration, we performed exomic sequencing of seven anaplastic oligodendrogliomas with chromosome 1p and 19q losses. Among other changes, we found that that CIC (homolog of the Drosophila gene capicua) on chromosome 19q was somatically mutated in six of the seven cases and that FUBP1 (far upstream element (FUSE) binding protein) on chromosome 1p was somatically mutated in two of the seven cases. Examination of 27 additional oligodendrogliomas revealed 12 and 3 more tumors with mutations of CIC and FUBP1, respectively, 58% of which were predicted to result in truncations of the encoded proteins. These results suggest a critical role for these genes in the biology and pathology of oligodendrocytes.",UNIV JOHNS HOPKINS;;UNIV DUKE,VOGELSTEIN BERT;;KINZLER KENNETH W;;BETTEGOWDA CHETAN;;AGRAWAL NISHANT;;PAPADOPOULOS NICKOLAS;;BIGNER DARELL;;YAN HAI;;MCLENDON ROGER,DUKE UNIVERSITY (2011-09-28);;THE JOHNS HOPKINS UNIVERSITY (2011-08-02),https://lens.org/126-199-984-318-476,Granted Patent,yes,5,0,11,11,1,C12Q1/6886;;C12Q1/6886;;C12Q2600/106;;C12Q2600/106;;C12Q2600/112;;C12Q2600/112;;C12Q2600/118;;C12Q2600/118;;C12Q2600/156;;C12Q2600/156;;C12Q2600/158;;C12Q2600/158,C12Q1/68;;C12Q1/6886,,59,53,050-941-654-379-143;;063-737-209-762-260;;007-185-748-098-342;;074-364-497-275-933;;074-974-263-553-003;;099-027-124-338-196;;024-276-736-339-938;;074-364-497-275-933;;040-988-224-915-933;;101-030-760-689-875;;010-740-316-667-52X;;030-797-126-102-74X;;099-027-124-338-196;;034-566-384-563-853;;040-356-236-898-08X;;011-509-993-590-368;;074-974-263-553-003;;094-535-915-312-274;;036-543-085-365-356;;126-006-647-030-363;;021-058-626-150-865;;042-732-073-403-706;;072-086-564-785-432;;107-882-904-538-397;;042-562-614-498-017;;019-392-813-016-049;;032-718-950-332-134;;001-568-098-749-368;;025-295-991-710-124;;016-743-989-375-187;;069-792-512-589-392;;003-715-915-052-975;;037-313-276-496-095;;063-375-682-056-905;;004-595-844-963-466;;144-175-140-718-29X;;007-942-565-150-254;;022-482-632-280-630;;129-895-037-908-505;;005-927-424-183-679;;038-927-746-063-781;;012-071-463-971-588;;056-708-566-346-648;;021-824-531-002-296;;101-030-760-689-875;;007-156-666-558-605;;003-307-016-010-015;;064-678-224-734-734;;019-231-639-785-506;;017-493-980-370-117;;089-153-856-694-844;;002-261-176-506-880;;040-511-066-712-912,10.1093/jnci/90.19.1473;;9776413;;19808792;;pmc2758710;;10.1093/hmg/ddp396;;12117714;;10.1161/01.atv.0000026801.56080.14;;10.1007/s00401-012-0993-5;;22588899;;10.1200/jco.2000.18.3.636;;10653879;;10.1126/science.281.5384.1787;;9776677;;pmc3170506;;10.1126/science.1210557;;21817013;;10.1007/s00401-012-0993-5;;22588899;;pmc2820383;;19228619;;10.1056/nejmoa0808710;;10.1007/s11060-004-4598-2;;15981098;;10.1158/0008-5472.can-04-1170;;15289301;;7977648;;pmc1887413;;10.1126/science.281.5384.1787;;9776677;;9083161;;10.1002/(sici)1097-0142(19970401)79:7<1381::aid-cncr16>3.0.co;2-w;;10.1634/theoncologist.2008-0248;;19182242;;9329453;;10.1097/00005072-199710000-00003;;10.1200/jco.2000.18.3.636;;10653879;;10.1097/ppo.0b013e31818d8178;;19060598;;17047046;;10.1158/0008-5472.can-06-1796;;17021403;;10.1097/01.jnen.0000235122.98052.8f;;10.1038/nrneurol.2010.159;;21045797;;10.1002/1097-0142(197503)35:3+<1022::aid-cncr2820350726>3.0.co;2-a;;163140;;10.1007/s12094-011-0658-1;;21596657;;pmc3080742;;21216738;;10.1093/bfgp/elq025;;pmc1866844;;10433931;;10.1016/s0002-9440(10)65134-6;;21252315;;10.1126/science.1200609;;pmc3144496;;20826764;;pmc3076894;;10.1126/science.1196333;;18772396;;pmc2820389;;10.1126/science.1164382;;10.1126/science.1096502;;15016963;;16364744;;10.1016/j.virol.2005.09.027;;12040186;;10.1126/science.296.5573.1655;;20535651;;10.1007/82_2010_68;;pmc3164550;;10.1038/nature14666;;26200345;;10.1016/s0513-5117(09)79085-4;;10.1158/0008-5472.can-09-2650;;19996293;;pmc2794981;;10.1016/s0513-5117(10)79305-4;;8601560;;10.1007/bf01366952;;10.1126/science.2649981;;2649981;;pmc2820387;;18692126;;10.1016/j.ygeno.2008.07.005;;10.1101/gad.14.2.224;;pmc316342;;10652276;;10.1146/annurev.ge.26.120192.001425;;1482114;;10.1242/dev.129.4.993;;11861482;;pmc3035094;;21270056;;10.1242/dev.057729;;17255944;;10.1038/sj.emboj.7601532;;pmc1794389;;10.1007/s11060-004-4598-2;;15981098;;17081983;;10.1016/j.cell.2006.09.026;;pmc48784;;1557402;;10.1073/pnas.89.7.2965;;3367154;;10.1097/00005072-198805000-00001;;10.1097/cco.0b013e32833edbdf;;20739887;;10.1101/gad.8.4.465;;8125259;;20420426;;10.1021/bi9021445;;16717057;;10.1093/hmg/ddl136;;10.1038/nature02399;;15057824,"Cairncross et al. (Journal of the National Cancer Institute, vol. 90, No. 19, Oct. 7, 1998, 1473-1479) (Year: 1998).;;Mardis eat al. (Human Molecular Genetics, 2009, vol. 18, Review Issue 2 R163-R168). (Year: 2009).;;Hegele (2002) Arterioscler Thromb Vas Biol, 22: 1058-1061 (Year: 2002).;;Sahm et al. Acta Neuropathol (2012) 123:853-860 (Year: 2012).;;Smith 2000. Journal of Clinical Oncology, vol. 18, No. 3 Feb. 2000; p. 636-645 (Year: 2000).;;Pennisi (1998) Science, New Series, vol. 281, No. 5384, p. 1787-1789 (Year: 1998).;;Lucentini (Dec. 2004) The Scientist, p. 20 (Year: 2004).;;Bettegowda, C. et al., ‘Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma’, Science, Sep. 9, 2011, vol. 333, pp. 1453-1455.;;Sahm, F. et al. , ‘CIC and FUBP1 Mutations in Oligodendrogliomas, Oligoastrocytoma and Astrocytomas’, Acta Neuropathol, May 17, 2012, vol. 123, pp. 853-860.;;Yan, H. et al., ‘IDH1 and IDH2 Mutations in Gliomas’, The New England Journal of Medicine, Feb. 19, 2009, vol. 360, No. 8, pp. 765-773.;;International Search Report and Written Opinion dated Jan. 28, 2013, for PCT/US2012/047211.;;Extended European Search Report issued in related European Application No. 12814956.4, dated Feb. 13, 2015.;;Lee et al., “CIC, a gene involved in cerebellar development and ErbB signaling, is significantly expressed in medulloblastomas,” Journal of Neuro-Oncology, vol. 73, No. 2, Jun. 1, 2005, pp. 101-108.;;Broderick et al. Cancer Research, 64, 5048-5050.;;Reifenberger et al. (American Journal of Pathology, vol. 145, No. 5, Nov. 1994, pp. 1175-1190).;;Hegele (2002) Arterioscler Thromb Vase Biol, 22:1-58-1061.;;Pennisi (1998), Science, New Series, vol. 281, No. 5384, p. 1787-1789.;;Lucentini (Dec. 2004) The Scientist, p. 20.;;Coons et al., “Improving Diagnostic Accuracy and Interobserver Concordance fin the Classification and Grading of Primary Gilomas” cancer 79, 1381 (1997).;;Bromberg et al., “Oligodendrogliomas: Molecular Biology and Treatment”, Oncologist 14, 155 (2009).;;Maintz et al., “Molecular Genetic Evidence for Subtypes of Oligoastrocytomas,” J Nemopathol Exp Neuroi 56, 1098 (1997).;;Smith et al., “Alterations of Chromosome Arms 1p and 19q as Predictors of Survival in Oligodendrogliomas, Astrocytomas, and Mixed Oligoastrocytomas,” J Clin Oncol 18, 636 (2000).;;Cairncross et al., “Gliomas With 1p/19q Codeletion: a.ka. Oligodendroglioma,” Cancer J 14, 352 (2008).;;Jenkins et al., “A t(1;19)(q10;p10) Mediates the combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with Oligodendroglioma” Cancer Res 66, 9852 (2006).;;Griffin et al., “Identification of der (1;19)(q10;p10) in Five Oligodendrogliomas Suggests Mechanism of Concurrent 1p and 19q Loss,” J Neuropathol Exp Neurol 65, 988 (2006).;;Bourne et al., “Update on Molecular Findings, Management, and Outcome in Low-grade Gliomas,” Nat Rev Neurol 6, 695-701.;;Knudson, Jr. et al., “The Genetics of Childhood Cancer,” Cancer 35, 1022 (1975).;;Sastre, “New DNA sequencing technologies open a promising era for cancer research and treatment,” Clin Transl Oncol 13, 301-306.;;Xi et al., “Detecting Structural Variations in the Human Genome Using Next Generation Sequencing,” Brief Funct Genomics, 2011 9:405.;;Bigner et al., “Molecular Genetic Aspects of Oligodendrogliomas Including Analysis by Comparative Genomic Hybridization,” Arn J Pathol 155, 375 ( 1999).;;Y. Jiao et al., DAXX/ATRX, MEN1 and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors Science 331, 1199-1203 (2011).;;Jones et al., “Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma,” Science 330, 228 (2010).;;Parsons et al., “An Integrated Genomic Analysis of Human Glioblastoma Multiforme,” Science 321, 1807 (2008).;;Samuels et al., “High Frequency of Mutations of the PIK3CA Gene in Human Cancers,” Science 304, 554 (2004).;;Vogt et al., “Phosphoinositide 3-kinase. From viral oncoprotein to drug target,” Virology 344, 131 (2006).;;Cantley, “The Phosphoinositide 3-Kinase Pathway” Science 296, 1655 (2002).;;Samuels et al., “Oncogenic Mutations of PIK3CA in Human Cancers,” Curr Top Microbiol Immunol, 2010 347, 21-41.;;The Cancer Genome Atlas Research Nenvork, Nature 455, 1061 (2008).;;Puente et al., “Non-coding recurrent mutations in chronic lymphocytic Leukaemia,” Nature, 2015, 526:519-541.;;H. Yan et al., “IDH1 and IDH2 Mutations in Gliomas,” N Engl J Med 360, 765 (2009).;;Yan et al., “Mutant Metabolic Enzymes Are at the Origin of Gliomas,” Cancer Res 69, 9157 (2009).;;Dang et al., “Cancer-associated IDH1 Mutations Produce 2-hydroxyglutarate,” Nature 465, 966 (2010).;;Knudson et al., “Hereditary cancer: two hits revisited,” J. Cancer Res. Clin. OncoL 122, 135 (1996).;;S. J. Baker et al., “Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas,” Science 244, 217 (1989).;;G. Parmigiani et al., “Design and Analysis Issues in Genome-Wide Somatic Mutation Studies of Cancer,” Genomics in press, (2008).;;Jimenez et al., “Relief of Gene Repression by Torso RTK Signaling: role of Capicua in Drosophila Terminal and Dorsoventral Patterning,” Genes Dev 14, 224 (2000).;;Garcia-Bellido et al., “Developmental Genetics of the Venation Pattern of Drosophila,” Annu Rev Genet 26, 277 (1992).;;Roch et al., “EGFR Signalling Inhibits Capicua-dependent Repression During Specification of Drosophila Wing Veins,”, Development 129, 993 (2002).;;Ajuria et al., “Capicua DNA-Binding Sites are General Response Elements for RTK Signaling in Drosophila,” Development 138, 915.;;Astigarraga et al., “a MAPK Docking Site is Critical for Downregulation of Capicua by Torso and EGFR RTK Signaling,” EMBO J 26, 668 (2007).;;Lee et al., “CIC, a gene involved in cerebellar development and ErbB signaling is significantly expressed in medulloblastomas,” JNeurnoncol 73, 101 (2005).;;Olsen et al., “Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks,” Cell 127, 635 (2006).;;Wong et al., “Structural Alterations of the Epidermal Growth Factor Receptor Gene in Human Gliomas,” Proc Natl Acad Sci US A 89, 2965 (1992).;;Bigner et al., “Gene Amplification in Malignant Human Gilomas: Clinical and Histopathologic Aspects,” JNeuropathol Exp Neurol 47, 191-205 (1988).;;Vivanco et al., “Epiderman growth factor receptor inhibitors in oncology,” 2010, Curr Opin Oncol 22, 573-578.;;Duncan et al., “A sequence-specific, single-strand binding protein activates the far upstream element of c-,myc and defines a new DNA-binding motif,” Genes Dev 8, 465 (1994).;;Hsiao et al., Quantitative Characterization of the Interactions among c-myc Transcriptional Regulators FUSE, FBP, and FIR Biochemistry 49, 4620 (2010).;;Kawamura-Saito et al., “Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like Sarcomas with t(4;19)(q35;q13) Translocation,” Hurn Mol Genet 15, 2125 (2006).;;Grimwood et al., “The DNA sequence and biology of human chromosome 19,” Nature 428, 529 (2004).",ACTIVE
74,JP,A,JP 2018050621 A,181-967-435-847-774,2018-04-05,2018,JP 2017194782 A,2017-10-05,US 201361765909 P;;US 201361766857 P;;US 201361772249 P,2013-02-18,TERT PROMOTER MUTATION IN GLIOMA AND TUMOR SUBSET,"PROBLEM TO BE SOLVED: To provide a method to elucidate mutations in the noncoding region of the human genome, in particular mutations in the telomerase reverse transcriptase (TERT) promoter in tumors.SOLUTION: In this method for providing mutations of TERT in tumors to help classify and prognosticate brain tumors, 60 different types of tumors from 1,230 cases were investigated and it was found that the tumors could be classified as those with a low frequency (<15%) and those with a high frequency (≥15%) of TERT promoter mutations. 9 types of high TERT tumors including melanoma, liposarcoma, hepatocellular carcinoma, urothelial carcinoma, squamous cell carcinoma of the tongue, medulloblastoma, and a subset of glioma (includes 83% of primary glioblastoma, the most common brain tumor type) almost always occur in tissue where the rate of self-replication is relatively low, and in addition to TERT mutations providing clues for understanding the relationship between telomere and tumorigenesis, biomarkers for early detection of tumors of the urinary tract and liver are provided.SELECTED DRAWING: Figure 1",UNIV DUKE;;UNIV JOHNS HOPKINS,YAN HAI;;BERT VOGELSTEIN;;NICKOLAS PAPADOPOULOS;;KINZLER KENNETH W;;JIAO YUCHEN;;CHETAN BETTEGOWDA;;DARELL D BIGNER,,https://lens.org/181-967-435-847-774,Patent Application,no,0,0,17,24,3,C12Q2600/112;;C12Q2600/156;;C12Q1/6886;;C12Q2600/156;;C12Q2600/112;;C12Q1/6886,C12Q1/68;;C12N15/09,,13,2,003-113-655-474-830;;137-629-232-369-55X,10.1126/science.1229259;;pmc4423787;;23348506;;23348503;;10.1126/science.1230062,"SCIENCE, (2013.01.24), 339, [6122], P.957-959, JPN6016027934, ISSN: 0004384847;;SCIENCE, (2013.01.24), 339, [6122], P.959-961, JPN6016027937, ISSN: 0004384836;;SCIENCE, (2013.01.24), 339, [6122], P.957-959&SUPPLEMENTARY MATERIALS, JPN6020001003, ISSN: 0004384835;;SNU-475 (ATCC CRL-2236), [ONLINE], ATCC, [RETRIEVED ON 2020-JAN-08], RETRIEVED FROM INTERNET:<URL:HT, JPN6020001011, ISSN: 0004384844;;JCRB0711 T24, [ONLINE], JCRB CELL BANK, [RETRIEVED ON 2020-JAN-08], RETRIEVED FROM INTERNET:<URL:HTT, JPN6020001012, ISSN: 0004384845;;U-87 MG (ATCC HTB-14), [ONLINE], ATCC, [RETRIEVED ON 2020-JAN-08], RETRIEVED FROM INTERNET:<URL:HTTP, JPN6020001013, ISSN: 0004384846;;5637 (ATCC HTB-9), [ONLINE], ATCC, [RETRIEVED ON 2020-JAN-08], RETRIEVED FROM INTERNET:<URL:HTTPS://, JPN6020001004, ISSN: 0004384837;;DAOY (ATCC HTB-186), [ONLINE], ATCC, [RETRIEVED ON 2020-JAN-08], RETRIEVED FROM INTERNET:<URL:HTTPS:, JPN6020001005, ISSN: 0004384838;;HEP G2[HEPG2] (ATCC HB-8065), [ONLINE], ATCC, [RETRIEVED ON 2020-JAN-08], RETRIEVED FROM INTERNET:<U, JPN6020001006, ISSN: 0004384839;;ONS-76, [ONLINE], JCRB CELL BANK, [RETRIEVED ON 2020-JAN-08], RETRIEVED FROM INTERNET:<URL:HTTPS://C, JPN6020001007, ISSN: 0004384840;;CELLOSAURUS RT-112(CVCL_1670), [ONLINE], EXPASY, [RETRIEVED ON 2020-JAN-08], RETRIEVED FROM INTERNET, JPN6020001008, ISSN: 0004384841;;SNU-387 (ATCC CRL-2237), [ONLINE], ATCC, [RETRIEVED ON 2020-JAN-08], RETRIEVED FROM INTERNET:<URL:HT, JPN6020001009, ISSN: 0004384842;;SNU-423 (ATCC CRL-2238), [ONLINE], ATCC, [RETRIEVED ON 2020-JAN-08], RETRIEVED FROM INTERNET:<URL:HT, JPN6020001010, ISSN: 0004384843",PENDING
75,EP,A2,EP 2734644 A2,028-501-530-378-847,2014-05-28,2014,EP 12814956 A,2012-07-18,US 201161509366 P;;US 2012/0047211 W,2011-07-19,OLIGODENDROGLIOMA DRIVER GENES,,UNIV JOHNS HOPKINS;;UNIV DUKE,VOGELSTEIN BERT;;KINZLER KENNETH W;;BETTEGOWDA CHETAN;;AGRAWAL NISHANT;;PAPADOPOULOS NICKOLAS;;BIGNER DARELL;;YAN HAI;;MCLENDON ROGER,,https://lens.org/028-501-530-378-847,Patent Application,yes,0,0,11,11,1,C12Q1/6886;;C12Q1/6886;;C12Q2600/106;;C12Q2600/106;;C12Q2600/112;;C12Q2600/112;;C12Q2600/118;;C12Q2600/118;;C12Q2600/156;;C12Q2600/156;;C12Q2600/158;;C12Q2600/158,C12Q1/68;;A61K39/00,,0,0,,,,ACTIVE
76,EP,B1,EP 2734644 B1,154-007-093-621-582,2016-12-21,2016,EP 12814956 A,2012-07-18,US 201161509366 P;;US 2012/0047211 W,2011-07-19,OLIGODENDROGLIOMA DRIVER GENES,,UNIV JOHNS HOPKINS;;UNIV DUKE,VOGELSTEIN BERT;;KINZLER KENNETH W;;BETTEGOWDA CHETAN;;AGRAWAL NISHANT;;PAPADOPOULOS NICKOLAS;;BIGNER DARELL;;YAN HAI;;MCLENDON ROGER,,https://lens.org/154-007-093-621-582,Granted Patent,yes,0,0,11,11,0,C12Q1/6886;;C12Q1/6886;;C12Q2600/106;;C12Q2600/106;;C12Q2600/112;;C12Q2600/112;;C12Q2600/118;;C12Q2600/118;;C12Q2600/156;;C12Q2600/156;;C12Q2600/158;;C12Q2600/158,C12Q1/68;;A61K39/00,,3,1,036-543-085-365-356,17047046;;10.1158/0008-5472.can-06-1796,"DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; February 2009 (2009-02-01), BROMBERG JACOLIEN E C ET AL: ""Oligodendrogliomas: molecular biology and treatment."", Database accession no. NLM19182242;;DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 15 October 2006 (2006-10-15), JENKINS ROBERT B ET AL: ""A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma."", Database accession no. NLM17047046;;DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; November 2007 (2007-11-01), IDBAIH AHMED ET AL: ""Molecular genetic markers as predictors of response to chemotherapy in gliomas."", Database accession no. NLM17906460",ACTIVE
77,US,A1,US 2014/0221219 A1,174-305-486-459-062,2014-08-07,2014,US 201214233296 A,2012-07-18,US 201214233296 A;;US 201161509366 P;;US 2012/0047211 W,2011-07-19,OLIGODENDROGLIOMA DRIVE GENES,"Oligodendrogliomas are the second most common malignant brain tumor in adults. These tumors often contain a chromosomal abnormality involving a pericentromeric fusion of chromosomes 1 and 19, resulting in losses of the entire short arm of the former and the long arm of the latter. To identify the molecular genetic basis for this alteration, we performed exomic sequencing of seven anaplastic oligodendrogliomas with chromosome 1p and 19q losses. Among other changes, we found that that CIC (homolog of the Drosophila gene capicua) on chromosome 19q was somatically mutated in six of the seven cases and that FUBP1 (far upstream element (FUSE) binding protein) on chromosome 1p was somatically mutated in two of the seven cases. Examination of 27 additional oligodendrogliomas revealed 12 and 3 more tumors with mutations of CIC and FUBP1, respectively, 58% of which were predicted to result in truncations of the encoded proteins. These results suggest a critical role for these genes in the biology and pathology of oligodendrocytes.",VOGELSTEIN BERT;;KINZLER KENNETH W;;BETTEGOWDA CHETAN;;AGRAWAL NISHANT;;PAPADOPOULOS NICKOLAS;;BIGNER DARELL;;YAN HAI;;MCLENDON ROGER;;UNIV DUKE;;UNIV JOHNS HOPKINS,VOGELSTEIN BERT;;KINZLER KENNETH W;;BETTEGOWDA CHETAN;;AGRAWAL NISHANT;;PAPADOPOULOS NICKOLAS;;BIGNER DARELL;;YAN HAI;;MCLENDON ROGER,DUKE UNIVERSITY (2020-09-01);;THE JOHNS HOPKINS UNIVERSITY (2020-08-22),https://lens.org/174-305-486-459-062,Patent Application,yes,0,1,11,11,1,C12Q1/6886;;C12Q1/6886;;C12Q2600/106;;C12Q2600/106;;C12Q2600/112;;C12Q2600/112;;C12Q2600/118;;C12Q2600/118;;C12Q2600/156;;C12Q2600/156;;C12Q2600/158;;C12Q2600/158,C12Q1/68,506/2;;435/6.11,5,4,010-740-316-667-52X;;030-797-126-102-74X;;007-185-748-098-342;;099-027-124-338-196,10.1158/0008-5472.can-04-1170;;15289301;;7977648;;pmc1887413;;12117714;;10.1161/01.atv.0000026801.56080.14;;10.1126/science.281.5384.1787;;9776677,"Broderick et al. Cancer Research, 64, 5048-5050;;Reifenberger et al. (American Journal of Pathology, Vol. 145, No. 5, November 1994, pages 1175-1190);;Hegele (2002) Arterioscler Thromb Vasc Biol, 22:1-58-1061.;;Pennisi (1998), Science, New Series, Vol. 281, No. 5384, p. 1787-1789;;Lucentini (December 2004) The Scientist, p. 20",ACTIVE
78,US,A1,US 2018/0195132 A1,069-231-067-841-843,2018-07-12,2018,US 201715834886 A,2017-12-07,US 201715834886 A;;US 201414233296 A;;US 2012/0047211 W;;US 201161509366 P,2011-07-19,OLIGODENDROGLIOMA DRIVE GENES,"Oligodendrogliomas are the second most common malignant brain tumor in adults. These tumors often contain a chromosomal abnormality involving a pericentromeric fusion of chromosomes 1 and 19, resulting in losses of the entire short arm of the former and the long arm of the latter. To identify the molecular genetic basis for this alteration, we performed exomic sequencing of seven anaplastic oligodendrogliomas with chromosome 1p and 19q losses. Among other changes, we found that that CIC (homolog of the Drosophila gene capicua) on chromosome 19q was somatically mutated in six of the seven cases and that FUBP1 (far upstream element (FUSE) binding protein) on chromosome 1p was somatically mutated in two of the seven cases. Examination of 27 additional oligodendrogliomas revealed 12 and 3 more tumors with mutations of CIC and FUBP1, respectively, 58% of which were predicted to result in truncations of the encoded proteins. These results suggest a critical role for these genes in the biology and pathology of oligodendrocytes.",UNIV JOHNS HOPKINS;;UNIV DUKE,VOGELSTEIN BERT;;KINZLER KENNETH W;;BETTEGOWDA CHETAN;;AGRAWAL NISHANT;;PAPADOPOULOS NICKOLAS;;BIGNER DARELL;;YAN HAI;;MCLENDON ROGER,DUKE UNIVERSITY (2011-09-28);;THE JOHNS HOPKINS UNIVERSITY (2011-08-02),https://lens.org/069-231-067-841-843,Patent Application,yes,0,0,11,11,1,C12Q1/6886;;C12Q1/6886;;C12Q2600/106;;C12Q2600/106;;C12Q2600/112;;C12Q2600/112;;C12Q2600/118;;C12Q2600/118;;C12Q2600/156;;C12Q2600/156;;C12Q2600/158;;C12Q2600/158,C12Q1/6886,,0,0,,,,ACTIVE
79,AU,A1,AU 2012/284100 A1,108-153-578-473-941,2014-02-27,2014,AU 2012/284100 A,2012-07-18,US 201161509366 P;;US 2012/0047211 W,2011-07-19,Oligodendroglioma driver genes,"Oligodendrogliomas are the second most common malignant brain tumor in adults. These tumors often contain a chromosomal abnormality involving a pericentromeric fusion of chromosomes 1 and 19, resulting in losses of the entire short arm of the former and the long arm of the latter. To identify the molecular genetic basis for this alteration, we performed exomic sequencing of seven anaplastic oligodendrogliomas with chromosome 1p and 19q losses. Among other changes, we found that that CIC (homolog of the Drosophila gene capicua) on chromosome 19q was somatically mutated in six of the seven cases and that FUBP1 (far upstream element (FUSE) binding protein) on chromosome 1p was somatically mutated in two of the seven cases. Examination of 27 additional oligodendrogliomas revealed 12 and 3 more tumors with mutations of CIC and FUBP1, respectively, 58% of which were predicted to result in truncations of the encoded proteins. These results suggest a critical role for these genes in the biology and pathology of oligodendrocytes.",UNIV DUKE;;UNIV JOHNS HOPKINS,VOGELSTEIN BERT;;KINZLER KENNETH W;;BETTEGOWDA CHETAN;;AGRAWAL NISHANT;;PAPADOPOULOS NICKOLAS;;BIGNER DARELL;;YAN HAI;;MCLENDON ROGER,,https://lens.org/108-153-578-473-941,Patent Application,no,0,0,11,11,0,C12Q1/6886;;C12Q1/6886;;C12Q2600/106;;C12Q2600/106;;C12Q2600/112;;C12Q2600/112;;C12Q2600/118;;C12Q2600/118;;C12Q2600/156;;C12Q2600/156;;C12Q2600/158;;C12Q2600/158,C12N15/11;;C12Q1/68,,0,0,,,,ACTIVE
80,WO,A2,WO 2013/012927 A2,003-216-011-058-454,2013-01-24,2013,US 2012/0047211 W,2012-07-18,US 201161509366 P,2011-07-19,OLIGODENDROGLIOMA DRIVER GENES,"Oligodendrogliomas are the second most common malignant brain tumor in adults. These tumors often contain a chromosomal abnormality involving a pericentromeric fusion of chromosomes 1 and 19, resulting in losses of the entire short arm of the former and the long arm of the latter. To identify the molecular genetic basis for this alteration, we performed exomic sequencing of seven anaplastic oligodendrogliomas with chromosome 1p and 19q losses. Among other changes, we found that that CIC (homolog of the Drosophila gene capicua) on chromosome 19q was somatically mutated in six of the seven cases and that FUBP1 (far upstream element (FUSE) binding protein) on chromosome 1p was somatically mutated in two of the seven cases. Examination of 27 additional oligodendrogliomas revealed 12 and 3 more tumors with mutations of CIC and FUBP1, respectively, 58% of which were predicted to result in truncations of the encoded proteins. These results suggest a critical role for these genes in the biology and pathology of oligodendrocytes.",UNIV JOHNS HOPKINS;;UNIV DUKE;;VOGELSTEIN BERT;;KINZLER KENNETH W;;BETTEGOWDA CHETAN;;AGRAWAL NISHANT;;PAPADOPOULOS NICKOLAS;;BIGNER DARELL;;YAN HAI;;MCLENDON ROGER,VOGELSTEIN BERT;;KINZLER KENNETH W;;BETTEGOWDA CHETAN;;AGRAWAL NISHANT;;PAPADOPOULOS NICKOLAS;;BIGNER DARELL;;YAN HAI;;MCLENDON ROGER,,https://lens.org/003-216-011-058-454,Patent Application,yes,2,1,11,11,1,C12Q1/6886;;C12Q1/6886;;C12Q2600/106;;C12Q2600/106;;C12Q2600/112;;C12Q2600/112;;C12Q2600/118;;C12Q2600/118;;C12Q2600/156;;C12Q2600/156;;C12Q2600/158;;C12Q2600/158,C12Q1/68;;C12N15/11,,3,2,040-988-224-915-933;;101-030-760-689-875,pmc2820383;;19228619;;10.1056/nejmoa0808710;;10.1007/s11060-004-4598-2;;15981098,"YAN HEI ET AL., NEW ENGLAND JOURNAL OF MEDICINE, vol. 360, 2009, pages 765 - 773;;CHING-JUNG ET AL., JOURNAL OF NEURO-ONCOLOGY, vol. 73, 2005, pages 101 - 108;;See also references of EP 2734644A4",PENDING
81,US,B2,US 9873917 B2,141-427-200-434-192,2018-01-23,2018,US 201214233296 A,2012-07-18,US 201214233296 A;;US 201161509366 P;;US 2012/0047211 W,2011-07-19,Oligodendroglioma drive genes,"Oligodendrogliomas are the second most common malignant brain tumor in adults. These tumors often contain a chromosomal abnormality involving a pericentromeric fusion of chromosomes 1 and 19, resulting in losses of the entire short arm of the former and the long arm of the latter. To identify the molecular genetic basis for this alteration, we performed exomic sequencing of seven anaplastic oligodendrogliomas with chromosome 1p and 19q losses. Among other changes, we found that that CIC (homolog of the Drosophila gene capicua) on chromosome 19q was somatically mutated in six of the seven cases and that FUBP1 (far upstream element (FUSE) binding protein) on chromosome 1p was somatically mutated in two of the seven cases. Examination of 27 additional oligodendrogliomas revealed 12 and 3 more tumors with mutations of CIC and FUBP1, respectively, 58% of which were predicted to result in truncations of the encoded proteins. These results suggest a critical role for these genes in the biology and pathology of oligodendrocytes.",VOGELSTEIN BERT;;KINZLER KENNETH W;;BETTEGOWDA CHETAN;;AGRAWAL NISHANT;;PAPADOPOULOS NICKOLAS;;BIGNER DARELL;;YAN HAI;;MCLENDON ROGER;;UNIV JOHNS HOPKINS;;UNIV DUKE,VOGELSTEIN BERT;;KINZLER KENNETH W;;BETTEGOWDA CHETAN;;AGRAWAL NISHANT;;PAPADOPOULOS NICKOLAS;;BIGNER DARELL;;YAN HAI;;MCLENDON ROGER,,https://lens.org/141-427-200-434-192,Granted Patent,yes,4,1,11,11,1,C12Q1/6886;;C12Q1/6886;;C12Q2600/106;;C12Q2600/106;;C12Q2600/112;;C12Q2600/112;;C12Q2600/118;;C12Q2600/118;;C12Q2600/156;;C12Q2600/156;;C12Q2600/158;;C12Q2600/158,C12Q1/68,,53,49,010-740-316-667-52X;;030-797-126-102-74X;;007-185-748-098-342;;099-027-124-338-196;;010-740-316-667-52X;;024-276-736-339-938;;074-364-497-275-933;;040-988-224-915-933;;101-030-760-689-875;;011-509-993-590-368;;074-974-263-553-003;;094-535-915-312-274;;021-058-626-150-865;;042-732-073-403-706;;072-086-564-785-432;;042-562-614-498-017;;019-392-813-016-049;;032-718-950-332-134;;003-715-915-052-975;;037-313-276-496-095;;144-175-140-718-29X;;007-942-565-150-254;;101-030-760-689-875;;064-678-224-734-734;;019-231-639-785-506;;017-493-980-370-117;;089-153-856-694-844;;002-261-176-506-880;;040-511-066-712-912;;034-566-384-563-853;;040-356-236-898-08X;;036-543-085-365-356;;126-006-647-030-363;;107-882-904-538-397;;001-568-098-749-368;;025-295-991-710-124;;016-743-989-375-187;;069-792-512-589-392;;063-375-682-056-905;;004-595-844-963-466;;022-482-632-280-630;;129-895-037-908-505;;005-927-424-183-679;;038-927-746-063-781;;012-071-463-971-588;;056-708-566-346-648;;021-824-531-002-296;;007-156-666-558-605;;003-307-016-010-015,10.1158/0008-5472.can-04-1170;;15289301;;7977648;;pmc1887413;;12117714;;10.1161/01.atv.0000026801.56080.14;;10.1126/science.281.5384.1787;;9776677;;10.1158/0008-5472.can-04-1170;;15289301;;pmc3170506;;10.1126/science.1210557;;21817013;;10.1007/s00401-012-0993-5;;22588899;;pmc2820383;;19228619;;10.1056/nejmoa0808710;;10.1007/s11060-004-4598-2;;15981098;;9329453;;10.1097/00005072-199710000-00003;;10.1200/jco.2000.18.3.636;;10653879;;10.1097/ppo.0b013e31818d8178;;19060598;;10.1038/nrneurol.2010.159;;21045797;;10.1002/1097-0142(197503)35:3+<1022::aid-cncr2820350726>3.0.co;2-a;;163140;;10.1007/s12094-011-0658-1;;21596657;;pmc1866844;;10433931;;10.1016/s0002-9440(10)65134-6;;21252315;;10.1126/science.1200609;;pmc3144496;;20826764;;pmc3076894;;10.1126/science.1196333;;20535651;;10.1007/82_2010_68;;pmc3164550;;10.1038/nature14666;;26200345;;10.1016/s0513-5117(10)79305-4;;8601560;;10.1007/bf01366952;;10.1007/s11060-004-4598-2;;15981098;;3367154;;10.1097/00005072-198805000-00001;;10.1097/cco.0b013e32833edbdf;;20739887;;10.1101/gad.8.4.465;;8125259;;20420426;;10.1021/bi9021445;;16717057;;10.1093/hmg/ddl136;;10.1038/nature02399;;15057824;;9083161;;10.1002/(sici)1097-0142(19970401)79:7<1381::aid-cncr16>3.0.co;2-w;;10.1634/theoncologist.2008-0248;;19182242;;17047046;;10.1158/0008-5472.can-06-1796;;17021403;;10.1097/01.jnen.0000235122.98052.8f;;pmc3080742;;21216738;;10.1093/bfgp/elq025;;18772396;;pmc2820389;;10.1126/science.1164382;;10.1126/science.1096502;;15016963;;16364744;;10.1016/j.virol.2005.09.027;;12040186;;10.1126/science.296.5573.1655;;10.1016/s0513-5117(09)79085-4;;10.1158/0008-5472.can-09-2650;;19996293;;pmc2794981;;10.1126/science.2649981;;2649981;;pmc2820387;;18692126;;10.1016/j.ygeno.2008.07.005;;10.1101/gad.14.2.224;;pmc316342;;10652276;;10.1146/annurev.ge.26.120192.001425;;1482114;;10.1242/dev.129.4.993;;11861482;;pmc3035094;;21270056;;10.1242/dev.057729;;17255944;;10.1038/sj.emboj.7601532;;pmc1794389;;17081983;;10.1016/j.cell.2006.09.026;;pmc48784;;1557402;;10.1073/pnas.89.7.2965,"Broderick et al. Cancer Research, 64, 5048-5050.;;Reifenberger et al. (American Journal of Pathology, vol. 145, No. 5, Nov. 1994, pp. 1175-1190).;;Hegele (2002) Arterioscler Thromb Vasc Biol, 22:1-58-1061.;;Pennisi (1998), Science, New Series, vol. 281, No. 5384, p. 1787-1789.;;Lucentini (Dec. 2004) The Scientist, p. 20.;;Broderick et al. Cancer Research, 64, 5048-5050, 2004 (Year: 2004).;;Bettegowda, C. et al., ‘Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma’, Science, Sep. 9, 2011, vol. 333, pp. 1453-1455.;;Sahm, F. et al. , ‘CIC and FUBP1 Mutations in Oligodendrogliomas, Oligoastrocytoma and Astrocytomas’, Acta Neuropathol, May 17, 2012, vol. 123, pp. 853-860.;;Yan, H. et al., ‘IDH1 and IDH2 Mutations in Gliomas’, The New England Journal of Medicine, Feb. 19, 2009, vol. 360, No. 8, pp. 765-773.;;International Search Report and Written Opinion dated Jan. 28, 2013, for PCT/US2012/047211.;;Extended European Search Report issued in related European Application No. 12814956.4, dated Feb. 13, 2015.;;Lee et al., “CIC, a gene involved in cerebellar development and ErbB signaling, is significantly expressed in medulloblastomas,” Journal of Neuro-Oncology, vol. 73, No. 2, Jun. 1, 2005, pp. 101-108.;;Maintz et al., “Molecular Genetic Evidence for Subtypes of Oligoastrocytomas,” J Nemopathol Exp Neuroi 56, 1098 (1997).;;Smith et al., “Alterations of Chromosome Arms 1p and 19q as Predictors of Survival in Oligodendrogliomas, Astrocytomas, and Mixed Oligoastrocytomas,” J Clin Oncol 18, 636 (2000).;;Cairncross et al., “Gliomas with lp/19q Codeletion: a.k.a. Oligodendroglioma,” Cancer J 14, 352 (2008).;;Bourne et al., “Update on Molecular Findings, Management, and Outcome in Low-grade Gliomas,” Nat Rev Neurol 6, 695-701.;;Knudson, Jr. et al., “The Genetics of Childhood Cancer,”Cancer 35, 1022 (1975).;;Sastre, “New DNA sequencing technologies open a promising era for cancer research and treatment,” Clin Transl Oncol 13, 301-306.;;Bigner et al., “Molecular Genetic Aspects of Oligodendrogliomas Including Analysis by Comparative Genomic Hybridization,” Arn J Pathol 155, 375 ( 1999).;;Y. Jiao et al., DAXX/ATRX, MEN1 and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors Science 331, 1199-1203 (2011).;;Jones et al., “Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma,” Science 330, 228 (2010).;;Samuels et al., “Oncogenic Mutations of PIK3CA in Human Cancers,” Curr Top Microbiol Immunol, 2010 347, 21-41.;;The Cancer Genome Atlas Research Nenvork, Nature 455, 1061 (2008).;;Puente et al., “Non-coding recurrent mutations in chronic lymphocytic Leukaemia,” Nature, 2015, 526:519-541.;;Dang et al., “Cancer-associated IDH1 Mutations Produce 2-hydroxyglutarate,” Nature 465, 966 (2010).;;Knudson et al., “Hereditary cancer: two hits revisited,” J. Cancer Res. Clin. OncoL 122, 135 (1996).;;Lee et al., “CIC, a gene involved in cerebellar development and ErbB signaling is significantly expressed in medulloblastomas,” JNeurnoncol 73, 101 (2005).;;Bigner et al., “Gene Amplification in Malignant Human Gilomas: Clinical and Histopathologic Aspects,” JNeuropathol Exp Neurol 47, 191-205 (1988).;;Vivanco et al., “Epiderman growth factor receptor inhibitors in oncology,”2010, Curr Opin Oncol 22, 573-578.;;Duncan et al., “A sequence-specific, single-strand binding protein activates the far upstream element of c-,myc and defines a new DNA-binding motif,” Genes Dev 8, 465 (1994).;;Hsiao et al., Quantitative Characterization of the Interactions among c-myc Transcriptional Regulators FUSE, FBP, and FIR Biochemistry 49, 4620 (2010).;;Kawamura-Saito et al., “Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like Sarcomas with t (4;19) (g35; q 13) Translocation,” Hum. Mol. Genet 15, 2125 (2006).;;Grimwood et al., “The DNA sequence and biology of human chromosome 19,” Nature 428, 529 (2004).;;Coons et al., “Improving Diagnostic Accuracy and Interobserver Concordance in the Classification and Grading of Primary Gliomas” cancer 79, 1381 (1997).;;Bromberg et al., “Oligodendrogliomas: Molecular Biology and Treatment”, Oncologist 14, 155 (2009).;;Jenkins et al., “A t(1;19)(q10;p10) Mediates the combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with Oligodendroglioma” Cancer Res 66, 9852 (2006).;;Griffin et al., “Identification of der (1;19)(q10;p10) in Five Oligodendrogliomas Suggests Mechanism of Concurrent 1p and 19q Loss,” J Neuropathol Exp Neurol 65, 988 (2006).;;Xi et al., “Detecting Structural Variations in the Human Genome Using Next Generation Sequencing,” Brief Funct Genomics, 2011 9:305.;;Parsons et al., “An Integrated Genomic Analysis of Human Glioblastoma Multiforme,” Science 321, 1807 (2008).;;Samuels et al., “High Frequency of Mutations of the PIK3CA Gene in Human Cancers,” Science 304, 554 (2004).;;Vogt et al., “Phosphoinositide 3-kinase: Front viral oncoprotein to drug target,” Virology 344, 131 (2006).;;Cantley, “The Phosphoinositide 3-Kinase Pathway” Science 296, 1655 (2002).;;H. Yan et al., “IDH1 and IDH2 Mutations in Gliomas,” N Engl J Med 360, 765 (2009).;;Yan et al., “Mutant Metabolic Enzymes Are at the Origin of Gliomas,” Cancer Res 69, 9157 (2009).;;S. J. Baker et al., “Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas,” Science 244, 217 (1989).;;G. Parmigiani et al., “Design and Analysis Issues in Genome-Wide Somatic Mutation Studies of Cancer,” Genomics in press, (2008).;;Jimenez et al., “Relief of Gene Repression by Torso RTK Signaling: role of Capicua in Drosophila Terminal and Dorsoventral Patterning,” Genes Dev 14, 224 (2000).;;Garcia-Bellido et al., “Developmental Genetics of the Venation Pattern of Drosophila,” Annu Rev Genet 26, 277 (1992).;;Roch et al., “EGFR Signalling Inhibits Capicua-dependent Repression During Specification of Drosophila Wing Veins,”, Development 129, 993 (2002).;;Ajuria et al., “Capicua DNA-Binding Sites are General Response Elements for RTK Signaling in Drosophila,” Development 138, 915.;;Astigarraga et al., “a MAPK Docking Site is Critical for Downregulation of Capicua by Torso and EGFR RTK Signaling,” Embo J 26, 668 (2007).;;Olsen et al., “Global, in Vivo, acid Site-Specific Phosphorylation Dynamics in Signaling Networks,” Cell 127, 635 (2006).;;Wong et al., “Structural Alterations of the Epidermal Growth Factor Receptor Gene in Human Gliomas,” Proc Natl Acad Sci US A 89, 2965 (1992).",ACTIVE
82,AU,B2,AU 2012/284100 B2,083-705-059-428-177,2016-12-15,2016,AU 2012/284100 A,2012-07-18,US 201161509366 P;;US 2012/0047211 W,2011-07-19,Oligodendroglioma driver genes,"Oligodendrogliomas are the second most common malignant brain tumor in adults. These tumors often contain a chromosomal abnormality involving a pericentromeric fusion of chromosomes 1 and 19, resulting in losses of the entire short arm of the former and the long arm of the latter. To identify the molecular genetic basis for this alteration, we performed exomic sequencing of seven anaplastic oligodendrogliomas with chromosome 1p and 19q losses. Among other changes, we found that that CIC (homolog of the Drosophila gene capicua) on chromosome 19q was somatically mutated in six of the seven cases and that FUBP1 (far upstream element (FUSE) binding protein) on chromosome 1p was somatically mutated in two of the seven cases. Examination of 27 additional oligodendrogliomas revealed 12 and 3 more tumors with mutations of CIC and FUBP1, respectively, 58% of which were predicted to result in truncations of the encoded proteins. These results suggest a critical role for these genes in the biology and pathology of oligodendrocytes.",UNIV DUKE;;UNIV JOHNS HOPKINS,VOGELSTEIN BERT;;KINZLER KENNETH W;;BETTEGOWDA CHETAN;;AGRAWAL NISHANT;;PAPADOPOULOS NICKOLAS;;BIGNER DARELL;;YAN HAI;;MCLENDON ROGER,,https://lens.org/083-705-059-428-177,Granted Patent,no,1,0,11,11,0,C12Q2600/112;;C12Q2600/156;;C12Q2600/106;;C12Q2600/118;;C12Q2600/158;;C12Q1/6886;;C12Q2600/106;;C12Q2600/118;;C12Q2600/158;;C12Q2600/112;;C12Q2600/156;;C12Q1/6886,C12N15/11;;C12Q1/68,,0,0,,,,ACTIVE
83,WO,A3,WO 2013/012927 A3,155-765-932-211-277,2013-03-21,2013,US 2012/0047211 W,2012-07-18,US 201161509366 P,2011-07-19,OLIGODENDROGLIOMA DRIVER GENES,"Oligodendrogliomas are the second most common malignant brain tumor in adults. These tumors often contain a chromosomal abnormality involving a pericentromeric fusion of chromosomes 1 and 19, resulting in losses of the entire short arm of the former and the long arm of the latter. To identify the molecular genetic basis for this alteration, we performed exomic sequencing of seven anaplastic oligodendrogliomas with chromosome 1p and 19q losses. Among other changes, we found that that CIC (homolog of the Drosophila gene capicua) on chromosome 19q was somatically mutated in six of the seven cases and that FUBP1 (far upstream element (FUSE) binding protein) on chromosome 1p was somatically mutated in two of the seven cases. Examination of 27 additional oligodendrogliomas revealed 12 and 3 more tumors with mutations of CIC and FUBP1, respectively, 58% of which were predicted to result in truncations of the encoded proteins. These results suggest a critical role for these genes in the biology and pathology of oligodendrocytes.",UNIV JOHNS HOPKINS;;UNIV DUKE;;VOGELSTEIN BERT;;KINZLER KENNETH W;;BETTEGOWDA CHETAN;;AGRAWAL NISHANT;;PAPADOPOULOS NICKOLAS;;BIGNER DARELL;;YAN HAI;;MCLENDON ROGER,VOGELSTEIN BERT;;KINZLER KENNETH W;;BETTEGOWDA CHETAN;;AGRAWAL NISHANT;;PAPADOPOULOS NICKOLAS;;BIGNER DARELL;;YAN HAI;;MCLENDON ROGER,,https://lens.org/155-765-932-211-277,Search Report,yes,2,0,11,11,1,C12Q1/6886;;C12Q1/6886;;C12Q2600/106;;C12Q2600/106;;C12Q2600/112;;C12Q2600/112;;C12Q2600/118;;C12Q2600/118;;C12Q2600/156;;C12Q2600/156;;C12Q2600/158;;C12Q2600/158,C12Q1/68;;C12N15/11,,4,3,024-276-736-339-938;;074-364-497-275-933;;040-988-224-915-933,pmc3170506;;10.1126/science.1210557;;21817013;;10.1007/s00401-012-0993-5;;22588899;;pmc2820383;;19228619;;10.1056/nejmoa0808710,"BETTEGOWDA, C. ET AL.: ""Mutations in CIC and FUBP1 Contribute to Human Olig odendroglioma"", SCIENCE, vol. 333, no. 6048, 9 September 2011 (2011-09-09), pages 1453 - 1455, XP055142306;;SAHM, F. ET AL.: ""CIC and FUBP1 Mutations in Oligodendrogliomas, Oligoastro cytomas and Astrocytomas"", ACTA NEUROPATHOL, vol. 123, no. 6, 17 May 2012 (2012-05-17), pages 853 - 860, XP035060624;;YAN, H. ET AL.: ""IDH1 and IDH2 Mutations in Gliomas"", THE NEW ENGLAND JOUR NAL OF MEDICINE, vol. 360, no. 8, 19 February 2009 (2009-02-19), pages 765 - 773, XP002538459;;See also references of EP 2734644A4",PENDING
84,EP,A1,EP 3360979 A1,137-263-907-346-96X,2018-08-15,2018,EP 18164632 A,2014-02-18,US 201361765909 P;;US 201361766857 P;;US 201361772249 P;;EP 14751900 A;;US 2014/0016906 W,2013-02-18,TERT PROMOTER MUTATIONS IN GLIOMAS AND A SUBSET OF TUMORS,"We surveyed 1,230 tumors of 60 different types and found that tumors could be divided into types with low (<15%) and high (≥15%) frequencies of TERT promoter mutations. The nine TERT-high tumor types almost always originated in tissues with relatively low rates of self renewal, including melanomas, liposarcomas, hepatocellular carcinomas, urothelial carcinomas, squamous cell carcinomas of the tongue, medulloblastomas, and subtypes of gliomas (including 83% of primary glioblastoma, the most common brain tumor type). TERT and ATRX mutations were mutually exclusive, suggesting that these two genetic mechanisms confer equivalent selective growth advantages. In addition to their implications for understanding the relationship between telomeres and tumorigenesis, TERT mutations provide a biomarker for the early detection of urinary tract and liver tumors and aid in the classification and prognostication of brain tumors.",UNIV DUKE;;UNIV JOHNS HOPKINS,YAN HAI;;VOGELSTEIN BERT;;KINZLER KENNETH;;PAPADOPOULOS NICKOLAS;;BIGNER DARELL;;JIAO YUCHEN;;BETTEGOWDA CHETAN;;REITMAN ZACHARY J;;KILLELA PATRICK J,DUKE UNIVERSITY (2020-08-26);;THE JOHNS HOPKINS UNIVERSITY (2020-08-26),https://lens.org/137-263-907-346-96X,Patent Application,yes,1,3,17,24,3,C12Q2600/112;;C12Q2600/156;;C12Q1/6886;;C12Q2600/156;;C12Q2600/112;;C12Q1/6886,C12Q1/6886;;C12N15/12,,51,51,003-113-655-474-830;;011-757-015-197-891;;078-392-642-391-062;;029-425-097-483-850;;032-606-072-102-354;;036-336-793-184-01X;;035-453-694-694-248;;092-805-696-098-697;;043-096-694-231-750;;078-169-002-114-751;;050-009-006-022-10X;;015-711-835-021-543;;025-180-991-800-058;;056-474-208-008-279;;019-392-813-016-049;;004-875-695-978-483;;111-018-449-235-636;;016-902-039-368-405;;137-629-232-369-55X;;003-113-655-474-830;;110-417-738-183-74X;;077-709-494-977-446;;026-817-358-672-814;;042-127-003-947-817;;013-128-975-647-723;;049-742-297-666-322;;083-497-099-695-233;;065-192-491-874-025;;074-769-942-532-201;;010-157-925-412-719;;026-004-690-180-768;;017-690-865-400-395;;075-185-129-149-469;;008-675-784-363-447;;000-797-171-812-419;;092-201-865-081-400;;001-568-098-749-368;;081-987-167-368-98X;;024-276-736-339-938;;040-356-236-898-08X;;011-509-993-590-368;;049-417-076-405-234;;018-719-167-941-509;;054-565-788-514-522;;026-315-603-754-419;;078-622-672-824-907;;011-725-636-482-445;;009-730-557-800-673;;030-711-189-393-281;;008-106-253-354-71X;;040-988-224-915-933,10.1126/science.1229259;;pmc4423787;;23348506;;10.1016/s0168-8278(10)60887-2;;16937491;;pmc4087398;;10.3748/wjg.v12.i31.4966;;10204615;;10.1007/s005350050220;;10.1002/hep.24217;;21520174;;10.1152/physrev.00026.2007;;18391173;;12097303;;10.1074/jbc.274.19.13085;;10224060;;9837921;;10.1074/jbc.273.50.33436;;7605428;;10.1126/science.7605428;;9282118;;10.1016/s0959-8049(97)00062-2;;8808676;;10.1016/s1074-7613(00)80316-7;;pmc2360127;;10.1038/sj.bjc.6603671;;17353922;;10.1046/j.1432-0436.2002.690412.x;;11841477;;21252315;;10.1126/science.1200609;;pmc3144496;;pmc3174141;;10.1126/science.1207313;;21719641;;10.1038/nrg2763;;20351727;;pmc3181356;;10.1016/j.ajpath.2011.06.018;;21888887;;23348503;;10.1126/science.1230062;;10.1126/science.1229259;;pmc4423787;;23348506;;21253554;;10.1155/2011/483154;;pmc3021868;;10.1038/onc.2008.378;;18850010;;10.1172/jci60015;;pmc3287226;;22293175;;16951210;;10.1158/0008-5472.can-06-0273;;10.1200/jco.2008.20.7753;;pmc2668555;;19224838;;pmc3819251;;22561517;;10.1038/ng.2256;;10.1038/ng.903;;pmc3163746;;21822264;;10.3322/caac.21166;;23335087;;pmc5373841;;21822268;;10.1038/ng.907;;10.1073/pnas.0906357106;;pmc2773972;;19843693;;10.1146/annurev.pathmechdis.3.121806.151518;;18039127;;pmc2943736;;20028867;;10.1158/0008-5472.can-09-2331;;10.1200/jco.2009.27.4324;;pmc4874239;;20823417;;10.1371/journal.pone.0003088;;pmc2518524;;18769486;;10.1016/s1474-4422(10)70105-8;;pmc3079431;;20610347;;10.1093/neuonc/nos218;;pmc3480240;;23095881;;18772396;;pmc2820389;;10.1126/science.1164382;;16685456;;10.3892/ijo.28.6.1555;;pmc3170506;;10.1126/science.1210557;;21817013;;10.1634/theoncologist.2008-0248;;19182242;;9329453;;10.1097/00005072-199710000-00003;;22869205;;pmc3443254;;10.18632/oncotarget.588;;10.1097/00005392-199601000-00131;;7490878;;10.1016/s0022-5347(01)66652-7;;10772830;;10.1006/excr.2000.4862;;10.1016/j.cell.2005.04.028;;16009139;;10.1016/j.humpath.2010.07.007;;21106220;;pmc5560895;;23337478;;10.1038/ajg.2012.449;;21937590;;pmc3245991;;10.1093/neuonc/nor169;;16959974;;10.1126/science.1133427;;pmc2992381;;10.18632/oncotarget.137;;21113414;;pmc2820383;;19228619;;10.1056/nejmoa0808710,"F. W. HUANG ET AL: ""Highly Recurrent TERT Promoter Mutations in Human Melanoma"", SCIENCE, vol. 339, no. 6122, 24 January 2013 (2013-01-24), US, pages 957 - 959, XP055109644, ISSN: 0036-8075, DOI: 10.1126/science.1229259;;PARK J Y ET AL: ""886 HTERT PROMOTER GENE POLYMORPHISM AND THE RISK OF HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH CHRONIC HEPATITIS B"", JOURNAL OF HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 52, 1 April 2010 (2010-04-01), pages S345, XP026998784, ISSN: 0168-8278, [retrieved on 20100401];;DENG-FU YAO: ""Dynamic alteration of telomerase expression and its diagnostic significance in liver or peripheral blood for hepatocellular carcinoma"", WORLD JOURNAL OF GASTROENTEROLOGY, vol. 12, no. 31, 1 January 2006 (2006-01-01), CN, pages 4966, XP055483632, ISSN: 1007-9327, DOI: 10.3748/wjg.v12.i31.4966;;KUMI NAGAO ET AL: ""Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma"", JOURNAL OF GASTROENTEROLOGY, vol. 34, no. 1, 22 January 1999 (1999-01-22), JP, pages 83 - 87, XP055483276, ISSN: 0944-1174, DOI: 10.1007/s005350050220;;DANIEL HARTMANN ET AL: ""Telomerase gene mutations are associated with cirrhosis formation"", HEPATOLOGY, vol. 53, no. 5, 1 May 2011 (2011-05-01), US, pages 1608 - 1617, XP055483248, ISSN: 0270-9139, DOI: 10.1002/hep.24217;;AUBERT G; LANSDORP PM, TELOMERES AND AGING. PHYSIOL REV., vol. 88, no. 2, 2008, pages 557 - 579;;AKIYAMA M ET AL.: ""Cytokines modulate telomerase activity in a human multiple myeloma cell line"", CANCER RES., vol. 62, no. 13, 2002, pages 3876 - 3882;;KANG SS; KWON T; KWON DY; DO SI: ""Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit"", J BIOL CHEM., vol. 274, no. 19, 1999, pages 13085 - 13090;;LI H; ZHAO L; YANG Z; FUNDER JW; LIU JP: ""Telomerase is controlled by protein kinase Calpha in human breast cancer cells"", J BIOL CHEM., vol. 273, no. 50, 1998, pages 33436 - 33442;;KIM NW ET AL.: ""Specific association of human telomerase activity with immortal cells and cancer"", SCIENCE, vol. 266, no. 5193, 1994, pages 2011 - 2015, XP002138759, DOI: doi:10.1126/science.7605428;;SHAY JW; BACCHETTI S: ""A survey of telomerase activity in human cancer"", EUR J CANCER, vol. 33, no. 5, 1997, pages 787 - 791, XP004282534, DOI: doi:10.1016/S0959-8049(97)00062-2;;MORRISON SJ; PROWSE KR; HO P; WEISSMAN IL: ""Telomerase activity in hematopoietic cells is associated with self-renewal potential"", IMMUNITY, vol. 5, no. 3, 1996, pages 207 - 216;;HIYAMA E; HIYAMA K: ""Telomere and telomerase in stem cells"", BR J CANCER, vol. 96, no. 7, 2007, pages 1020 - 1024, XP055061521, DOI: doi:10.1038/sj.bjc.6603671;;FORSYTH NR; WRIGHT WE; SHAY JW: ""Telomerase and differentiation in multicellular organisms: Turn it off, turn it on, and turn it off again"", DIFFERENTIATION, vol. 69, no. 4-5, 2002, pages 188 - 197, XP026792136;;JIAO Y ET AL.: ""DAXX/ATRX, MEN I, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors"", SCIENCE, vol. 331, no. 6021, 2011, pages 1199 - 1203, XP055166205, DOI: doi:10.1126/science.1200609;;HEAPHY CM ET AL.: ""Altered telomeres in tumors with ATRX and DAXX mutations"", SCIENCE, vol. 333, no. 6041, 2011, pages 425, XP055140966, DOI: doi:10.1126/science.1207313;;CESARE AJ; REDDEL RR: ""Alternative lengthening of telomeres: Models, mechanisms and implications"", NAT REV GENET, vol. 11, no. 5, 2010, pages 319 - 330, XP055166193, DOI: doi:10.1038/nrg2763;;HEAPHY CM ET AL.: ""Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes"", AM J PATHOL., vol. 179, no. 4, 2011, pages 1608 - 1615;;HORN S ET AL.: ""TERT promoter mutations in familial and sporadic melanoma"", SCIENCE, vol. 339, no. 6122, 2013, pages 959 - 961, XP055110024, DOI: doi:10.1126/science.1230062;;HUANG FW ET AL.: ""Highly recurrent TERT promoter mutations in human melanoma"", SCIENCE, vol. 339, no. 6122, 2013, pages 957 - 959, XP055109644, DOI: doi:10.1126/science.1229259;;CONYERS R; YOUNG S; THOMAS DM: ""Liposarcoma: Molecular genetics and therapeutics"", SARCOMA, vol. 2011, 2011, pages 483154;;GORANSSON M ET AL.: ""The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ"", ONCOGENE, vol. 28, no. 2, 2009, pages 270 - 278, XP055070857, DOI: doi:10.1038/onc.2008.378;;CHARYTONOWICZ E ET AL.: ""PPARy agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma"", J CLIN INVEST., vol. 122, no. 3, 2012, pages 886 - 898;;COSTA A ET AL.: ""Telomere maintenance mechanisms in liposarcomas: Association with histologic subtypes and disease progression"", CANCER RES., vol. 66, no. 17, 2006, pages 8918 - 8924;;ALTEKRUSE SF; MCGLYNN KA; REICHMAN ME: ""Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005"", J CLIN ONCOL., vol. 27, no. 9, 2009, pages 1485 - 1491;;GUICHARD C ET AL.: ""Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma"", NAT GENET, vol. 44, no. 6, 2012, pages 694 - 698;;LI M ET AL.: ""Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma"", NAT GENET, vol. 43, no. 9, 2011, pages 828 - 829;;SIEGEL R; NAISHADHAM D; JEMAL A: ""Cancer statistics, 2013"", CA CANCER J CLIN., vol. 63, no. 1, 2013, pages 11 - 30;;GUI Y ET AL.: ""Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder"", NAT GENET, vol. 43, no. 9, 2011, pages 875 - 878;;LIU X ET AL.: ""HPV E6 protein interacts physically and functionally with the cellular telomerase complex"", PROC NATL ACAD SCI USA., vol. 106, no. 44, 2009, pages 18780 - 18785;;GILBERTSON RJ; ELLISON DW: ""The origins of medulloblastoma subtypes"", ANNU REV PATHOL., vol. 3, 2008, pages 341 - 365, XP009154575, DOI: doi:10.1146/annurev.pathmechdis.3.121806.151518;;ADAMSON DC ET AL.: ""OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas"", CANCER RES., vol. 70, no. 1, 2010, pages 181 - 191;;NORTHCOTT PA ET AL.: ""Medulloblastoma comprises four distinct molecular variants"", J CLIN ONCOL., vol. 29, no. 11, 2011, pages 1408 - 1414;;KOOL M ET AL.: ""Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features"", PLOS ONE, vol. 3, no. 8, 2008, pages e3088;;JANSEN M; YIP S; LOUIS DN: ""Molecular pathology in adult gliomas: Diagnostic, prognostic, and predictive markers"", LANCET NEUROL, vol. 9, no. 7, 2010, pages 717 - 726, XP027598947, DOI: doi:10.1016/S1474-4422(10)70105-8;;DOLECEK TA; PROPP JM; STROUP NE; KRUCHKO C: ""CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2005-2009"", NEURO ONCOL., vol. 14, no. 5, 2012, pages vl - v49;;PARSONS DW ET AL.: ""An integrated genomic analysis of human glioblastoma multiforme"", SCIENCE, vol. 321, no. 5897, 2008, pages 1807 - 1812, XP002555012, DOI: doi:10.1126/science.1164382;;BOLDRINI L ET AL.: ""Telomerase activity and hTERT mRNA expression in glial tumors"", INT J ONCOL., vol. 28, no. 6, 2006, pages 1555 - 1560;;BETTEGOWDA C ET AL.: ""Mutations in CIC and FUBP1 contribute to human oligodendroglioma"", SCIENCE, vol. 333, no. 6048, 2011, pages 1453 - 1455, XP055142306, DOI: doi:10.1126/science.1210557;;BROMBERG JE; VAN DEN BENT MJ: ""Oligodendrogliomas: Molecular biology and treatment"", ONCOLOGIST, vol. 14, no. 2, 2009, pages 155 - 163;;MAINTZ D ET AL.: ""Molecular genetic evidence for subtypes of oligoastrocytomas"", J NEUROPATHOL EXP NEUROL., vol. 56, no. 10, 1997, pages 1098 - 1104, XP009003087, DOI: doi:10.1097/00005072-199710000-00003;;JIAO Y ET AL.: ""Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas"", ONCOTARGET, vol. 3, no. 7, 2012, pages 709 - 722, XP055400595;;KING ED; MATTESON J; JACOBS SC; KYPRIANOU N: ""Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: Association with tumor progression"", J UROL., vol. 155, no. 1, 1996, pages 316 - 320, XP005576815, DOI: doi:10.1016/S0022-5347(01)66652-7;;AIKATA H ET AL.: ""Telomere reduction in human liver tissues with age and chronic inflammation"", EXP CELL RES., vol. 256, no. 2, 2000, pages 578 - 582;;SPALDING KL; BHARDWAJ RD; BUCHHOLZ BA; DRUID H; FRISEN J: ""Retrospective birth dating of cells in humans"", CELL, vol. 122, no. 1, 2005, pages 133 - 143;;CHENG ET AL.: ""Bladder cancer: Translating molecular genetic insights into clinical practice"", HUM PATHOL., vol. 42, no. 4, 2011, pages 455 - 481, XP028367813, DOI: doi:10.1016/j.humpath.2010.07.007;;SINGAL AG ET AL.: ""Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C Trial: Where did surveillance fail?"", AM J GASTROENTEROL., vol. 108, no. 3, 2012, pages 425 - 432;;BARANISKIN A ET AL.: ""Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma"", NEURO ONCOL., vol. 14, no. 1, 2012, pages 29 - 33;;SJOBLOM T ET AL.: ""The consensus coding sequences of human breast and colorectal cancers"", SCIENCE, vol. 314, no. 5797, 2006, pages 268 - 274, XP055205458, DOI: doi:10.1126/science.1133427;;DUNCAN CG ET AL.: ""Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes"", ONCOTARGET, vol. 1, no. 4, 2010, pages 265 - 277;;YAN H ET AL.: ""IDH1 and IDH2 mutations in gliomas"", N ENGL J MED., vol. 360, no. 8, 2009, pages 765 - 773, XP002555011, DOI: doi:10.1056/NEJMoa0808710",INACTIVE
85,EP,B1,EP 3360979 B1,104-561-753-687-179,2020-05-20,2020,EP 18164632 A,2014-02-18,US 201361765909 P;;US 201361766857 P;;US 201361772249 P;;EP 14751900 A;;US 2014/0016906 W,2013-02-18,TERT PROMOTER MUTATIONS IN HEPATOCELLULAR CARCINOMA,,UNIV DUKE;;UNIV JOHNS HOPKINS,YAN HAI;;VOGELSTEIN BERT;;KINZLER KENNETH;;PAPADOPOULOS NICKOLAS;;BIGNER DARELL;;JIAO YUCHEN;;BETTEGOWDA CHETAN;;REITMAN ZACHARY J;;KILLELA PATRICK J,DUKE UNIVERSITY (2020-08-26);;THE JOHNS HOPKINS UNIVERSITY (2020-08-26),https://lens.org/104-561-753-687-179,Granted Patent,yes,5,0,17,24,0,C12Q2600/112;;C12Q2600/156;;C12Q1/6886;;C12Q2600/156;;C12Q2600/112;;C12Q1/6886,C12Q1/6886;;C12N15/12,,17,15,059-233-414-195-767;;004-355-142-438-015;;016-564-303-653-514;;053-644-146-413-710;;105-995-175-655-531;;058-494-912-407-59X;;010-132-033-750-586;;010-132-033-750-586;;003-113-655-474-830;;003-113-655-474-830;;113-653-136-719-512;;029-418-419-989-470;;078-169-002-114-751;;137-629-232-369-55X;;137-629-232-369-55X,29881823;;10.1002/hep4.1187;;pmc5983165;;23434901;;pmc3691946;;10.1093/jnci/djt007;;17960586;;10.1002/ijc.23233;;10.4161/cbt.7.5.5712;;18277095;;10.1155/2010/297671;;pmc2810468;;20111735;;23887712;;10.1038/ncomms3218;;10.1038/ncomms3577;;pmc3731665;;23530248;;pmc3625331;;10.3410/f.718015949.793477772;;10.1073/pnas.1303607110;;23530248;;pmc3625331;;10.3410/f.718015949.793477772;;10.1073/pnas.1303607110;;10.1126/science.1229259;;pmc4423787;;23348506;;10.1126/science.1229259;;pmc4423787;;23348506;;24030752;;10.1038/modpathol.2013.167;;23766237;;10.1530/erc-13-0210;;pmc3782569;;7605428;;10.1126/science.7605428;;23348503;;10.1126/science.1230062;;23348503;;10.1126/science.1230062,"JIAO JINGJING ET AL: ""Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factors."", HEPATOLOGY COMMUNICATIONS JUN 2018, vol. 2, no. 6, June 2018 (2018-06-01), pages 718 - 731, ISSN: 2471-254X;;SOUSSI: ""HANDBOOK OF p53 MUTATION IN CELL LINES"", 1 July 2007 (2007-07-01), XP055589869, Retrieved from the Internet <URL:http://p53.free.fr/Database/Cancer_cell_lines/cell_lines_1.0.pdf> [retrieved on 20190517];;GILLET JEAN-PIERRE ET AL: ""The clinical relevance of cancer cell lines."", JOURNAL OF THE NATIONAL CANCER INSTITUTE 03 APR 2013, vol. 105, no. 7, 3 April 2013 (2013-04-03), pages 452 - 458, ISSN: 1460-2105;;LACROIX MARC: ""Persistent use of ""false"" cell lines."", INTERNATIONAL JOURNAL OF CANCER 01 JAN 2008, vol. 122, no. 1, 1 January 2008 (2008-01-01), pages 1 - 4, ISSN: 1097-0215;;BERGLIND HANNA ET AL: ""Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination."", CANCER BIOLOGY & THERAPY MAY 2008, vol. 7, no. 5, May 2008 (2008-05-01), pages 699 - 708, ISSN: 1555-8576;;KIM M. HIRSHFIELD ET AL: ""Germline Mutations and Polymorphisms in the Origins of Cancers in Women"", JOURNAL OF ONCOLOGY, vol. 2010, 1 January 2010 (2010-01-01), US, pages 1 - 11, XP055589867, ISSN: 1687-8450, DOI: 10.1155/2010/297671;;NAULT ET AL.: ""High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions"", NATURE COMMUNICATIONS, vol. 4, 26 July 2013 (2013-07-26), XP055483232, DOI: 10.1038/ncomms3218;;""Supplementary Table S1: TERT promoter mutations in hepatocellular carcinoma (n=305)"", XP055783878;;KILLELA ET AL.: ""TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal"", PNAS, vol. 110, no. 15, 25 March 2013 (2013-03-25), pages 6021 - 6026, XP055110090, DOI: 10.1073/pnas.1303607110;;KILLELA, J.: ""TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal : SUPPORTING INFORMATION"", 2013, pages 1 - 5, XP055783870;;HUANG F W ET AL: ""Highly recurrent TERT Published online on promoter mutations in human melanoma"", SCIENCE, vol. 339, no. 6122, 24 January 2013 (2013-01-24), pages 957 - 959, XP055109644, DOI: 10.1126/science.1229259;;HUANG F W; HODIS E; XU M J; KRYUKOV G V; CHIN L; GARRAWAY L A: ""Highly Recurrent TERT Promoter Mutations in Human Melanoma (supplementary material)"", February 2013 (2013-02-01), XP055593044, DOI: 10.1126/science.1229259;;SCOTT ET AL.: ""Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma"", MODERN PATHOLOGY, vol. 27, 13 September 2013 (2013-09-13), pages 516 - 523, XP055782917;;LIU ET AL.: ""Highly prevalent TERT 12 July 2013 promoter mutations in aggressive thyroid Cancers"", ; ENDOCRINE-RELATED CANCER, vol. 20, 12 July 2013 (2013-07-12), pages 603 - 610, XP055110005, DOI: 10.1530/ERC-13-0210;;KIM NW ET AL.: ""Specific association of human telomerase activity with immortal cells and cancer"", SCIENCE, vol. 266, 23 December 1994 (1994-12-23), pages 2011 - 5, XP002138759, DOI: 10.1126/science.7605428;;HORN ET AL.: ""TERT Promoter Mutations in Familial and Sporadic Melanoma"", SCIENCE, vol. 339, 24 January 2013 (2013-01-24), pages 959 - 961, XP055110024, DOI: 10.1126/science.1230062;;HORN, SUSANNE AND ADINA FIGI, P. SIVARAMAKRISHNA RACHAKONDA, CHRISTINE FISCHER, ANTJE SUCKER. ANDREAS GAST, STEPHANIE KADEL, IRIS : ""Supplementary Materials for ""TERT Promoter Mutations in Familial and Sporadic Melanoma"""", SCIENCEMAG.ORG, 24 January 2013 (2013-01-24), pages 1 - 30, XP055783884",INACTIVE
86,EP,B1,EP 2956556 B1,069-406-932-782-625,2019-04-10,2019,EP 14751900 A,2014-02-18,US 201361765909 P;;US 201361766857 P;;US 201361772249 P;;US 2014/0016906 W,2013-02-18,TERT PROMOTER MUTATIONS IN GLIOMAS AND A SUBSET OF TUMORS,,UNIV DUKE;;UNIV JOHNS HOPKINS,YAN HAI;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;KINZLER KENNETH W;;JIAO YUCHEN;;BETTEGOWDA CHETAN;;BIGNER DARELL D;;REITMAN ZACHARY J;;KILLELA PATRICK J,,https://lens.org/069-406-932-782-625,Granted Patent,yes,0,0,17,24,0,C12Q2600/112;;C12Q2600/156;;C12Q1/6886;;C12Q2600/156;;C12Q2600/112;;C12Q1/6886,C12Q1/6886,,1,0,,,"""Abeloff's Clinical Oncology: Fifth Edition"", 22 October 2013, ELSEVIER, article E.R. FEARON: ""Genetic and Epigenetic Alterations in Cancer"", pages: 188 - 203.e.1, XP055483127, DOI: 10.1016/B978-1-4557-2865-7.00013-8",ACTIVE
87,US,A1,US 2020/0399708 A1,180-638-798-734-10X,2020-12-24,2020,US 202016928164 A,2020-07-14,US 202016928164 A;;US 2014/0016906 W;;US 201361772249 P;;US 201361766857 P;;US 201261765909 P,2012-02-18,TERT Promoter Mutations in Gliomas and a Subset of Tumors,"We surveyed 1,230 tumors of 60 different types and found that tumors could be divided into types with low (<15%) and high (≥15%) frequencies of TERT promoter mutations. The nine TERT-high tumor types almost always originated in tissues with relatively low rates of self renewal, including melanomas, liposarcomas, hepatocellular carcinomas, urothelial carcinomas, squamous cell carcinomas of the tongue, medulloblastomas, and subtypes of gliomas (including 83% of primary glioblastoma, the most common brain tumor type). TERT and ATRX mutations were mutually exclusive, suggesting that these two genetic mechanisms confer equivalent selective growth advantages. In addition to their implications for understanding the relationship between telomeres and tumorigenesis, TERT mutations provide a biomarker for the early detection of urinary tract and liver tumors and aid in the classification and prognostication of brain tumors.",UNIV DUKE;;UNIV JOHNS HOPKINS,YAN HAI;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;KINZLER KENNETH W;;JIAO YUCHEN;;BETTEGOWDA CHETAN;;BIGNER DARELL D;;REITMAN ZACHARY J;;KILLELA PATRICK J,DUKE UNIVERSITY (2015-09-18);;THE JOHNS HOPKINS UNIVERSITY (2016-01-14),https://lens.org/180-638-798-734-10X,Patent Application,yes,0,1,2,24,0,C12Q1/6886;;C12Q2600/112;;C12Q2600/156;;C12Q1/6886;;C12Q2600/112;;C12Q2600/156,C12Q1/6886,,0,0,,,,ACTIVE
88,JP,A,JP 2021078521 A,009-691-678-139-886,2021-05-27,2021,JP 2021032229 A,2021-03-02,US 201361765909 P;;US 201361766857 P;;US 201361772249 P,2013-02-18,TERT PROMOTER MUTATION IN GLIOMA AND TUMOR SUBSET,"To provide a method to elucidate mutations in the noncoding region of the human genome, in particular mutations in the telomerase reverse transcriptase (TERT) promoter in tumors.SOLUTION: In this method for providing mutations of TERT in tumors to help classify and prognosticate brain tumors, 60 different types of tumors from 1,230 cases were investigated and it was found that the tumors could be classified as those with a low frequency (<15%) and those with a high frequency (≥15%) of TERT promoter mutations. 9 types of high TERT tumors including melanoma, liposarcoma, hepatocellular carcinoma, urothelial carcinoma, squamous cell carcinoma of the tongue, medulloblastoma, and a subset of glioma (includes 83% of primary glioblastoma, the most common brain tumor type) almost always occur in tissue where the rate of self-replication is relatively low, and in addition to TERT mutations providing clues for understanding the relationship between telomere and tumorigenesis, biomarkers for early detection of tumors of the urinary tract and liver are provided.SELECTED DRAWING: Figure 1",UNIV DUKE;;UNIV JOHNS HOPKINS,YAN HAI;;BERT VOGELSTEIN;;NICKOLAS PAPADOPOULOS;;KINZLER KENNETH W;;JIAO YUCHEN;;CHETAN BETTEGOWDA;;DARELL D BIGNER;;ZACHARY J REITMAN;;PATRICK J KILLELA,,https://lens.org/009-691-678-139-886,Patent Application,no,0,0,17,24,0,C12Q2600/112;;C12Q2600/156;;C12Q1/6886;;C12Q2600/156;;C12Q2600/112;;C12Q1/6886,C12Q1/6886;;C12Q1/6813;;C12Q1/6844;;C12Q1/6869,,1,1,003-113-655-474-830,10.1126/science.1229259;;pmc4423787;;23348506,"SCIENCE, (2013.01.24), 339, [6122], P.957-959, JPN6016027934, ISSN: 0004729959",ACTIVE
89,US,B2,US 11306364 B2,042-750-543-560-845,2022-04-19,2022,US 202016928164 A,2020-07-14,US 202016928164 A;;US 2014/0016906 W;;US 201361772249 P;;US 201361766857 P;;US 201261765909 P,2012-02-18,TERT promoter mutations in gliomas and a subset of tumors,"We surveyed 1,230 tumors of 60 different types and found that tumors could be divided into types with low (<15%) and high (≥15%) frequencies of TERT promoter mutations. The nine TERT-high tumor types almost always originated in tissues with relatively low rates of self renewal, including melanomas, liposarcomas, hepatocellular carcinomas, urothelial carcinomas, squamous cell carcinomas of the tongue, medulloblastomas, and subtypes of gliomas (including 83% of primary glioblastoma, the most common brain tumor type). TERT and ATRX mutations were mutually exclusive, suggesting that these two genetic mechanisms confer equivalent selective growth advantages. In addition to their implications for understanding the relationship between telomeres and tumorigenesis, TERT mutations provide a biomarker for the early detection of urinary tract and liver tumors and aid in the classification and prognostication of brain tumors.",UNIV DUKE;;UNIV JOHNS HOPKINS,YAN HAI;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;KINZLER KENNETH W;;JIAO YUCHEN;;BETTEGOWDA CHETAN;;BIGNER DARELL D;;REITMAN ZACHARY J;;KILLELA PATRICK J,DUKE UNIVERSITY (2015-09-18);;THE JOHNS HOPKINS UNIVERSITY (2016-01-14),https://lens.org/042-750-543-560-845,Granted Patent,yes,5,0,2,24,0,C12Q1/6886;;C12Q2600/112;;C12Q2600/156;;C12Q1/6886;;C12Q2600/112;;C12Q2600/156,C07H21/04;;C12Q1/6886,,47,28,058-494-912-407-59X;;058-494-912-407-59X;;010-132-033-750-586;;010-132-033-750-586;;010-132-033-750-586;;003-113-655-474-830;;113-653-136-719-512;;029-418-419-989-470;;078-169-002-114-751;;137-629-232-369-55X;;003-113-655-474-830;;137-629-232-369-55X;;048-015-888-162-479;;011-757-015-197-891;;078-392-642-391-062;;029-425-097-483-850;;032-606-072-102-354;;010-713-119-509-940;;003-166-392-538-562;;040-988-224-915-933;;010-132-033-750-586;;038-932-572-979-55X;;059-233-414-195-767;;004-355-142-438-015;;016-564-303-653-514;;053-644-146-413-710;;105-995-175-655-531;;003-113-655-474-830,23887712;;10.1038/ncomms3218;;10.1038/ncomms3577;;pmc3731665;;23887712;;10.1038/ncomms3218;;10.1038/ncomms3577;;pmc3731665;;23530248;;pmc3625331;;10.3410/f.718015949.793477772;;10.1073/pnas.1303607110;;23530248;;pmc3625331;;10.3410/f.718015949.793477772;;10.1073/pnas.1303607110;;23530248;;pmc3625331;;10.3410/f.718015949.793477772;;10.1073/pnas.1303607110;;10.1126/science.1229259;;pmc4423787;;23348506;;24030752;;10.1038/modpathol.2013.167;;23766237;;10.1530/erc-13-0210;;pmc3782569;;7605428;;10.1126/science.7605428;;23348503;;10.1126/science.1230062;;10.1126/science.1229259;;pmc4423787;;23348506;;23348503;;10.1126/science.1230062;;10.1093/neuonc/nos284;;pmc3635509;;23161787;;10.1016/s0168-8278(10)60887-2;;16937491;;pmc4087398;;10.3748/wjg.v12.i31.4966;;10204615;;10.1007/s005350050220;;10.1002/hep.24217;;21520174;;10.1007/s11060-007-9378-3;;17410334;;20373057;;10.1007/s12032-010-9506-3;;pmc2820383;;19228619;;10.1056/nejmoa0808710;;23530248;;pmc3625331;;10.3410/f.718015949.793477772;;10.1073/pnas.1303607110;;10.1007/s00401-013-1141-6;;23764841;;29881823;;10.1002/hep4.1187;;pmc5983165;;23434901;;pmc3691946;;10.1093/jnci/djt007;;17960586;;10.1002/ijc.23233;;10.4161/cbt.7.5.5712;;18277095;;10.1155/2010/297671;;pmc2810468;;20111735;;10.1126/science.1229259;;pmc4423787;;23348506,"Feb. 2, 20216—(EP) Notice of Opposition—Patent No. 3360979.;;Nault et al., “High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions,” Nature Communications, 4:2218, (2013).;;Nault et al., “High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions,” Nature Communications, Supplementary Material (2013).;;Killela et al., “TERT promoter mutations occur frequently in gliomas and a subsest of tumors derived from cells with low rates of self-renewal,” PNAS, vol. 110, No. 15, pp. 6021-6026 (2013).;;Killela et al., “TERT promoter mutations occur frequently in gliomas and a subsest of tumors derived from cells with low rates of self-renewal,” PNAS, vol. 110, No. 15, Supporting Information (2013).;;Killela et al., “TERT promoter mutations occur frequently in gliomas and a subsest of tumors derived from cells with low rates of self-renewal,” PNAS, vol. 110, No. 15, Supporting Data (2013).;;Huang et al. “Highly Recurrent TERT Promoter Mutations in Human Melanoma” Science, vol. 339, Supplementary Fig. S1 (2013).;;Scott et al., “Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma,” Modern Pathology, vol. 27, pp. 516-526 (2014).;;Liu et al., “Highly prevalent TERT promoter mutations in aggressive thyroid cancers,” Endocrine-Related Cancer, vol. 20, No. 4, pp. 603-610 (2013).;;Kim et al., “Specific Association of Human Telomerase Activity with Immortal Cells and Cancer,” Science, vol. 266, pp. 2011-2015 (1994).;;Horn et al., “TERT Promoter Mutations in Familial and Sporadic Melanoma,” Science, vol. 339, Supplementary Materials (2013).;;Japanese Office Action issued in related Japanese Application No. 2015-558198, dated Jul. 21, 2016.;;Huang et al. “Highly Recurrent TERT Promoter Mutations in Human Melanoma” Science, vol. 339, Feb. 22, 2013, pp. 957-959.;;Horn et al., “TERT Promoter Mutatiosn in Familial and Sporadic Melanoma,” Science, vol. 339, Feb. 22, 2013, pp. 959-961.;;Di Stefano et al., “Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies,” Neuro-Oncology 15(5):1542-547, 2013.;;Extended European Search Report issued in related European Application No. 18164632.4, dated Jul. 11, 2018.;;Park et al., “886 HTERT Promoter Gene Polymorphism and the Risk of Hepatocellular Carcinoma (HCC) in Patients with Chronic Hepatitis B,” Journal of Hepatology, vol. 52, Apr. 1, 2010, p. S345.;;Yao, “Dynamic alteration of telomerase expression and its diagnostic significance in liver or periperal blood for hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 12, No. 31, Jan. 1, 2006, p. 4966.;;Nagao et al., “Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma,” Journal of Gastroenterology, vol. 34, No. 1, Jan. 22, 1999, pp. 83-87.;;Hartmann et al., “Telomerase gene mutations are associated with cirrhosis formation,” Hepatology, vol. 53, No. 5, May 1, 2011, pp. 1608-1617.;;Carpentier et al. “Association of telomerase gene hTERT polymorphism and malignant gliomas” J. Neurononcolo. (2007) 84:249-253.;;Jun. 12, 2019—(EP) Summons to attend Oral Proceedings—App. 18164632.4.;;Kheirollahi et al. “Alterations of telomere length in human brain tumors” Medical Oncology, vol. 28, No. 3, 2011, pp. 864-870.;;Yan et al. “IDH1 and IDH2 mutations in gliomas” The New England Journal of Medicine, vol. 360, No. 8, 2009, pp. 765-773.;;Killela et al. “TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal” PNAS, vol. 110, No. 15, Mar. 25, 2013, pp. 6021-6026.;;Arita et al. “Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss” Acta Neuropathologica, vol. 126, No. 2, Jun. 14, 2013, pp. 267-276.;;Fearon et al. “Genetic and Epigenetic Alterations in Cancer” In: “Abeloff's Clinical Oncology: Fifth Edition” Oct. 22, 2013, pp. 188-203.e.1.;;Jiao et al. “Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factors” Hepatology Communications, Jun. 2018, vol. 2, No. 6, pp. 718-731.;;Gillet et al. “The clinical relevance of cancer cell lines” Journal of the National Cancer Institute, vol. 105, No. 7, Apr. 3, 2013, pp. 452-458.;;Lacroix “Persistent use of “false” cell lines” International Journal of Cancer, vol. 122, No. 1, Jan. 1, 2008, pp. 1-4.;;Berglind et al. “Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination” Cancer Biology & Therapy, vol. 7, No. 5, May 2008, pp. 699-708.;;Hirshfield et al. “Germline Mutations and Polymorphisms in the Origins of Cancers in women” Journal of Oncology, vol. 2010, Jan. 1, 2010, pp. 1-11.;;Soussi “Handbook of p53 Mutation in Cell Lines” Jul. 1, 2007, Retrieved from the Internet: URL:http://p53.free.fr/Database/Cancer_cell_lines/cell_lines_1.0.pdf.;;Dec. 19, 2019—(JP) Notification of Third-Party Submission of Information—App 2017-194782.;;Dec. 17, 2019—(JP) Third-Party Submission of Information—App 2017-194782.;;Huang et al. “Highly Recurrent TERT Promoter Mutations in Human Melanoma” Science, vol. 339, Feb. 22, 2013, pp. 957-959; Supplementary Materials 1 (www.sciencemag.org/cgi/content/full/science.1229259/DC1 <https://protect-us.mimecast.com/s/sdX7C0RAgMi2Qm7wTwbXBz>) and Table S1 of Supplementary Materials (https://science.sciencemag.org/highwire/filestream/594302/field_highwire_adjunct_files/0/1229259TableS1.xl <https://protect-us.mimecast.com/s/MtRsCwpnjxULkyq3cAGLme>sx).;;Websiteof ATCC [5637 (ATCC HTB-9)](https://www.atcc.org/products/all/HTB-9 <https://protect-us.mimecast.com/s/HigBCxkoGyiJDx7otNi1LG>.aspx)], Mar. 1974.;;Website of ATCC [Daoy (ATCC HTB-186)](https://www.atcc.org/products/all/HTB-186.aspx <https://protect-us.mimecast.com/s/4P2_CkR65ginA5KzU9nFjG>), 1985.;;Website of ATCC [Hep G2 [HEPG2] (ATCC HB-8065](https://www.atcc.org/products/all/HB-8065.aspx <https://protect-us.mimecast.com/s/zd6JCIY8O0somXVNC1DcjL>), 1983.;;Website of JCRB Cell Bank [ONS-76](https://cellbank.nibiohn.go.jp/˜cellbank/en/search_res_det.cgi?RNO=IFO50355 <https://protect-us.mimecast.com/s/72qJCmZ7wkU58WgNiDIwrM>), 2005-2015.;;Website of ExPASy [RT-112](https://web.expasy.org/cellosaurus/CVCL_1670 <https://protect-us.mimecast.com/s/Xw9JCn5GZIUGgmPNipUEcC>), Apr. 4, 2012.;;Website of ATCC [SNU-387 (ATCC CRL-2237)](https://www.atcc.org/products/all/CRL-2237.aspx <https://protect-us.mimecast.com/s/QYsQCo2AYmCX5vg3C7Cj5c>), 1990.;;Website of ATCC [SNU-423 (ATCC CRL-2238)](https://www.atcc.org/products/all/CRL-2238.aspx <https://protect-us.mimecast.com/s/bbZVCpY9gnszqAV3UxMZ2o>), 1990.;;Website of ATCC [SNU-475 (ATCC CRL-2236)](https://www.atcc.org/products/all/CRL-2236.aspx <https://protect-us.mimecast.com/s/1YL4CqxAjoHOnXEjfp3Me4>), 1990.;;Website of JCRB Cell Bank [T24](https://cellbank.nibiohn.go.jp/˜cellbank/cgi-bin/search_res_det.cgi?ID=491), 2005-2015.;;Website of KAC Co., Ltd [U-87MG](https://www.saibou.jp/service/kensaku/detail.php?catalogno=EC89081402-F0 <https://protect-us.mimecast.com/s/KwSrCv2mgwCWqAYzigEdTa>), 2020.;;Dec. 12, 2019—(JP) Notice of Opposition—JP Patent No. 6574385—Eng. Transl.",ACTIVE
90,US,B2,US 10711310 B2,120-326-569-434-155,2020-07-14,2020,US 201414765692 A,2014-02-18,US 201414765692 A;;US 201361765909 P;;US 201361766857 P;;US 201361772249 P;;US 2014/0016906 W,2013-02-18,Tert promoter mutations in gliomas and a subset of tumors,"We surveyed 1,230 tumors of 60 different types and found that tumors could be divided into types with low (<15%) and high (≥15%) frequencies of TERT promoter mutations. The nine TERT-high tumor types almost always originated in tissues with relatively low rates of self renewal, including melanomas, liposarcomas, hepatocellular carcinomas, urothelial carcinomas, squamous cell carcinomas of the tongue, medulloblastomas, and subtypes of gliomas (including 83% of primary glioblastoma, the most common brain tumor type). TERT and ATRX mutations were mutually exclusive, suggesting that these two genetic mechanisms confer equivalent selective growth advantages. In addition to their implications for understanding the relationship between telomeres and tumorigenesis, TERT mutations provide a biomarker for the early detection of urinary tract and liver tumors and aid in the classification and prognostication of brain tumors.",UNIV DUKE;;UNIV JOHNS HOPKINS,YAN HAI;;VOGELSTEIN BERT;;PAPADOPOULOS NICKOLAS;;KINZLER KENNETH W;;JIAO YUCHEN;;BETTEGOWDA CHETAN;;BIGNER DARELL D;;REITMAN ZACHARY J;;KILLELA PATRICK J,DUKE UNIVERSITY (2013-04-24);;THE JOHNS HOPKINS UNIVERSITY (2013-05-13),https://lens.org/120-326-569-434-155,Granted Patent,yes,2,0,17,24,3,C12Q2600/112;;C12Q2600/156;;C12Q1/6886;;C12Q2600/156;;C12Q2600/112;;C12Q1/6886,C12Q1/6886;;C12P19/34,,42,24,048-015-888-162-479;;010-713-119-509-940;;003-113-655-474-830;;137-629-232-369-55X;;003-113-655-474-830;;137-629-232-369-55X;;003-166-392-538-562;;040-988-224-915-933;;010-132-033-750-586;;038-932-572-979-55X;;011-757-015-197-891;;078-392-642-391-062;;029-425-097-483-850;;032-606-072-102-354;;003-166-392-538-562;;040-988-224-915-933;;010-132-033-750-586;;038-932-572-979-55X;;059-233-414-195-767;;004-355-142-438-015;;016-564-303-653-514;;053-644-146-413-710;;105-995-175-655-531;;003-113-655-474-830,10.1093/neuonc/nos284;;pmc3635509;;23161787;;10.1007/s11060-007-9378-3;;17410334;;10.1126/science.1229259;;pmc4423787;;23348506;;23348503;;10.1126/science.1230062;;10.1126/science.1229259;;pmc4423787;;23348506;;23348503;;10.1126/science.1230062;;20373057;;10.1007/s12032-010-9506-3;;pmc2820383;;19228619;;10.1056/nejmoa0808710;;23530248;;pmc3625331;;10.3410/f.718015949.793477772;;10.1073/pnas.1303607110;;10.1007/s00401-013-1141-6;;23764841;;10.1016/s0168-8278(10)60887-2;;16937491;;pmc4087398;;10.3748/wjg.v12.i31.4966;;10204615;;10.1007/s005350050220;;10.1002/hep.24217;;21520174;;20373057;;10.1007/s12032-010-9506-3;;pmc2820383;;19228619;;10.1056/nejmoa0808710;;23530248;;pmc3625331;;10.3410/f.718015949.793477772;;10.1073/pnas.1303607110;;10.1007/s00401-013-1141-6;;23764841;;29881823;;10.1002/hep4.1187;;pmc5983165;;23434901;;pmc3691946;;10.1093/jnci/djt007;;17960586;;10.1002/ijc.23233;;10.4161/cbt.7.5.5712;;18277095;;10.1155/2010/297671;;pmc2810468;;20111735;;10.1126/science.1229259;;pmc4423787;;23348506,"Di Stefano (Neuro-Oncology, 15(5): 542-547, 2013).;;Carpentier (J Neurooncol, 2007, 84:249-253.;;Japanese Office Action issued in related Japanese Application No. 2015-558198, dated Jul. 21, 2016.;;Huang et al., “Highly Recurrent TERT Promoter Mutations in Human Melanoma,” Science, vol. 339, Feb. 22, 2013, pp. 957-959.;;Horn et al., “TERT Promoter Mutatiosn in Familial and Sporadic Melanoma,” Science, vol. 339, Feb. 22, 2013, pp. 959-961.;;Huang et al., ‘Highly recurrent TERT promoter mutations in human melanoma’ Science, vol. 339, No. 6122, pp. 957-959 (Epub Jan. 24, 2013).;;Horn et al., TERT promoter mutations in familial and sporadic melanoma Science, vol. 339, No. 6122, pp. 959-961 (Epub Jan. 24, 2013).;;Kheirollahi et al., ‘Alterations of telomere length in human brain tumors’ Medical Oncology, vol. 28, No. 3, pp. 864-870 (2011).;;Yan et al., ‘IDH1 and IDH2 mutations in gliomas’ The New England Journal of Medicine, vol. 360, No. 8, pp. 765-773 (2009).;;Killela et al., ‘TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal’ PNAS, vol. 110, No. 15, pp. 6021-6026 (Epub Mar. 25, 2013).;;Arita et al., ‘Upregulating mutations 1n the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19Q loss’ Acta Neuropathologica, vol. 126, No. 2, pp. 267-276 (Epub Jun. 14, 2013).;;International Search Report—PCT/US2014/016906—dated May 26, 2014.;;Extended European Search Report issued in related European Application No. 18164632.4, dated Jul. 11, 2018.;;Park et al., “886 HTERT Promoter Gene Polymorphism and the Risk of Hepatocellular Carcinoma (HCC) in Patients with Chronic Hepatitis B,” Journal of Hepatology, vol. 52, Apr. 1, 2010, p. S345.;;Yao, “Dynamic alteration of telomerase expression and its diagnostic significance in liver or periperal blood for hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 12, No. 31, Jan. 1, 2006, p. 4966.;;Nagao et al., “Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma,” Journal of Gastroenterology, vol. 34, No. 1, Jan. 22, 1999, pp. 83-87.;;Hartmann et al., “Telomerase gene mutations are associated with cirrhosis formation,” Hepatology, vol. 53, No. 5, May 1, 2011, pp. 1608-1617.;;Jun. 12, 2019—(EP) Summons to attend Oral Proceedings—App. 18164632.4.;;Kheirollahi et al. “Alterations of telomere length in human brain tumors” Medical Oncology, vol. 28, No. 3, 2011, pp. 864-870.;;Yan et al. “IDH1 and IDH2 mutations in gliomas” The New England Journal of Medicine, vol. 360, No. 8, 2009, pp. 765-773.;;Killela et al. “TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal” PNAS, vol. 110, No. 15, Mar. 25, 2013, pp. 6021-6026.;;Arita et al. “Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss” Acta Neuropathologica, vol. 126, No. 2, Jun. 14, 2013, pp. 267-276.;;Fearon et al. “Genetic and Epigenetic Alterations in Cancer” In: “Abeloff's Clinical Oncology: Fifth Edition” Oct. 22, 2013, pp. 188-203.e.1.;;Jiao et al. “Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factors” Hepatology Communications, Jun. 2018, vol. 2, No. 6, pp. 718-731.;;Gillet et al. “The clinical relevance of cancer cell lines” Journal of the National Cancer Institute, vol. 105, No. 7, Apr. 3, 2013, pp. 452-458.;;Lacroix “Persistent use of “false” cell lines” International Journal of Cancer, vol. 122, No. 1, Jan. 1, 2008, pp. 1-4.;;Berglind et al. “Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination” Cancer Biology & Therapy, vol. 7, No. 5, May 2008, pp. 699-708.;;Hirshfield et al. “Germline Mutations and Polymorphisms in the Origins of Cancers in women” Journal of Oncology, vol. 2010, Jan. 1, 2010, pp. 1-11.;;Soussi “Handbook of p53 Mutation in Cell Lines” Jul. 1, 2007, Retrieved from the Internet: URL:http://p53.free.fr/Database/Cancer_cell_lines/cell_lines_1.0.pdf.;;Huang et al. “Highly Recurrent TERT Promoter Mutations in Human Melanoma” Science, vol. 339, Feb. 22, 2013, pp. 957-959; Supplementary Materials 1 (www.sciencemag.org/cgi/content/full/science.1229259/DC1 <https://protect-us.mimecast.com/s/sdX7C0RAgMi2Qm7wTwbXBz>) and Table S1 of Supplementary Materials (https://science.sciencemag.org/highwire/filestream/594302/field_highwire_adjunct_files/0/1229259TableS1.xl <https://protect-us.mimecast.com/s/MtRsCwpnjxULkyq3cAGLme>sx).;;Dec. 19, 2019—(JP) Notification of Third-Party Submission of Information—App 2017-194782.;;Dec. 17, 2019—(JP) Third-Party Submission of Information—App 2017-194782.;;Website of ATCC [5637 (ATCC HTB-9)](https://www.atcc.org/products/all/HTB-9 <https://protect-us.mimecast.com/s/HigBCxkoGyiJDx7otNi1LG>.aspx) , Mar. 1974.;;Website of ATCC [Daoy (ATCC HTB-186)](https://www.atcc.org/products/all/HTB-186.aspx <https://protect-us.mimecast.com/s/4P2_CkR65ginA5KzU9nFjG>), 1985.;;Website of ATCC [Hep G2 [HEPG2] (ATCC HB-80651](https://www.atcc.org/products/all/HB-8065.aspx <https://protect-us.mimecast.com/s/zd6JCIY800somXVNC1DcjL>), 1983.;;Website of JCRB Cell Bank [ONS-76](https://cellbank.nibiohn.go.jp/˜cellbank/en/search_res_det.cgi?RNO=IFO50355 <https://protect-us.mimecast.com/s/72qJCmZ7wkU58WgNiDlwrM>), 2005-2015.;;Website of ExPASy [RT-112](https://web.expasy.org/cellosaurus/CVCL_1670 <https://protect-us.mimecast.com/s/Xw9JCn5GZIUGgmPNipUEcC>), Apr. 4, 2012.;;Website of ATCC [SNU-387 (ATCC CRL-2237)](https://www.atcc.org/products/all/CRL-2237.aspx <https://protect-us.mimecast.com/s/QYsQCo2AYmCX5vg3C7Cj5c>), 1990.;;Website of ATCC [SNU-423 (ATCC CRL-2238)](https://www.atcc.org/products/all/CRL-2238.aspx <https://protect-us.mimecast.com/s/bbZVCpY9gnszqAV3UxMZ2o>), 1990.;;Website of ATCC [SNU-475 (ATCC CRL-2236)](https://www.atcc.org/products/all/CRL-2236.aspx <https://protect-us.mimecast.com/s/1YL4CqxAjoHOnXEjfp3Me4>), 1990.;;Website of JCRB Cell Bank [T24](https://cellbank.nibiohn.go.jp/˜cellbank/cgi-bin/search_res_det.cgi?ID=491), 2005-2015.;;Website of KAC Co., Ltd [U-87MG](https://www.saibou.jp/service/kensaku/detail.php?catalogno=EC89081402-F0 <(https://protect-us.mimecast.com/s/KwSrCv2mgwCWqAYzigEdTa>), 2020.",ACTIVE
91,US,A1,US 2017/0056075 A1,187-322-067-129-380,2017-03-02,2017,US 201515308885 A,2015-05-06,US 201515308885 A;;US 201461989339 P;;US 2015/0029371 W,2014-05-06,A SPINAL PROBE INCORPORATING AN ELECTROMECHANICAL SYSTEM FOR DETECTION AND PREVENTION OF BREACHES DURING SURGERY,"The present invention is directed to an innovative pedicle probe that uses a force-sensing electromechanical system coupled with haptic and visual feedback. The probe of the present invention reduces the rate of pedicle screw breaches during spinal fusion surgery. The probe provides an effective guidance system to aid surgeons in detecting and preventing cortical bone breaches, thereby minimizing risk of intraoperative injury to the patient. Moreover, the probe invention decreases surgeon reliance on intraoperative radiation, reducing harmful exposure to both patients and surgeons.",UNIV JOHNS HOPKINS,ANNADANAM ANVESH;;ALLEN ROBERT;;BETTEGOWDA CHETAN;;GADDIPATI RAVI;;HERRERA LUIS;;ISAACS BRADLEY;;LO SHENG-FU;;XIE ERIC;;ANDREWS CLAY;;MALLA ADARSHA;;SCHWARZ ERICA,,https://lens.org/187-322-067-129-380,Patent Application,yes,4,2,2,2,0,A61B2017/00115;;A61B2090/064;;A61B90/06;;A61B2090/066;;A61B17/3472;;A61B17/7092;;A61B2017/00115;;A61B2090/064;;A61B90/06;;A61B2090/066;;A61B17/3472;;A61B17/7092;;A61B17/7074,A61B17/70;;A61B17/34;;A61B90/00,,0,0,,,,DISCONTINUED
92,WO,A1,WO 2015/171697 A1,101-583-074-157-828,2015-11-12,2015,US 2015/0029371 W,2015-05-06,US 201461989339 P,2014-05-06,A SPINAL PROBE INCORPORATING AN ELECTROMECHANICAL SYSTEM FOR DETECTION AND PREVENTION OF BREACHES DURING SURGERY,"The present invention is directed to an innovative pedicle probe that uses a force-sensing electromechanical system coupled with haptic and visual feedback. The probe of the present invention reduces the rate of pedicle screw breaches during spinal fusion surgery. The probe provides an effective guidance system to aid surgeons in detecting and preventing cortical bone breaches, thereby minimizing risk of intraoperative injury to the patient. Moreover, the probe invention decreases surgeon reliance on intraoperative radiation, reducing harmful exposure to both patients and surgeons.",UNIV JOHNS HOPKINS,ANNADANAM ANVESH;;ALLEN ROBERT;;BETTEGOWDA CHETAN;;GADDIPATI RAVI;;HERRERA LUIS;;ISAACS BRADLEY;;LO SHENG-FU;;XIE ERIC;;ANDREWS CLAY;;MALLA ADARSHA;;SCHWARZ ERICA,,https://lens.org/101-583-074-157-828,Patent Application,yes,3,1,2,2,0,A61B2017/00115;;A61B2090/064;;A61B90/06;;A61B2090/066;;A61B17/3472;;A61B17/7092;;A61B2017/00115;;A61B2090/064;;A61B90/06;;A61B2090/066;;A61B17/3472;;A61B17/7092;;A61B17/7074,A61B17/56,,3,2,043-455-481-715-817;;031-007-189-700-138,pmc3899254;;24466043;;10.1371/journal.pone.0086346;;10.1109/robot.2008.4543807,"TIAN ET AL.: ""A robot-assisted surgical system using a force-image control method for pedicle screw insertion"", PLOS ONE, vol. 9, no. Issue 1, 2014, pages 1 - 9, XP002732262, ISSN: 1932-6203, [retrieved on 20140122];;LEE ET AL.: ""Human-guided surgical robot system for spinal fusion surgery: CoRASS"", IEEE INTERNATIONAL CONFERENCE ON ROBOTICS AND AUTOMATION, 2008, pages 3881 - 3887, XP031340751;;""Project Description, Accuspine"", 6 October 2014 (2014-10-06), Retrieved from the Internet <URL:https://www.nibib.nih.gov/sites/default/files/AccuSpine.pdf>",PENDING
